Modified norovirus VP1 protein and VLPs containing modified norovirus VP1 protein
Modified Norovirus VP1 proteins and VLPs produced in plants address the challenges of strain diversity and immunity by inducing broad and durable protection against norovirus infections through targeted amino acid modifications and plant-based expression.
Patent Information
- Application Number
- JP2020547260
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-11-30
- Filing Date
- 2018-11-30
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2038-11-30
AI Technical Summary
The development of effective norovirus vaccines is hindered by the rapid evolution of norovirus strains, lack of robust cell culture systems, strain-specific immunity, and limited cross-immunity among genogroups, making it challenging to create a vaccine that provides long-lasting protection.
Modified Norovirus VP1 proteins and VLPs are produced in plants using recombinant polynucleotides with specific amino acid substitutions, deletions, and optimizations for human codon usage, allowing for the expression of VP1 and VP2 proteins to induce broad immunity against multiple norovirus strains.
The modified VP1 proteins and VLPs elicit an immune response, providing protection against a range of norovirus strains with improved stability and durability, overcoming the limitations of existing vaccine technologies.
Smart Images

Figure 0007579143000018 
Figure 0007579143000019 
Figure 0007579143000020
Abstract
Description
[Technical field]
[0001] The present invention relates to modified Norovirus VP1 proteins, VLPs comprising modified Norovirus VP1 proteins, and methods for producing them. [Background technology]
[0002] The global disease burden attributable to norovirus infection is high, with norovirus infections associated with an estimated 20% of all diarrheal cases worldwide and causing over 200,000 deaths annually. Norovirus is the leading cause of foodborne illness outbreaks in North America and the causative agent of the majority of healthcare-associated outbreaks among the elderly. Norovirus strains are also recognized as a leading cause of pediatric gastrointestinal illness worldwide.
[0003] Noroviruses constitute one of several genera in the family Caliciviridae. The human norovirus genome is a single-stranded, positive-sense RNA molecule encoding three open reading frames (ORFs), capped at its 5' end by the VPg protein. ORF1 encodes six nonstructural viral proteins, including the VPg, RNA-dependent RNA polymerase, and viral protease. ORF2 encodes the major structural capsid protein (VP1). ORF3 encodes the minor capsid protein (VP2).
[0004] VP1 is composed of two domains, the shell (S) domain and the protruding (P) domain. For example, the S domain of the GI.1 strain comprises the first 225 N-terminal amino acids and contains the structural elements required for capsid assembly and formation of the viral icosahedron. The P domain constitutes the remainder of the VP1 protein and is further composed of the P1 and P2 subdomains. The P2 subdomain is called the hypervariable domain and is believed to play an important role in receptor binding and immune response.
[0005] VP1 proteins form dimers through P domain-mediated protein interactions. Dimerization increases the stability of the virion capsid and results in the formation of protrusions extending from the base core of the norovirus particle formed by the S domain. When expressed, norovirus VP1 proteins can automatically assemble to form two virion structures: a 180-mer capsid structure with T=3 icosahedral symmetry of 38-40 nm in diameter, and a 60-mer capsid structure with T=1 icosahedral symmetry of 23 nm in diameter.
[0006] VP2, a minor structural protein, has a molecular weight (MW) of about 21 kDa to about 24 kDa. Studies suggest that VP2 is highly basic and located within the capsid. The function of VP2 is not yet fully understood, but it is generally believed to play a role in capsid stability by protecting the virion from disassembly and disassembly (Bertolotti-Ciarlet A., Crawford SE, Hutson AM, Estes MK 2003, J. Virol. 77:11603-11615). VP2 may also have some function during packaging of the RNA genome. The amount of VP2 minor structural protein in the virion is relatively small, with 1.5 to 8 copies incorporated into mature virions. Bertolotti-Ciarlet et al. (2003) reported that in insect and mammalian cells, VLPs composed of VP1 / VP2 were more resistant to protease cleavage than those with only VP1, and expression of VP2 in cis increased VP1 protein production. Furthermore, the presence of the 3'UTR downstream of the ORF2 gene increased steady-state levels of NV ORF2 mRNA. The greatest increase in VP1 expression was observed when ORF2+ORF3+3'UTR were expressed on the same construct and under the control of one promoter. Expression of VP2 in trans did not result in an increase in VP1 expression, indicating that the subgenomic organization of ORF2-ORF2-3'UTR was necessary for the observed increase in VP1 production.
[0007] Noroviruses are classified according to phylogenetic clustering of VP1 amino acid sequences. Seven genogroups have been classified to date (GI to GVII), with only genogroups GI, GII, and GIV known to infect humans. Of the 32 specific genotypes currently associated with human infections, GII.4 noroviruses are responsible for the majority of recent norovirus outbreaks. New strains of GII.4 emerge every 2–3 years and evolve by a process driven by mutations in the epitope-determining region of the hypervariable P2 domain of VP1. This process allows noroviruses to evade humoral immune responses acquired by previous exposure to earlier strains.
[0008] While facing the challenge of rapidly evolving and genetically diverse norovirus strains, the development of an effective norovirus vaccine is exacerbated by new challenges: until recently, human noroviruses could not be grown in cell culture, and even now, there is a lack of robust cell culture systems for both VLPs and live-attenuated noroviruses.
[0009] Another challenge in vaccine development is that immunity against norovirus infection is strain- and genotype-specific, with minimal cross-immunity conferred against other genogroups. Furthermore, immunity against norovirus strains is not lifelong immunity, and is estimated to last anywhere from six months to nine years.
[0010] Various approaches have been undertaken to develop suitable vaccines against Norovirus infection, including the production of recombinant Norovirus proteins in insect and plant expression systems.
[0011] Huo et al. (Virus Research, 2015, 204:1-5) demonstrated that the M27G mutant capsid protein of norovirus VP1 VLP produced in insect SF9 cells resulted in the production of 38 nm and 21 nm VLPs containing 58 kDa and 55 kDa proteins. The 55 kDa protein was the result of degradation or cleavage of the full-length P1 capsid protein as opposed to the translation product of an internal start codon. N-terminal deletion mutants of the VP1 protein with 26 or 38 amino acid residues deleted produced 21 nm VLPs. The 26 amino acid deletion mutant produced a small number of 38 nm VLPs, and the 38 amino acid deletion mutant did not form 38 nm VLPs.
[0012] US 2013 / 0273105 teaches the production of Norovirus formulations that contain antigenic peptides, proteins or VLPs derived from genogroup I (G1), genogroup II (GII), or consensus viral sequences. Norovirus antigens can include mutants of capsid proteins expressed within the VLPs.
[0013] US2015 / 0023995 provides a vaccine formulation comprising VLPs produced in insect Sf9 cells, the VLPs comprising composite amino acid sequences derived from at least two viral protein sequences. For example, composite GII.4 VP1 VLPs comprising VP1 sequences from GII.4 Minerva 2006-a, GII.4 Laurens 2006-b and GII.4 Houston 2002 norovirus strains are described. Also described are composite sequences from GII.1, GII.2 Snow Mountain and GII.3, and GI composite sequences from Norwalk GI.1, Southampton GI.1 and Chiba GI.1.
[0014] Mason et al. (Proc Natl Acad Sci USA, 1996, 93(11):5335-40) teach the use of transgenic tobacco plants and potato tubers to express GI.1 norovirus VLPs from the native VP1 protein. The plant-produced norovirus VLPs are morphologically and physically similar to the 38 nm Norwalk VLPs produced in insect cells. Oral administration of purified tobacco-produced Norwalk VLPs, either derived from the native capsid protein or from potato tubers expressing the GI.1 capsid protein, induced humoral immune responses in mice and humans (Tacket et al., J. Infect. Dis., 2000, 182(1):302-5).
[0015] Huang et al. (Biotechnol. Bioeng., 2009, 103(4):706-14) described a geminivirus-derived DNA replicon vector for producing GI.1 norovirus VLPs in plants. Co-delivery of a Bean dwarf virus-derived vector and a Rep / RepA supplying vector in Nicotiana benthamiana resulted in rapid and robust protein production. Summary of the Invention
[0016] The present invention relates to modified Norovirus proteins, virus-like particles (VLPs) comprising modified Norovirus proteins, and methods for producing Norovirus proteins and virus-like particles (VLPs) comprising modified Norovirus proteins.
[0017] It is an object of the present invention to produce modified Norovirus proteins, to produce VLPs comprising modified Norovirus proteins, and to produce VLPs comprising modified Norovirus proteins in plants.
[0018] As described herein, a recombinant polynucleotide is provided comprising a nucleotide sequence encoding a modified Norovirus VP1 protein, the modified Norovirus VP1 protein comprising: one or more substitutions at positions selected from amino acids 43, 57, 84 and 94 in a sequence aligned with Norovirus VP1 genotype GI.1 (SEQ ID NO:1); Deletion of a peptide fragment of amino acids 39 to 46 in a sequence aligned with norovirus VP1 genotype GI.1 (SEQ ID NO: 1); Amino acids 39-46 in a sequence aligned with norovirus VP1 genotype GI.1 are altered to the sequence SSTAVATA; or A combination of them. The nucleotide sequence is not derived from genotype GI.1 norovirus VP1.
[0019] Also provided is the above recombinant polynucleotide, wherein the nucleotide sequence is derived from a Norovirus VP1 selected from the group consisting of genotypes GI.2, GI.3.GI.5, GI.7, GII.2, GII.3, GII.4, GII.6, GII.12 and GII.17. For example, but not to be considered limiting, the nucleotide sequence may be derived from the group consisting of G1.2 / Leuven / 2003 / BEL GI.3 / S29 / 2008 / Lilla Edet / Sweden, GI.5 / Siklos-HUN5407 / 2013 / HUN, GI.7 / USA / 2014 / GA5043, GII.2 / CGMH47 / 2011 / TW; GII.3 / Jingzhou / 2013402 / CHN, GII.4 / Sydney / NSW0514 / 2012 / AU, GII.6 / Ohio / 490 / 2012 / USA, GII.12 / HS206 / 2010 / USA, and GII.17_Kawa_2014_A0A077KVU6.
[0020] The recombinant polynucleotide is a substitution, modification or mutation at amino acid position 43 of VP1 genotype GI.1 with valine, isoleucine, leucine, methionine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine; a substitution, modification or mutation to isoleucine, leucine, valine, alanine, glycine, serine, threonine, asparagine, glutamine, lysine or histidine at amino acid position 57 in the aligned sequences of VP1 genotype GI.1; A substitution, modification or mutation to serine, asparagine, cysteine, threonine, alanine, lysine or histidine at amino acid position 84 in the aligned sequences of VP1 genotype GI.1, and The amino acid sequence may include a specific substitution, modification or mutation independently selected from a substitution, modification or mutation to leucine, isoleucine, methionine, valine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine at amino acid position 94 within the aligned sequences of VP1 genotype GI.1.
[0021] Any of the above recombinant polynucleotides can also be optimized for human codon usage, increased GC content, or a combination thereof.
[0022] The modified Norovirus VP1 protein encoded by any one of the above recombinant polynucleotides is also described herein.Furthermore, the VLP comprising the modified Norovirus VP1 protein encoded by any one of the above recombinant polynucleotides is also disclosed.The VLP comprising the Norovirus VP1 protein encoded by any one of the above recombinant polynucleotides can further comprise Norovirus VP2 protein.
[0023] Also provided herein is a method of producing a modified Norovirus VP1 in a plant, plant part, or plant cell. The modified Norovirus VP1 may be encoded by any one of the recombinant polynucleotides described above. The method includes introducing one or more of the recombinant polynucleotides described above into a plant, plant part, or plant cell, and incubating the plant, plant part, or plant cell under conditions that allow expression of one or more modified Norovirus VP1 proteins. The method provided herein may further include harvesting the plant, plant part, or plant cell. Additionally, the method may include extracting, purifying, or extracting and purifying one or more modified Norovirus VP1 proteins from the plant, plant part, or plant cell. Additionally, in the introducing step, the method may further include introducing a second nucleic acid sequence encoding a Norovirus VP2 protein into the plant, plant part, or plant cell, and in the incubating step, the conditions allow co-expression and co-production of both the one or more modified Norovirus VP1 proteins and the Norovirus VP2 proteins in the plant, plant part, or plant cell.
[0024] Also described are methods of producing Norovirus virus-like particles (VLPs) in plants, plant parts, or plant cells, where the VLPs contain one or more of the modified Norovirus VP1 proteins encoded by one or more of the recombinant polynucleotides described above. The methods include introducing one or more of the recombinant polynucleotides described above into a plant, plant part, or plant cell, and incubating the plant, plant part, or plant cell under conditions that allow expression of one or more modified Norovirus VP1 proteins, thereby producing Norovirus VLPs. The methods provided herein may further include harvesting the plant, plant part, or plant cell. Additionally, the methods may include extracting, purifying, or extracting and purifying the Norovirus VLPs from the plant, plant part, or plant cell. Additionally, in the introducing step, the method may further comprise introducing into the plant, plant part, or plant cell a second nucleic acid sequence encoding a Norovirus VP2 protein, and in the incubating step, the conditions allow for co-expression and co-production of both the modified Norovirus VP1 protein and the Norovirus VP2 protein within the plant, plant part, or plant cell, thereby producing a Norovirus VLP. The Norovirus VLP produced by the methods described herein may have a diameter of about 15 nm to about 50 nm. Alternatively, the VLP may have a diameter of about 23 nm (for T=1 icosahedral symmetry) or about 38 nm (for T=3 icosahedral symmetry).
[0025] Provided herein is a method for producing an antibody or antibody fragment, the method comprising administering to a subject or host animal one or more of the modified Norovirus VP1 proteins encoded by one or more of the above-described recombinant polynucleotides, or a Norovirus VLP comprising one or more of the modified Norovirus VP1 proteins, thereby producing the antibody or antibody fragment.
[0026] Also provided herein are plants, plant parts, or plant cells comprising the above-described recombinant polynucleotides, modified Norovirus VP1 encoded by one or more of the recombinant polynucleotides, or Norovirus VLPs comprising one or more modified Norovirus VP1 proteins.
[0027] Also described herein is a composition for inducing an immune response. The composition comprises an effective dose of one or more of the modified Norovirus VP1 proteins encoded by one or more of the above recombinant polynucleotides, or a Norovirus VLP comprising one or more of the modified Norovirus VP1 proteins, and a pharma- ceutically acceptable carrier, adjuvant, vehicle, or excipient.
[0028] The present disclosure also provides a vaccine for eliciting an immune response, the vaccine comprising an effective dose of one or more of the modified Norovirus VP1 proteins encoded by one or more of the above recombinant polynucleotides, or a VLP comprising one or more of the modified Norovirus VP1 proteins.
[0029] Multiple strains of Norovirus have been characterized, and Norovirus strains may evolve over time. Thus, the present disclosure also relates to VP1 and VP2 proteins from Norovirus that exhibit about 30% to about 100%, or any amount therebetween, amino acid sequence identity to the VP1 protein, VP2 protein, or both the VP1 protein and VP2 protein of any of the Norovirus strains listed in Figures 2A and 2B, provided that the VP1 protein can be expressed in a plant and that when the VP1 protein is administered to a subject, the VP1 protein induces immunity to Norovirus in the subject. For example, Norovirus strains include strains having 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 100%, or any amount of amino acid sequence identity (sequence similarity, percent identity, percent similarity) to the VP1 protein, the VP2 protein, or both the VP1 protein and the VP2 protein, with any of the strains listed in Figures 2A and 2B, provided that the VP1 protein can be expressed in a plant and that when the VP1 protein is administered to a subject, the VP1 protein induces immunity to Norovirus in the subject.
[0030] Provided herein is an antibody or antibody fragment, which is prepared by administering to a subject or host animal one or more of the modified Norovirus VP1s encoded by one or more of the above-described recombinant polynucleotides, or a Norovirus VLP containing one or more of the modified Norovirus VP1s.
[0031] Also described herein are methods of inducing immunity to Norovirus infection in a subject, the methods comprising administering one or more of the modified Norovirus VP1 proteins encoded by one or more of the recombinant polynucleotides described above, or a Norovirus VLP comprising one or more of the modified Norovirus VP1 proteins. The one or more of the modified Norovirus VP1 proteins or the Norovirus VLP may be administered to the subject orally, intranasally, intramuscularly, intraperitoneally, intravenously, subcutaneously, rectally, or intravaginally.
[0032] This summary of the invention does not necessarily describe all features of the invention.
[0033] These and other features of the present invention will become more apparent from the following description taken in conjunction with the accompanying drawings. [Brief description of the drawings]
[0034] [Figure 1A] 1 shows a schematic representation of the linear structure of the Norovirus genome and the polyproteins and proteins translated therefrom. [Figure 1B] 1 shows a ribbon diagram representation of the three-dimensional structure of norovirus VP1 protein, including the shell (S) domain, the P1 subdomain (P1), and the P2 subdomain (P2). [Figure 1C] 1 shows a ribbon diagram representation of the three-dimensional structure of the norovirus VP1 protein dimer, which is composed of two S domains (S), two P1 subdomains (P1), and two P2 subdomains (P2).
[0035] [Figure 2A] Uniprot and NCBI references for several norovirus VP1 (top panel) and VP2 (bottom panel) proteins are shown. [Figure 2B] NCBI references for several norovirus VP1 (top panel) and VP2 (bottom panel) nucleic acid sequences are shown. [Figure 2C] 1 shows an alignment of several S domains of the Norovirus VP1 protein. The Norovirus GI.1 sequence (SEQ ID NO:1) is used as a reference sequence to which other Norovirus VP1 sequences (GI.2, SEQ ID NO:4; GI.3, SEQ ID NO:6; GI.5, SEQ ID NO:12; GI.7 SEQ ID NO:101; GII.1, SEQ ID NO:13; GII.2, SEQ ID NO:14; GII.3, SEQ ID NO:15; GII.4, SEQ ID NO:16; GII.5, SEQ ID NO:17; GII.6, SEQ ID NO:20; GII.7, SEQ ID NO:18; GII.12, SEQ ID NO:19; GII.13, SEQ ID NO:22; GII.14, SEQ ID NO:32; GII.17, SEQ ID NO:24; and GII.21, SEQ ID NO:26) are aligned. The VP1 amino acid sequence for the "GII" family of VP1 proteins contains three amino acid deletions at amino acids 14-16 and one amino acid deletion at position 26, which results in an alignment offset of four amino acids between the GII VP1 sequence and the GI VP1 sequence.
[0036] [Figure 3A]Left panel: wild-type (wt) human codon optimized (hCod) GI.1 / United States / Norwalk / 1968 VP1 (construct #2724; SEQ ID NO:3 (nucleotide); SEQ ID NO:1 (amino acid)) and hCod GI.5 VP1 (construct #3980; SEQ ID NO:33 (nucleotide); SEQ ID NO:12 (amino acid); middle panel: wild-type GI.1 and wt hCod GII.12 / United States / HS206 / 2010 VP1 (construct #3995; SEQ ID NO:87 (nucleotide); SEQ ID NO:19 (amino acid)); and right panel: wild-type GI.1 and wt hCod GII.4 / Sydney / NSW0514 / 2012 VP1 (construct #3760; SEQ ID NO:52 (nucleotide); SEQ ID NO:16 (amino acid)) at 9 days post infiltration (DPI). Figure 1 shows Coomassie stained SDS-PAGE of crude protein extracts prepared from mock-infiltered N. benthamiana leaves. Arrows: VP1 norovirus protein. First lane of each panel, crude protein extracts prepared from mock-infiltered N. benthamiana leaves. [Figure 3B] The top panel shows norovirus protein expression and VLP assembly using Coomassie stained SDS-PAGE analysis of fractions from iodixanol density gradient separation of crude protein extracts prepared from N. benthamiana leaves expressing wt hCod VP1 GI.1 / United States / Norwalk / 1968 VP1 (construct no. 2724) or wt hCod VP1 (construct no. 2724) and co-expressing wt hCod VP2 (construct no. 2725). The bottom panel shows electron micrographs of norovirus VLPs purified from 33% iodixanol gradient fractions of VP1, or co-expression of VP1 and VP2 proteins. For comparison, electron micrographs of native norovirus VLPs are shown. [Figure 3C]Left panel: Coomassie stained SDS-PAGE analysis of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt hCod GI.5 / Hungary / Siklos / HUN5407 / 2013 VP1 (construct number 3980; SEQ ID NO: 33 (nucleotide); SEQ ID NO: 12 (amino acid)); right panel: GII.12 / United States / HS206 / 2010 VP1 (construct number 3995; SEQ ID NO: 87 (nucleotide); SEQ ID NO: 19 (amino acid). [Figure 3D] GL.1 VLP-specific total IgG titers measured on serum samples obtained from animals after IM immunization with one (day 21) and two (day 42) doses of 1 μg or 10 μg of each formulation are shown. Total IgG titers were measured by ELISA using GI.1 VLP-coated plates (LOQ=100). Total IgG titers are represented per treatment group (n=8 animals / group) by geometric mean titer (GMT) with 95% confidence intervals. Same letters (A, B, C, D): no significant differences were detected between treatment groups (p>0.05).
[0037] [Figure 4A] FIG. 1 shows Coomassie-stained SDS-PAGE analysis of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt hCod GI.2 VP1 (construct number 3300; SEQ ID NO:5 (nucleotide); SEQ ID NO:4 (amino acid)). [Figure 4B] Electron micrographs of norovirus VLPs purified from 29-35% iodixanol gradient fractions of VP1 are shown.
[0038] [Figure 5A]wt hCod GI.3 / S29 / 2008 / Lila Edet / Sweden VP1 (construct no. 3979; SEQ ID NO:7 (nucleotide); SEQ ID NO:6 (amino acid)), with or without wt hCod GI.3 / S29 / 2008 / Lila Edet / Sweden VP2 (construct no. 3303; SEQ ID NO:95 (nucleotide); SEQ ID NO:94 (amino acid)), mut hCod GI.3 / S29 / 2008 / Lila Edet / Sweden_S94L VP1 (construct no. 4141; SEQ ID NO:9 (nucleotide); SEQ ID NO:8 (amino acid)), or mut hCod GI.3 / S29 / 2008 / Lila Edet / Sweden_Q84S+S94L Figure 1 shows a Coomassie stained SDS-PAGE of crude protein extracts prepared from agroinfiltrated N. benthamiana leaves 9 days post infiltration (DPI) with VP1 (construct number 4142; SEQ ID NO: 11 (nucleotide); SEQ ID NO: 10 (amino acid)). First lane: crude protein extract prepared from mock infiltrated N. benthamiana leaves. [Figure 5B] FIG. 1 shows Coomassie-stained SDS-PAGE analysis of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt hCod GI.3 / S29 / 2008 / Lila Edet / Sweden VP1 (construct no. 3979, left panel), mut hCod GI.3 / S29 / 2008 / Lila Edet / Sweden VP1_S94L (construct no. 4141, middle panel), or mut hCod GI.3 / S29 / 2008 / Lila Edet / Sweden VP1_Q84S+S94L (construct no. 4142, right panel). [Figure 5C]5B ) expressing wt hCod GI.3 / S29 / 2008 / Lila Edet / Sweden VP1 (construct no. 3979, left panel; fractions F2+F3, F6+F7 in FIG. 5B ), mut hCod GI.3 / S29 / 2008 / Lila Edet / Sweden VP1_S94L (construct no. 4141, middle panel; fractions F2-F6 in FIG. 5B ), or mut hCod GI.3 / S29 / 2008 / Lila Edet / Sweden VP1_Q84S+S94L (construct no. 4142, right panel; fractions F2-F6 in FIG. 5B ). Magnification 15,000X; scale bar = 500 nm. [Figure 5D] FIG. 1 shows a Coomassie stained SDS-PAGE of crude protein extracts prepared from agroinfiltrated N. benthamiana leaves 9 days post infiltration (DPI) with mut hCod GI.3 / S29 / 2008 / Lila Edet / Sweden_M57I+S94L VP1 (construct number 4180; SEQ ID NO: 171 (nucleotide); SEQ ID NO: 172 (amino acid)). [Figure 5E] Transmission electron micrograph (TEM) of virus-like particles (VLPs) purified from 31-35% iodixanol gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing mut hCod GI.3 / S29 / 2008 / Lila Edet / Sweden_M57I+S94L VP1 (construct no. 4180). Magnification 15,000X; Scale bar = 500 nm. [Figure 5F] The relative yield of VLPs containing non-native VP1 GI.3 with a substitution at amino acid position 94 is shown compared to the VLP yield of wild-type GI.3 (set as "fold change" of GI.3 S94;1). C#: construct no.
[0039] [Figure 6A]wt hCod GI.1 / United States / Norwalk / 1968 VP1 (construct number 2724; SEQ ID NO:3 (nucleotide); SEQ ID NO:1 (amino acid)), wt hCod GI.5 / Siklos / HUN5407 / 2013 / HUN VP1 (construct number 3980; SEQ ID NO:33 (nucleotide); SEQ ID NO:12 (amino acid)), mut hCod GI.5 / Siklos / HUN5407 / 2013 / HUN_Q84S VP1 (construct number 4130; SEQ ID NO:35 (nucleotide); SEQ ID NO:34 (amino acid)), mut hCod GI.5 / Siklos / HUN5407 / 2013 / HUN_A94L VP1 (construct number 4131; SEQ ID NO:37 (nucleotide); SEQ ID NO:36 (amino acid)) or mut hCod Coomassie stained SDS-PAGE of crude protein extracts prepared from agroinfiltrated N. benthamiana leaves 9 days post infiltration (DPI) with GI.5 / Siklos / HUN5407 / 2013 / HUN_Q84S+A94L VP1 (construct no. 4132; SEQ ID NO: 39 (nucleotide); SEQ ID NO: 38 (amino acid)). Arrows: VP1 norovirus protein; first lane = crude protein extract prepared from mock infiltrated N. benthamiana leaves. [Figure 6B] From left to right, wt hCod GI.5 / Siklos / HUN5407 / 2013 / HUN VP1 (construct no. 3980), mut hCod GI.5 / Siklos / HUN5407 / 2013 / HUN_Q84S VP1 (construct no. 4130, left panel), mut hCod GI.5 / Siklos / HUN5407 / 2013 / HUN_A94L VP1 (construct no. 4131, center panel), or mut HCod GI.5 / Siklos / HUN5407 / 2013 / HUN_Q84S+A94L FIG. 1 shows Coomassie-stained SDS-PAGE analysis of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing VP1 (construct no. 4132, right panel). [Figure 6C]From left to right, wt hCod GI.5 / Siklos / HUN5407 / 2013 / HUN VP1 (construct no. 3980), wt hCod GI.5 / Siklos / HUN5407 / 2013 / HUN_Q84S VP1 (construct no. 4130, left panel), mut hCod GI.5 / Siklos / HUN5407 / 2013 / HUN_A94L VP1 (construct no. 4131, center panel), or mut hCod GI.5 / Siklos / HUN5407 / 2013 / HUN_Q84S+A94L Transmission electron micrograph (TEM) of virus-like particles (VLPs) purified from 31-35% iodixanol gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing VP1 (construct no. 4132, right panel). Magnification 15,000X; Scale bar = 200 nm. [Figure 6D] From left to right: wt hCod GI.7 / GA5043 / USA / 2014 VP1 (construct no. 4209; SEQ ID NO: 101 (nucleotide); SEQ ID NO: 204 (amino acid)), mut hCod GI.7 / GA5043 / USA / 2014_R84S (construct no. 4210; SEQ ID NO: 176 (nucleotide); SEQ ID NO: 177 (amino acid)), mut hCod GI.7 / GA5043 / USA / 2014_M57I (construct no. 4217; SEQ ID NO: 178 (nucleotide); SEQ ID NO: 179 (amino acid)), mut hCod 6E shows Coomassie stained SDS-PAGE analysis of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing GI.7 / GA5043 / USA / 2014_M57I+R84S (construct number 4218; SEQ ID NO: 180 (nucleotide); SEQ ID NO: 181 (amino acid)). *Sample obtained for TEM analysis (see FIG. 6E). [Figure 6E]Shown are transmission electron micrographs (TEM) of virus-like particles (VLPs) purified from 31-35% iodixanol gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt hCod GI.7 / GA5043 / USA / 2014 VP1 (construct no. 4209); top right: mut hCod GI.7 / GA5043 / USA / 2014_R84S (construct no. 4210); bottom left: mut hCod GI.7 / GA5043 / USA / 2014_M57I (construct no. 4217); bottom right mut hCod GI.7 / GA5043 / USA / 2014_M57I+R84S (construct no. 4218). Magnification 15,000X; Scale bar = 500 nm. [Figure 6F] The relative yield of VLPs containing non-native VP1 GI.7 with a substitution at amino acid position 57 is shown compared to the VLP yield of wild type GI.7 (GI.7 M57; set as a "fold change" of 1). C#: construct no.
[0040] [Figure 7A]wt hCod GII.2 / CGMH47 / 2011 / TW VP1 (construct number 3982; SEQ ID NO: 40 (nucleotide); SEQ ID NO: 14 (amino acid)), mut hCod GII.2 / CGMH47 / 2011 / TW_E80S VP1 (construct number 4143; SEQ ID NO: 86 (nucleotide); SEQ ID NO: 85 (amino acid)), mut hCod GII.2 / CGMH47 / 2011 / TW _A90L VP1 (construct number 4144; SEQ ID NO: 42 (nucleotide); SEQ ID NO: 41 (amino acid)) or mut hCod GII.2 / CGMH47 / 2011 / TW_E80S+A90L Coomassie stained SDS-PAGE of crude protein extracts prepared from agroinfiltrated N. benthamiana leaves 9 days post infiltration (DPI) with VP1 (construct #4145; SEQ ID NO:44 (nucleotide); SEQ ID NO:43 (amino acid)). Arrows: VP1 norovirus protein; first lane = crude protein extract prepared from mock infiltrated N. benthamiana leaves. [Figure 7B] From left to right, Coomassie-stained SDS-PAGE analysis of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt hCod GII.2 / CGMH47 / 2011 / TW VP1 (construct no. 3982), mut hCod GII.2 / CGMH47 / 2011 / TW_E80S VP1 (construct no. 4143), mut hCod GII.2 / CGMH47 / 2011 / TW_A90L (construct no. 4144), or mut hCod GII.2 / CGMH47 / 2011 / TW_E80S+A90L VP1 (construct no. 4145). [Figure 7C]Top left panel: wt hCod GII.2 / CGMH47 / 2011 / TW VP1 (construct no. 3982), top right panel mut hCod GII.2 / CGMH47 / 2011 / TW_E80S+A90L VP1 (construct no. 4145); bottom left panel: mut hCod GII.2 / CGMH47 / 2011 / TW_A39V+E80S+A90L VP1 (construct no. 4182; SEQ ID NO: 183 (nucleotides); SEQ ID NO: 182 (amino acids)); bottom right panel: mut hCod GII.2 / CGMH47 / 2011 / TW_M53I+E80S+A90L Coomassie-stained SDS-PAGE analysis (top of each panel) of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing VP1 (construct no. 4183 SEQ ID NO: 185 (nucleotide); SEQ ID NO: 184 (amino acid)), and transmission electron micrographs (TEM) (bottom of each panel) of virus-like particles (VLPs) purified from 29-35% iodixanol gradient fractions of crude protein extracts prepared from N. benthamiana leaves. Magnification 15,000X; scale bar = 500 nm.
[0041] [Figure 8A]From left to right: wt hCod GII.3 / Jingzhou / 2013402 / CHN VP1 (construct no. 3983; SEQ ID NO: 45 (nucleotides); SEQ ID NO: 15 (amino acids; first panel)), mut hCod GII.3 / Jingzhou / 2013402 / CHN_E80S VP1 (construct no. 4146; SEQ ID NO: 47 (nucleotides); SEQ ID NO: 46 (amino acids; second panel)), mut hCod GII.3 / Jingzhou / 2013402 / CHN_A90L VP1 (construct no. 4147; SEQ ID NO: 49 (nucleotides); SEQ ID NO: 48 (amino acids; third panel)), or mut hCod GII.3 / Jingzhou / 2013402 / CHN_E80S+A90L FIG. 2 shows Coomassie-stained SDS-PAGE analysis of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing VP1 (construct number 4148, SEQ ID NO:51 (nucleotide); SEQ ID NO:50 (amino acid; fourth panel)). [Figure 8B] Transmission electron micrographs (TEM) of virus-like particles (VLPs) purified from 31-35% iodixanol gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt hCod GII.3 / Jingzhou / 2013402 / CHN VP1 (construct no. 3983, first panel), or mut hCod GII.3 / Jingzhou / 2013402 / CHN_E80S VP1 (construct no. 4146, second panel). Magnification 15,000X; Scale bar = 500 nm.
[0042] [Figure 9A]wt GI.1 / United States / Norwalk / 1968 VP1 (construct no. 2724; SEQ ID NO:3 (nucleotide); SEQ ID NO:1 (amino acid)), wt hCod GII.4 / Sydney / NSW0514 / 2012 / AU VP1 (construct no. 3760; SEQ ID NO:52 (nucleotide); SEQ ID NO:16 (amino acid)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_A39V VP1 (construct no. 4155; SEQ ID NO:54 (nucleotide); SEQ ID NO:53 (amino acid)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_V47P VP1 (construct no. 4156; SEQ ID NO:56 (nucleotide); SEQ ID NO:55 (amino acid)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_R53I VP1 (construct number 4157; SEQ ID NO: 58 (nucleotides); SEQ ID NO: 57 (amino acids)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S VP1 (construct number 4133; SEQ ID NO: 60 (nucleotides); SEQ ID NO: 59 (amino acids)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_S90L VP1 (construct number 4134; SEQ ID NO: 62 (nucleotides); SEQ ID NO: 61 (amino acids)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_Δ35-42 VP1 (construct number 4158; SEQ ID NO: 64 (nucleotides); SEQ ID NO: 63 (amino acids)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_SSTAVATA VP1 (construct no. 4159; SEQ ID NO: 66 (nucleotides); SEQ ID NO: 65 (amino acids)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S+A39V (construct no. 4165; SEQ ID NO: 68 (nucleotides); SEQ ID NO: 67 (amino acids)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S+V47P VP1 (construct no. 4166; SEQ ID NO: 70 (nucleotides); SEQ ID NO: 69 (amino acids)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_ P80S+R53I VP1 (construct no. 4167; SEQ ID NO: 72 (nucleotide); SEQ ID NO: 71 (amino acid)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S+S90L VP1 (construct no. 4135; SEQ ID NO: 74 (nucleotide); SEQ ID NO: 73 (amino acid)), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S+Δ35-42 VP1 (construct no. 4168; SEQ ID NO: 76 (nucleotide); SEQ ID NO: 75 (amino acid)), or mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S+SSTAVATA Coomassie stained SDS-PAGE of crude protein extracts prepared from agroinfiltrated N. benthamiana leaves 9 days post infiltration (DPI) with VP1 (construct #4169; SEQ ID NO:78 (nucleotide); SEQ ID NO:77 (amino acid)). Arrows: VP1 norovirus protein; first lane = crude protein extract prepared from mock infiltrated N. benthamiana leaves. [Figure 9B] wt hCod GII.4 / Sydney / NSW0514 / 2012 / AU VP1 (construct no. 3760), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S VP1 (construct no. 4133), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_S90L VP1 (construct no. 4134), GII.4 / Sydney / NSW0514 / 2012 / AU_P80S+S90L Coomassie-stained SDS-PAGE analysis (top panel) and transmission electron micrograph (TEM; bottom panel; magnification 15,000X; scale bar = 200 nm) of virus-like particles (VLPs) purified from iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing VP1 (construct no. 4135). [Figure 9C]wt hCod GII.4 / Sydney / NSW0514 / 2012 / AU VP1 (construct number 3760), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S VP1 (construct number 4133), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU _A39V VP1 (construct number 4155), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_ P80S+A39V (construct number 4165), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_Δ35-42 VP1 (construct number 4158), mut hCod Coomassie-stained SDS-PAGE analysis (top panel) and transmission electron micrograph (TEM; bottom panel; magnification 15,000X; scale bar = 200 nm) of virus-like particles (VLPs) purified from iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing GII.4 / Sydney / NSW0514 / 2012 / AU_P80S+Δ35-42 VP1 (construct no. 4168). [Figure 9D] wt hCod GII.4 / Sydney / NSW0514 / 2012 / AU VP1 (construct number 3760), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S VP1 (construct number 4133), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_R53I VP1 (construct number 4157), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_R53I+P80S Coomassie-stained SDS-PAGE analysis (top panel) and transmission electron micrograph (TEM; bottom panel; magnification 15,000X; scale bar = 200 nm) of virus-like particles (VLPs) purified from iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing VP1 (construct no. 4167). [Figure 9E]FIG. 1 shows Coomassie stained SDS-PAGE analysis of virus-like particles (VLPs) purified from iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt hCod GII.4 / Sydney / NSW0514 / 2012 / AU VP1 (construct no. 3760), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S VP1 (construct no. 4133), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_V47P VP1 (construct no. 4156), and mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S+V47P VP1 (construct no. 4166). [Figure 9F] FIG. 1 shows Coomassie stained SDS-PAGE analysis of virus-like particles (VLPs) purified from iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt hCod GII.4 / Sydney / NSW0514 / 2012 / AU VP1 (construct no. 3760), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_P80S VP1 (construct no. 4133), mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_SSTAVATA VP1 (construct no. 4159), and mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_SSTAVATA+P80S VP1 (construct no. 4169). [Figure 9G]Left panel: Coomassie stained SDS-PAGE analysis of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_R53I+P80S VP1 (construct number 4167); right panel: mut hCod GII.4 / Sydney / NSW0514 / 2012 / AU_A39V+R53I+P80S VP1 (construct number 4186; SEQ ID NO: 191 (nucleotide); SEQ ID NO: 190 (amino acid)). Magnification 15,000X; scale bar = 500 nm. [Figure 9H] The relative yield of VLPs containing non-native VP1 GII.4 / 2012 with a substitution at amino acid position 80 is shown compared to the VLP yield of wild-type (native) GII.4 / 2012 (set as "fold change" of GII.4 / 2012 P80;1). C#: construct no. [Figure 9I] A39.GII.4 / 2012(P80S)A39;1 (set as "fold change" of 1) compared to the VLP yield of GII.4 / 2012(P80S) with an additional substitution at amino acid position 39. C#: construct no.
[0043] [Figure 10A]wt hCod GII.6 / Ohio / 490 / 2012 / USA VP1 (construct no. 3993; SEQ ID NO:21 (nucleotide); SEQ ID NO:20 (amino acid)) and wt hCod GII.6 / HS245 / 2010 / USA VP2 (construct no. 3307; SEQ ID NO:97 (nucleotide); SEQ ID NO:96 (amino acid)), mut hCod GII.6 / Ohio / 490 / 2012 / USA_E80S VP1 (construct no. 4149; SEQ ID NO:80 (nucleotide); SEQ ID NO:79 (amino acid)) and wt hCod GII.6 / HS245 / 2010 / USA VP2 (construct no. 3307), mut hCod GII.6 / Ohio / 490 / 2012 / USA_S90L VP1 (construct no. 4150; SEQ ID NO:82 (nucleotide); SEQ ID NO:81 (amino acid)) and wt 1 shows Coomassie stained SDS-PAGE analysis of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing hCod GII.6 / HS245 / 2010 / USA VP2 (construct no. 3307), or mut hCod GII.6 / Ohio / 490 / 2012 / USA_E80S+S90L VP1 (construct no. 4151; SEQ ID NO: 84 (nucleotide); SEQ ID NO: 83 (amino acid)) and wt hCod GII.6 / HS245 / 2010 / USA VP2 (construct no. 3307). [Figure 10B] Transmission electron micrographs (TEM) of virus-like particles (VLPs) purified from 31-35% iodixanol gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt hCod GII.6 / Ohio / 490 / 2012 / USA VP1 (construct no. 3993) and wt hCod GII.6 / HS245 / 2010 / USA VP2 (construct no. 3307), mut hCod GII.6 / Ohio / 490 / 2012 / USA_S90L VP1 (construct no. 4150) and wt hCod GII.6 / HS245 / 2010 / USA VP2 (construct no. 3307). Magnification 15,000X; Scale bar = 200 nm.
[0044] [Figure 11A] wt hCod GI.1 / United States / Norwalk / 1968 VP1 (construct number 2724; SEQ ID NO:3 (nucleotide); SEQ ID NO:1 (amino acid)), wt hCod GII.12 / HS206 / 2010 / USA VP1 (construct number 3995; SEQ ID NO:87 (nucleotide); SEQ ID NO:19 (amino acid)), mut hCod GII.12 / HS206 / 2010 / USA_E80S VP1 (construct number 4136; SEQ ID NO:89 (nucleotide); SEQ ID NO:88 (amino acid)), mut hCod GII.12 / HS206 / 2010 / USA_A90L VP1 (construct number 4137; SEQ ID NO:91 (nucleotide); SEQ ID NO:90 (amino acid)), or mut hCod GII.12 / HS206 / 2010 / USA_E80S+A90L Figure 1 shows a Coomassie stained SDS-PAGE of crude protein extracts prepared from agroinfiltrated N. benthamiana leaves 9 days post infiltration (DPI) with VP1 (construct #4138; SEQ ID NO:93 (nucleotide); SEQ ID NO:92 (amino acid)). First lane = crude protein extract prepared from mock infiltrated N. benthamiana leaves. [Figure 11B] 1 shows Coomassie-stained SDS-PAGE analysis of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt GII.12 / HS206 / 2010 / USA VP1 (construct no. 3995), GII.12 / HS206 / 2010 / USA_E80S VP1 (construct no. 4136), GII.12 / HS206 / 2010 / USA_A90L VP1 (construct no. 4137), or GII.12 / HS206 / 2010 / USA_E80S+A90L VP1 (construct no. 4138). [Figure 11C]Figure 2 shows transmission electron micrographs (TEM) of virus-like particles (VLPs) purified from 31-35% iodixanol gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing wt GII.12 / HS206 / 2010 / USA VP1 (construct no. 3995, first panel), GII.12 / HS206 / 2010 / USA_P80S VP1 (construct no. 4136, second panel), GII.12 / HS206 / 2010 / USA_S90L VP1 (construct no. 4137, third panel), or GII.12 / HS206 / 2010 / USA_P80S+S90L VP1 (construct no. 4138, fourth panel). Magnification 15,000X, scale bar = 500 nm. [Figure 11D] Top left panel: wt hCod GII.17 Kawa 2014 A0A077KVU6VP1 (construct number 3998; SEQ ID NO: 25 (nucleotide); SEQ ID NO: 24 (amino acid)), top right panel mut hCod GII.17 Kawa 2014 A0A077KVU6_A90L VP1 (construct number 4232; SEQ ID NO: 197 (nucleotide); SEQ ID NO: 196 (amino acid)); bottom left panel: mut hCod GII.17 Kawa 2014 A0A077KVU6_A39V VP1 (construct number 4234; SEQ ID NO: 193 (nucleotide); SEQ ID NO: 192 (amino acid)); bottom right panel: mut hCod GII.17 Kawa 2014 A0A077KVU6_R53I Shown are Coomassie-stained SDS-PAGE analysis (top of each panel) of iodixanol density gradient fractions of crude protein extracts prepared from N. benthamiana leaves expressing VP1 (construct number 4235; SEQ ID NO: 195 (nucleotide); SEQ ID NO: 194 (amino acid)), and transmission electron micrographs (TEM) (bottom of each panel) of virus-like particles (VLPs) purified from 31-35% iodixanol gradient fractions of crude protein extracts prepared from N. benthamiana leaves. Magnification 15,000X; scale bar = 500 nm.
[0045] [Figure 12A]The amino acid sequence of VP1 GI.1 United States Norwalk 1968 is shown (SEQ ID NO:1). [Figure 12B] The nucleic acid sequence of wild-type VP1 GI.1 United States Norwalk 1968 is shown (SEQ ID NO:2). [Figure 12C] The nucleic acid sequence of hCod VP1 GI.1 United States Norwalk 1968 is shown (SEQ ID NO:3).
[0046] [Figure 13A] The amino acid sequence of VP1 G1.2 Leuven 2003 D2DEL3 is shown (SEQ ID NO: 4). [Figure 13B] The nucleic acid sequence of hCod VP1 G1.2 Leuven 2003 D2DEL3 is shown (SEQ ID NO:5).
[0047] [Figure 14A] The amino acid sequence of VP1 GI.3 LillaEdet 2008 H2DG70 is shown (sequence number 6). [Figure 14B] The nucleic acid sequence of hCod GI.3 LillaEdet 2008 H2DG70 is shown (sequence number 7).
[0048] [Figure 15A] The amino acid sequence of VP1 GI.5 Siklos HUN5407 2013 HUN AHW99832 is shown (sequence number 12). [Figure 15B] The nucleic acid sequence of hCod VP1 GI.5 Siklos HUN5407 2013 HUN AHW99832 is shown (sequence number 33).
[0049] [Figure 16A] The amino acid sequence of GI.7 / GA5043 / USA / 2014 VP1 is shown (sequence number 101). [Figure 16B] The nucleic acid sequence of GI.7 / GA5043 / USA / 2014 VP1 is shown (sequence number 175). [Figure 16C]The amino acid sequence of VP1 GII.1 Ascension208 2010 USA AFA55174 is shown (SEQ ID NO: 13).
[0050] [Figure 17A] The amino acid sequence of VP1 GII.2 CGMH47 2011 TW AGT39206 is shown (sequence number 14). [Figure 17B] The nucleic acid sequence of hCod VP1 GII.2 CGMH47 2011 TW AGT39206 is shown (sequence number 40).
[0051] [Figure 18A] The amino acid sequence of VP1 GII.3 Jingzhou 2013402 CHN AGX01095 is shown (sequence number 15). [Figure 18B] The nucleic acid sequence of hCod VP1 GII.3 Jingzhou 2013402 CHN AGX01095 is shown (sequence number 45).
[0052] [Figure 19A] The amino acid sequence of VP1 GII.4 Sydney NSW0514 2012 is shown (SEQ ID NO: 16). [Figure 19B] The nucleic acid sequence of hCod VP1 GII.4 Sydney NSW0514 2012 is shown (sequence number 52). [Figure 19C] The amino acid sequence of VP1 US96:GII.4 Dresden174 1997 DE AY741811 is shown (sequence number 27). [Figure 19D] The amino acid sequence of VP1 FH02:GII.4 FarmingtonHills 2002 US AY502023 is shown (sequence number 28). [Figure 19E] 2 shows the amino acid sequence of VP1 Hnt04:GII.4 Hunter-NSW504D 2004 AU DQ078814 (sequence number 29). [Figure 19F]The amino acid sequence of VP1 2006b:GII.4 Shellharbour-NSW696T 2006 AU EF684915 is shown (sequence number 30). [Figure 19G] VP1NO09: The amino acid sequence of GII.4 Orange-NSW001P 2008 AU GQ845367 is shown (sequence number 31).
[0053] [Figure 20] The amino acid sequence of VP1 GII.5 Alberta 2013 CA ALT54485 is shown (sequence number 17).
[0054] [Figure 21A] The amino acid sequence of VP1 GII.6 Ohio 2012 M9T020 is shown (SEQ ID NO: 20). [Figure 21B] The nucleic acid sequence of hCod-optimized VP1 GII.6 Ohio 2012 M9T020 is shown (sequence number 21).
[0055] [Figure 22] The amino acid sequence of VP1 GII.7 Musa 2010 AII73774 is shown (sequence number 18).
[0056] [Figure 23A] The amino acid sequence of VP1 GII.12_HS206_2010_USA_AEI29586 is shown (sequence number 19). [Figure 23B] The nucleic acid sequence of hCod VP1 GII.12_HS206_2010_USA AEI29586 is shown (sequence number 87).
[0057] [Figure 24A] The amino acid sequence of VP1 GII.13 VA173 2010 H9AWU4 is shown (sequence number 22). [Figure 24B] The nucleic acid sequence of human codon-optimized VP1 GII.13 VA173 2010 H9AWU4 is shown (sequence number 23).
[0058] [Diagram 25] The amino acid sequence of VP1 GII.14 Saga 2008 JPN ADE28701 is shown (sequence number 32).
[0059] [Figure 26A] The amino acid sequence of VP1 GII.17 Kawa 2014 A0A077KVU6 is shown (sequence number 24). [Figure 26B] The nucleic acid sequence of human codon-optimized VP1 GII.17 Kawa 2014 A0A077KVU6 is shown (sequence number 25).
[0060] [Figure 27] The amino acid sequence of VP1 GII.21 Sali 2011 USA AFC89665 is shown (sequence number 26).
[0061] [Figure 28A] The amino acid sequence of modified VP1 GI.3_Lil08_Q84S is shown (sequence number 98). [Figure 28B] The nucleic acid sequence of VP1 GI.3_Lil08_Q84S is shown (sequence number 167). [Figure 28C] The amino acid sequence of VP1 GI.3 Lil08_S94L is shown (sequence number 8). [Figure 28D] The nucleic acid sequence of hCod VP1 GI.3 Lil08_S94L is shown (SEQ ID NO: 9). [Figure 28E] The amino acid sequence of VP1 GI.3 Lil08_Q84S+S94L is shown (sequence number 10). [Figure 28F] The nucleic acid sequence of hCod VP1 GI.3 Lil08_Q84S+S94L is shown (SEQ ID NO: 11). [Figure 28G] The amino acid sequence of VP1 GI.3 Lil08_A43V+S94L is shown (sequence number 170). [Fig. 28H] The nucleic acid sequence of hCod VP1 GI.3 Lil08_A43V+S94L is shown (sequence number 169). [Figure 28I] The amino acid sequence of VP1 GI.3 Lil08_M57I+S94L is shown (sequence number 172). [Figure 28J] The nucleic acid sequence of hCod VP1 GI.3 Lil08_M57I+S94L is shown (sequence number 171). [Figure 28K] The amino acid sequence of VP1 GI.3 Lil08_A43V+M57I+S94L is shown (sequence number 174). [Figure 28L] The nucleic acid sequence of hCod VP1 GI.3 Lil08_A43V+M57I+S94L is shown (sequence number 173). [Figure 28M]
[0023] Figure 2 shows the amino acid sequence of VP1_GI.3_Lil08_S94X (SEQ ID NO: 292), where X is selected from V, IM, T, E, D, N, Q, K, or H. [Figure 28N]
[0023] Figure 2 shows the human codon-optimized sequence of VP1_GI.3_Lil08_S94X (SEQ ID NO:293), where X is selected from a codon encoding V (e.g., XXX=GTG), I (e.g., XXX=ATC), M (e.g., XXX=ATG), T (e.g., XXX=ACC), E (e.g., XXX=GAG), D (e.g., XXX=GAC), N (e.g., XXX=AAC), Q (e.g., XXX=CAG), K (e.g., XXX=AAG), or H (e.g., XXX=CAC).
[0062] [Figure 29A] The amino acid sequence of modified VP1 GI.5 Siklos Q84S is shown (sequence number 34). [Figure 29B] The nucleic acid sequence of modified VP1 GI.5 Siklos Q84S is shown (sequence number 35). [Figure 29C] The amino acid sequence of VP1 GI.5 Siklos A94L is shown (sequence number 36). [Figure 29D] The nucleic acid sequence of hCod VP1 GI.5 Siklos A94L is shown (sequence number 37). [Figure 29E] The amino acid sequence of VP1 GI.5 Siklos Q84S+A94L is shown (sequence number 38). [Figure 29F] The nucleic acid sequence of hCod VP1 GI.5 Siklos Q84S+A94L is shown (sequence number 39). [Figure 29G] The amino acid sequence of modified VP1 GI.7 / GA5043 / USA / 2014_R84S is shown (sequence number 177). [Figure 29H] The nucleic acid sequence of modified VP1 hCod GI.7 / GA5043 / USA / 2014_R84S is shown (sequence number 176). [Figure 29I] The amino acid sequence of modified VP1 GI.7 / GA5043 / USA / 2014_M57I is shown (sequence number 179). [Figure 29J] The nucleic acid sequence of modified VP1 hCod GI.7 / GA5043 / USA / 2014_M57I is shown (sequence number 178). [Figure 29K] The amino acid sequence of modified VP1GI.7 / GA5043 / USA / 2014_M57I+R84S is shown (sequence number 181). [Figure 29L] The nucleic acid sequence of modified VP1 hCod GI.7 / GA5043 / USA / 2014_M57I+R84S is shown (sequence number 180). [Figure 29M] 2 shows the amino acid sequence of VP1_GI.7 / GA5043 / USA / 2014_M57X (SEQ ID NO:290), where X is selected from L, G, S, T, N, Q, K, or H. [Figure 29N]
[0033] Figure 291 depicts human codon-optimized VP1_GI.7 / GA5043 / USA / 2014_M57X (SEQ ID NO:291), where X is selected from codons encoding L (e.g., XXX=CTG), G (e.g., XXX=GGC), S (e.g., XXX=AGC), T (e.g., XXX=ACC), N (e.g., XXX=AAC), Q (e.g., XXX=CAG), K (e.g., XXX=AAG), or H (e.g., XXX=CAC).
[0063] [Figure 30A] The amino acid sequence of VP1 GII.2 CGMH47 E80S is shown (sequence number 85). [Figure 30B] The nucleic acid sequence of hCod VP1 GII.2 CGMH47 E80S is shown (sequence number 86). [Figure 30C] The amino acid sequence of VP1 GII.2 CGMH47 A90L is shown (sequence number 41). [Figure 30D] The nucleic acid sequence of hCod VP1 GII.2 CGMH47 A90L is shown (sequence number 42). [Figure 30E] The amino acid sequence of VP1_GII.2_CGMH47_E80S+A90L is shown (sequence number 43). [Figure 30F] The nucleic acid sequence of hCod VP1_GII.2_CGMH47_E80S+A90L is shown (sequence number 44). [Figure 30G] The amino acid sequence of VP1_GII.2_CGMH47_A39V+E80S+A90L is shown (sequence number 182). [Figure 30H] The nucleic acid sequence of hCod VP1_GII.2_CGMH47_A39V+E80S+A90L is shown (sequence number 183). [Figure 30I] The amino acid sequence of VP1_GII.2_CGMH47_R53I+E80S+A90L is shown (sequence number 184). [Figure 30J] The nucleic acid sequence of hCod VP1_GII.2_CGMH47_R53I+E80S+A90L is shown (sequence number 185). [Figure 30K] The amino acid sequence of VP1_GII.2_CGMH47_A39V+R53I+E80S+A90L is shown (sequence number 186). [Figure 30L] The nucleic acid sequence of hCod VP1_GII.2_CGMH47_A39V+R53I+E80S+A90L is shown (sequence number 187).
[0064] [Figure 31A] The amino acid sequence of VP1 GII.3_Jing_E80S is shown (sequence number 46). [Figure 31B] The nucleic acid sequence of hCod VP1 GII.3_Jing_E80S is shown (sequence number 47). [Figure 31C] Amino acid sequence of VP1 GII.3_Jing_A90L (sequence number 48). [Figure 31D] The nucleic acid sequence of hCod VP1 GII.3_Jing_A90L is shown (sequence number 49). [Figure 31E] Amino acid sequence of VP1 GII.3_Jing_E80S+A90L (sequence number 50). [Fig. 31F] The nucleic acid sequence of hCod VP1 GII.3_Jing_E80S+A90L is shown (sequence number 51).
[0065] [Figure 32A] The amino acid sequence of VP1 GII.4 Syd12 A39V is shown (sequence number 53). [Figure 32B] The nucleic acid sequence of hCod VP1 GII.4_Syd12_A39V is shown (sequence number 54). [Figure 32C] The amino acid sequence of VP1 GII.4_Syd12_V47P is shown (sequence number 55). [Fig. 32D] The nucleic acid sequence of hCod VP1 GII.4_Syd12_V47P is shown (sequence number 56). [Figure 32E] The amino acid sequence of VP1 GII.4_Syd12_R53I is shown (sequence number 57). [Fig. 32F] The nucleic acid sequence of hCod VP1 GII.4_Syd12_R53I is shown (sequence number 58). [Fig. 32G] The amino acid sequence of VP1;GII.4_Syd12_P80S is shown (sequence number 59). [Fig. 32H] The nucleic acid sequence of hCod VP1 GII.4_Syd12_P80S is shown (sequence number 60). [Fig. 32I] The amino acid sequence of VP1 GII.4_Syd12_S90L is shown (sequence number 61). [Fig. 32J] The nucleic acid sequence of hCod VP1 GII.4_Syd12_S90L is shown (sequence number 62). [Figure 32K]The amino acid sequence of VP1GII.4_Syd12_Δ35-42 is shown (sequence number 63). [Figure 32L] The nucleic acid sequence of hCod VP1GII.4_Syd12_Δ35-42 is shown (sequence number 64). [Figure 32M] The amino acid sequence of VP1 GII.4_Syd12_SSTAVATA is shown (sequence number 65). [Figure 32N] The nucleic acid sequence of hCodVP1 GII.4_Syd12_SSTAVATA is shown (sequence number 66). [Fig. 32O] The amino acid sequence of VP1GII.4_Syd12_P80S+A39V is shown (sequence number 67). [Figure 32P] The nucleic acid sequence of hCod VP1 GII.4_Syd12_P80S+A39V is shown (sequence number 68). [Figure 32Q] The amino acid sequence of VP1 GII.4_Syd12_P80S+V47P is shown (sequence number 69). [Figure 32R] The nucleic acid sequence of hCod VP1 GII.4_Syd12_P80S+V47P is shown (sequence number 70). [Fig. 32S] The amino acid sequence of VP1GII.4_Syd12_P80S+R53I is shown (sequence number 71). [Figure 32T] The nucleic acid sequence of hCod VP1 GII.4_Syd12_P80S+R53I is shown (sequence number 72). [Fig.32U] The amino acid sequence of VP1 GII.4_Syd12_P80S+S90L is shown (sequence number 73). [Fig. 32V] The nucleic acid sequence of hCod VP1 GII.4_Syd12_P80S+S90L is shown (sequence number 74). [Fig. 32W] The amino acid sequence of VP1 GII.4_Syd12_P80S+Δ35-42 is shown (sequence number 75). [Fig. 32X] The nucleic acid sequence of hCod VP1 GII.4_Syd12_P80S+Δ35-42 is shown (sequence number 76). [Fig. 32Y]The amino acid sequence of VP1 GII.4_Syd12_P80S+SSTAVATA is shown (sequence number 77). [Fig.32Z] The nucleic acid sequence of hCod VP1 GII.4_Syd12_P80S+SSTAVATA is shown (sequence number 78). [Figure 32AA] The amino acid sequence of VP1 GII.4 Syd12 A39V+R53I is shown (sequence number 188). [Diagram 32BB] The nucleic acid sequence of hCod VP1 GII.4_Syd12_A39V+R53I is shown (sequence number 189). [Fig. 32CC] The amino acid sequence of VP1 GII.4 Syd12 A39V+R53I+P80S is shown (sequence number 190). [Fig.32DD] The nucleic acid sequence of hCod VP1 GII.4_Syd12_A39V+R53I+P80S is shown (sequence number 191). [Diagram 32EE]
[0033] Figure 287 shows the nucleic acid sequence of human codon-optimized VP1 GII.4_Syd12_P80X (SEQ ID NO:287), where X is selected from a codon encoding A (e.g., XXX=GCC), N (e.g., XXX=AAC), K (e.g., XXX=AAG), or H (e.g., XXX=CAC). [Diagram 32FF] 2 shows the amino acid sequence of VP1_GII.4_Syd12_P80X (SEQ ID NO: 286), where X is selected from A, N, K or H. [Figure 32GG]
[0023] Figure 2 shows the nucleic acid sequence of the human codon-optimized sequence of VP1 GII.4_Syd12_P80S+A39X (SEQ ID NO: 289), where X is selected from codons encoding I (e.g., XXX=ATC), M (e.g., XXX=ATG), G (e.g., XXX=GGC), S (e.g., XXX=AGC), E (e.g., XXX=GAG), D (e.g., XXX=GAC), N (e.g., XXX=AAC), Q (e.g., XXX=CAG), K (e.g., XXX=AAG), or H (e.g., XXX=CAC). [Fig. 32HH]2 shows the amino acid sequence of VP1_GII.4_Syd12_P80S+A39X (SEQ ID NO: 288), where X is selected from I, M, G, S, E, D, N, Q, K, or H.
[0066] [Figure 33A] The amino acid sequence of VP1 GII.6_Ohio_E80S is shown (sequence number 79). [Figure 33B] The nucleic acid sequence of hCod VP1 GII.6_Ohio_E80S is shown (sequence number 80). [Figure 33C] The amino acid sequence of VP1 GII.6_Ohio_S90L is shown (sequence number 81). [Figure 33D] The nucleic acid sequence of hCod VP1 GII.6_Ohio_S90L is shown (sequence number 82). [Figure 33E] The amino acid sequence of VP1 GII.6_Ohio_E80S+S90L is shown (sequence number 83). [Figure 33F] The nucleic acid sequence of hCod VP1 GII.6_Ohio_E80S+S90L is shown (sequence number 84). [Figure 34A] The amino acid sequence of VP1 GII.12_HS10_E80S is shown (sequence number 88). [Figure 34B] The nucleic acid sequence of hCod VP1 GII.12_HS10_E80S is shown (sequence number 89). [Figure 34C] The amino acid sequence of VP1 GII.12_HS10_A90L is shown (sequence number 90). [Fig. 34D] The nucleic acid sequence of hCod VP1 GII.12_HS10_A90L is shown (sequence number 91). [Figure 34E] The amino acid sequence of VP1 GII.12_HS10_E80S+A90L is shown (sequence number 92). [Fig. 34F] The nucleic acid sequence of hCod VP1 GII.12_HS10_E80S+A90L is shown (sequence number 93). [Figure 34G]The amino acid sequence of VP1 GII.17 Kawa 2014 A0A077KVU6_A39V is shown (sequence number 192). [Fig. 34H] The nucleic acid sequence of VP1 hCod GII.17 Kawa 2014 A0A077KVU6_A39V is shown (sequence number 193). [Fig. 34I] The amino acid sequence of VP1GII.17 Kawa 2014 A0A077KVU6_R53I is shown (sequence number 194). [Fig. 34J] The nucleic acid sequence of VP1 hCod GII.17 Kawa 2014 A0A077KVU6_R53I is shown (sequence number 195). [Figure 34K] The amino acid sequence of VP1GII.17 Kawa 2014 A0A077KVU6_A90L is shown (sequence number 196). [Figure 34L] The nucleic acid sequence of VP1 hCod GII.17 Kawa 2014 A0A077KVU6_A90L is shown (sequence number 197). [Figure 34M] The amino acid sequence of VP1GII.17 Kawa 2014 A0A077KVU6_A39V+M53I is shown (sequence number 198). [Figure 34N] The nucleic acid sequence of VP1 hCod GII.17 Kawa 2014 A0A077KVU6_A39V+M53I is shown (sequence number 199). [Fig. 34O] The amino acid sequence of VP1GII.17 Kawa 2014 A0A077KVU6_E80S+A90L is shown (sequence number 200). [Figure 34P] The nucleic acid sequence of VP1 hCod GII.17 Kawa 2014 A0A077KVU6_E80S+A90L is shown (sequence number 201).
[0067] [Figure 35A] The amino acid sequence of VP2_GI.1_Norwalk is shown (sequence number 99). [Figure 35B] The nucleic acid sequence of human codon-optimized VP.2_GI1_Norwalk is shown (SEQ ID NO: 100).
[0068] [Figure 36A] The amino acid sequence of VP2_GI.3_Lil08 is shown (sequence number 94). [Figure 36B] The nucleic acid sequence of human codon-optimized VP2_GI.3_Lil08 is shown (SEQ ID NO: 95).
[0069] [Figure 37A] The amino acid sequence of VP2_GII.6_HS10 is shown (sequence number 96). [Figure 37B] The nucleic acid sequence of human codon-optimized VP2_GII6_HS10 is shown (SEQ ID NO: 97).
[0070] [Figure 38A] The cloning vector 1190 from the left T-DNA to the right T-DNA is shown (SEQ ID NO: 162). [Figure 38B] Construct 2724 is shown from the 2X35S promoter to the NOS terminator (SEQ ID NO: 163). [Figure 38C] The cloning vector 3677 from the left T-DNA to the right T-DNA is shown (SEQ ID NO: 164). [Figure 38D] Construct 4133 is shown from the 2X35S promoter to the NOS terminator (SEQ ID NO: 165). [Figure 38E] Construct 4135 is shown from the 2X35S promoter to the NOS terminator (SEQ ID NO: 166).
[0071] [Figure 39A] A schematic diagram of construct 2724 (VP1 Wt GI.1 hCod) is shown. [Figure 39B] A schematic diagram of construct 3300 (VP1 Wt GI.2 hCod) is shown. [Figure 39C] A schematic diagram of construct 3979 (VP1 Wt GI.3 hCod) is shown.
[0072] [Figure 40A]A schematic diagram of construct 4140 (VP1 GI.3_Q84S hCod) is shown. [Figure 40B] A schematic diagram of construct 4141 (VP1 GI.3_S94L hCod) is shown. [Figure 40C] A schematic diagram of construct 4142 (VP1 GI.3_P84S+S94L hCod) is shown. [Figure 40D] A schematic diagram of construct 4179 (VP1 GI.3_A43V+S94L hCod) is shown. [Figure 40E] A schematic diagram of construct 4180 (VP1 GI.3_M57I+S94L hCod) is shown. [Diagram 40F] A schematic diagram of construct 4181 (VP1 GI.3_A43V+M57I+S94L hCod) is shown.
[0073] [Figure 41A] A schematic diagram of construct 3980 (VP1 Wt GI.5 hCod (Wt GI.5 hCod) is shown. [Figure 41B] A schematic diagram of construct 4130 (VP1 GI.5_Q84S) is shown. [Figure 41C] A schematic diagram of construct 4131 (VP1 GI.5_A94L hCod) is shown. [Figure 41D] A schematic diagram of construct 4132 (VP1 GI.5_Q84S+A94L hCod) is shown. [Figure 41E] A schematic diagram of construct 4210 (VP1 GI.7_R84S hCod) is shown. [Fig.41F] A schematic diagram of construct 4217 (VP1 GI.7_M57I hCod) is shown. [Figure 41G] A schematic diagram of construct 4218 (VP1 GI.7_M57I+R84S hCod) is shown.
[0074] [Figure 42A] A schematic diagram of construct 3982 (Wt VP1 GII.2 hCod) is shown. [Figure 42B] A schematic diagram of construct 4143 (VP1 GII.2_E80S) is shown. [Figure 42C] A schematic diagram of construct 4144 (VP1 GII.2_A90L hCod) is shown. [Fig.42D] A schematic diagram of construct 4145 (VP1 GII.2_E80S+A90L hCod) is shown. [Figure 42E] A schematic diagram of construct 4182 (VP1 GII.2_A39V+E80S+A90L hCod) is shown. [Fig.42F] A schematic diagram of construct 4183 (VP1 GII.2_R53I+E80S+A90L hCod) is shown. [Fig.42G] A schematic diagram of construct 4184 (VP1 GII.2_A39V+R53I+E80S+A90L hCod) is shown.
[0075] [Figure 43A] A schematic diagram of construct 3983 (Wt VP1 GII.3 hCod) is shown. [Figure 43B] A schematic diagram of construct 4146 (VP1 GII.3_E80S hCod) is shown. [Figure 43C] A schematic diagram of construct 4147 (VP1 GII.3_A90L hCod) is shown. [Fig. 43D] A schematic diagram of construct 4148 (VP1 GII.3_E80S+A90L) is shown.
[0076] [Figure 44A] A schematic diagram of construct 3760 (Wt VP1 GII.4 hCod) is shown. [Figure 44B] A schematic diagram of construct 4155 (VP1 GII.4_A39V hCod) is shown. [Figure 44C] A schematic diagram of construct 4156 (VP1 GII.4_V47P hCod) is shown. [Fig.44D] A schematic diagram of construct 4157 (VP1 GII.4_R53I hCod) is shown. [Figure 44E] A schematic diagram of construct 4133 (VP1 GII.4_P80S hCod) is shown. [Fig.44F]A schematic diagram of construct 4134 (VP1 GII.4_S90L hCod) is shown. [Figure 44G] A schematic diagram of construct 4158 (VP1 GII.4_Δ35-42 hCod) is shown. [Fig.44H] A schematic diagram of construct 4159 (VP1 GII.4_SSTAVATA hCod) is shown. [Fig.44I] A schematic diagram of construct 4165 (VP1 GII.4_A39V+P80S hCod) is shown. [Fig.44J] A schematic diagram of construct 4166 (VP1 GII.4_V47P+P80S hCod) is shown. [Figure 44K] A schematic diagram of construct 4167 (VP1 GII.4_R53I+P80S hCod) is shown. [Figure 44L] A schematic diagram of construct 4135 (VP1 GII.4_P80S+S90L hCod) is shown. [Figure 44M] A schematic diagram of construct 4168 (GII.4_P80S+Δ35-42 hCod) is shown. [Figure 44N] A schematic diagram of construct 4169 (VP1 GII.4_P80S+SSTAVATA hCod) is shown. [Fig.44O] A schematic diagram of construct 4185 (VP1 GII.4_A39V+R53I hCod) is shown. [Figure 44P] A schematic diagram of construct 4186 (VP1 GII.4_A39V+R53I+P80S hCod) is shown.
[0077] [Figure 45A] A schematic diagram of construct 3993 (Wt VP1 GII.6 hCod) is shown. [Figure 45B] A schematic diagram of construct 4149 (VP1 GII.6_E80S hCod) is shown. [Figure 45C] A schematic diagram of construct 4150 (VP1 GII.6_S90L hCod) is shown. [Figure 45D] A schematic diagram of construct 4151 (VP1 GII.6_E80S+S90L) is shown.
[0078] [Figure 46A] A schematic diagram of construct 3995 (Wt VP1 GII.12 hCod) is shown. [Figure 46B] A schematic diagram of construct 4136 (VP1 GII.12_E80S hCod) is shown. [Figure 46C] A schematic diagram of construct 4137 (VP1 GII.12_A90L hCod) is shown. [Figure 46D] A schematic diagram of construct 4138 (VP1 GII.12_E80S+A90L) is shown. [Figure 46E] A schematic diagram of construct 4234 (VP1 GII.17_A39V) is shown. [Figure 46F] A schematic diagram of construct 4235 (VP1 GII.17_R53I) is shown. [Figure 46G] A schematic diagram of construct 4232 (VP1 GII.17_A90L) is shown. [Fig. 46H] A schematic diagram of construct 4236 (VP1 GII.17_A39V+R53I) is shown. [Figure 46I] A schematic diagram of construct 4233 (VP1 GII.17_E80S+A90L) is shown.
[0079] [Figure 47A] A schematic diagram of construct 2725 (Wt VP2 GI.1) is shown. [Figure 47B] A schematic diagram of construct 3303 (Wt VP2 GI.3 hCod) is shown. [Figure 47C] A schematic diagram of construct 3307 (Wt VP2 GII.6) is shown.
[0080] [Figure 48] A schematic diagram of construct 1190 (cloning vector 1190) is shown.
[0081] [Figure 49] A schematic diagram of construct 3677 (cloning vector 3677) is shown.
[0082] [Figure 50A] 4 shows a schematic diagram of a GII.4 P80X construct (cloning vector), where X is selected from A (construct 4281), N (construct 4285), K (construct 4286) or H (construct 4287). [Figure 50B] 4 shows a schematic diagram of the GII.4 P80s+A39X construct (cloning vector), where X is selected from I (construct 4256), M (construct 4257), G (construct 4258), S (construct 4259), E (construct 4260), D (construct 4261), N (construct 4262), Q (construct 4263), construct K (4264) or H (construct 4265).
[0083] [Figure 51] GI.7 A schematic diagram of M57X construct (cloning vector), where X is selected from L (construct 4266), G (construct 4268), S (construct 4269), T (construct 4270), N (construct 4273), Q (construct 4274), K (construct 4275) or H (construct 4276).
[0084] [Figure 52] G.3 Schematic diagram of S94X construct (cloning vector), where X is selected from V (construct 4288), I (construct 4289), M (construct 4290), T (construct 4292), E (construct 4293), D (construct 4294), N (construct 4295), Q (construct 4296), K (construct 4297) or H (construct 4298).
[0085] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0086] A preferred embodiment will now be described.
[0087] As used herein, the terms "comprising," "having," "including," and "containing," as well as grammatical variations thereof, are inclusive or open-ended and do not exclude additional, unrecited elements and / or method steps. The term "consisting essentially of," when used herein in connection with a use or method, means that additional elements and / or method steps may be present, but that these additions do not substantially affect the way in which the described method or use functions. The term "consisting of," when used herein in connection with a use or method, excludes the presence of additional elements and / or method steps. A use or method described herein as including certain elements and / or steps may also, in certain embodiments, consist essentially of those elements and / or steps, and in other embodiments, consist of those elements and / or steps, regardless of whether those embodiments are specifically mentioned. Additionally, the use of the singular includes the plural, and "or" means "and / or" unless otherwise specified. As used herein, the term "plurality" means more than one, e.g., two or more, three or more, four or more, etc. Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. As used herein, the term "about" refers to about ±10% variation from a given value. It should be understood that such variation is always included in any given value provided herein, whether or not it is specifically mentioned. When used herein in conjunction with the term "comprising," the use of the words "a" or "an" can mean "one," but is also consistent with the meaning of "one or more," "at least one," and "one or more."
[0088] As used herein, the terms "plant," "part of a plant," "plant part," "plant matter," "plant biomass," "plant material," "plant extract," or "plant leaf" can include a whole plant, tissue, cell or any fraction thereof, intracellular plant components, extracellular plant components, liquid or solid extracts of a plant, or combinations thereof, which can provide the transcriptional, translational and post-translational machinery for expression of one or more nucleic acids described herein and / or from which expressed proteins or VLPs can be extracted and purified. Plants include, but are not limited to, canola, Brassica spp., maize, Nicotiana spp., (tobacco) e.g., Nicotiana benthamiana, Nicotiana rustica, Nicotiana tabacum, Nicotiana alata, Arabidopsis thaliana, alfalfa, potato, sweet potato (Ipomoea batatus), ginseng, pea, oat, rice, soybean, wheat, barley, sunflower, cotton, corn, rye (Secale cereale), sorghum (Sorghum bicolor, Sorghum vulgare), and the like. In some embodiments, crops may include, for example, olive oil (Olea europaea (Olea europaea)), safflower (Carthamus tinctorius), and safflower (Carthamus vulgare).
[0089] As used herein, the term "plant part" refers to any part of a plant, including, but not limited to, leaves, stems, roots, flowers, fruits; plant cells obtained from leaves, stems, roots, flowers, fruits; plant extracts obtained from leaves, stems, roots, flowers, fruits; or combinations thereof. As used herein, the term "plant extract" refers to a plant-derived product obtained after treating a plant, a plant part, a plant cell, or a combination thereof, physically (e.g., by freezing and then extracting in a suitable buffer), mechanically (e.g., by grinding or homogenizing the plant or plant part and then extracting in a suitable buffer), enzymatically (e.g., using cell wall degrading enzymes), chemically (e.g., using one or more chelating agents or buffers), or a combination thereof. The plant extract may be further processed to remove undesirable plant components, such as cell wall debris. The plant extract may be obtained to aid in the recovery of one or more components from the plant, plant part, or plant cell, such as proteins (including protein complexes, protein superstructures, and / or VLPs), nucleic acids, lipids, carbohydrates, or combinations thereof from the plant, plant part, or plant cell. When the plant extract contains protein, it can be called protein extract.The protein extract can be a crude plant extract, a partially purified plant or protein extract, or a purified product, which contains one or more proteins, protein complexes, protein superstructures, and / or VLPs from plant tissue.If desired, the protein extract or plant extract can be partially purified using techniques known to those skilled in the art, for example, the extract can be subjected to salt precipitation or pH precipitation, centrifugation, gradient density centrifugation, filtration, chromatography, such as size exclusion chromatography, ion exchange chromatography, affinity chromatography, or a combination thereof.The protein extract can be purified using techniques known to those skilled in the art.
[0090] As used herein, the term "nucleic acid segment" refers to a sequence of nucleic acid that encodes a protein of interest. In addition to the sequence of the nucleic acid, the nucleic acid segment includes regulatory regions and terminators operably linked to the sequence of the nucleic acid. The regulatory region may include, for example, a promoter and, optionally, an enhancer element operably linked to the promoter.
[0091] As used herein, the term "nucleic acid complex" refers to a combination of two or more than two nucleic acid segments. Two or more than two nucleic acid segments may be present in a single nucleic acid, whereby the nucleic acid complex comprises two or more nucleic acid segments, each nucleic acid segment being under the control of a regulatory region and a terminator. Alternatively, the nucleic acid complex may comprise two or more separate nucleic acids, each of the nucleic acids comprising one or more nucleic acid segments, each nucleic acid segment being under the control of a regulatory region and a terminator. For example, the nucleic acid complex may comprise one nucleic acid comprising two nucleic acid segments, the nucleic acid complex may comprise two nucleic acids, each nucleic acid comprising one nucleic acid segment, or the nucleic acid complex may comprise two or more nucleic acids, each nucleic acid comprising one or more nucleic acid segments.
[0092] As used herein, the term "vector" or "expression vector" refers to a recombinant nucleic acid for transferring an exogenous nucleic acid sequence into a host cell (e.g., a plant cell) and directing the expression of the exogenous nucleic acid sequence in the host cell. An "expression cassette" refers to a nucleotide sequence that includes a nucleic acid of interest under the control of and operably linked to an appropriate promoter or other regulatory element for transcription of the nucleic acid of interest in the host cell. As will be understood by those skilled in the art, an expression cassette may include a termination (terminator) sequence, which is any sequence active in a plant host. For example, the termination sequence may be derived from the RNA-2 genome segment of a bipartite RNA virus, e.g., a comovirus, the termination sequence may be a NOS terminator, or the terminator sequence may be obtained from the 3'UTR of the alfalfa plastocyanin gene.
[0093] The constructs of the present disclosure may further comprise a 3' untranslated region (UTR). The 3' untranslated region comprises a polyadenylation signal and any other regulatory signals that can affect mRNA processing or gene expression. A polyadenylation signal is usually characterized by the addition of a polyadenylic acid track to the 3' end of a pre-mRNA. A polyadenylation signal is generally recognized by the presence of homology to the canonical form 5'AATAAA-3', although variations are not uncommon. Non-limiting examples of suitable 3' untranslated regions include the 3' transcribed untranslated regions containing the polyadenylation signals of Agrobacterium tumor-inducing (Ti) plasmid genes, e.g., nopaline synthase (Nos gene), and plant genes such as soybean storage protein genes, the small subunit of the ribulose-1,5-bisphosphate carboxylase gene (ssRUBISCO; U.S. Pat. No. 4,962,028, incorporated herein by reference), and promoters used to regulate plastocyanin expression.
[0094] "Regulatory region", "regulatory element" or "promoter" refers to a portion of nucleic acid upstream of the protein coding region of a gene, which may typically, but not always, be composed of either DNA or RNA, or both DNA and RNA. When the regulatory region is active and functionally associated or operably linked to a nucleotide sequence of interest, it may result in expression of the nucleotide sequence of interest. Regulatory elements may mediate organ specificity or control developmental or temporal gene activation. "Regulatory region" includes promoter elements, core promoter elements that exhibit basal promoter activity, elements that mediate promoter activity, such as elements that are inducible in response to external stimuli, negative regulatory elements, or transcriptional enhancers. As used herein, "regulatory region" also includes elements that are post-transcriptionally active, such as regulatory elements that regulate gene expression, such as translational and transcriptional enhancers, translational and transcriptional repressors, upstream activating sequences, and mRNA instability determinants. Some of these latter elements may be located proximal to the coding region.
[0095] In the context of this disclosure, the term "regulatory element" or "regulatory region" typically refers to a sequence of DNA, usually but not always upstream (5') to the coding sequence of a structural gene, which controls the expression of the coding region by providing recognition for RNA polymerase and / or other factors required to initiate transcription at a specific site. However, it should be understood that other nucleotide sequences located within introns or within the 3' of the sequence may also contribute to regulating the expression of a coding region of interest. Examples of regulatory elements that provide recognition for RNA polymerase or other transcription factors to ensure initiation at a specific site include promoter elements. Most, but not all, eukaryotic promoter elements contain a TATA box, a conserved nucleic acid sequence composed of adenosine and thymidine nucleotide base pairs, usually located about 25 base pairs upstream of the transcription start site. Promoter elements can include basal promoter elements involved in the initiation of transcription, as well as other regulatory elements that modify gene expression.
[0096] There are several types of regulatory regions, including developmentally regulated, inducible, or constitutive. Developmentally regulated regulatory regions, or regulatory regions that control differential expression of genes under their control, are activated in a particular organ, or tissue of an organ, at a particular time during the development of that organ or tissue. However, some developmentally regulated regulatory regions may be preferentially active in a particular organ or tissue at a particular developmental stage, and they may be active in a developmentally regulated manner or at a basal level in other organs or tissues in the plant as well. Examples of tissue-specific regulatory regions are, for example, specific regulatory regions including the napin promoter and the cruciferin promoter (Rask et al., 1998, J. Plant Physiol. 152:595-599; Bilodeau et al., 1994, Plant Cell 14:125-130). Examples of leaf-specific promoters include the plastocyanin promoter (see U.S. Pat. No. 7,125,978, incorporated herein by reference).
[0097] An inducible regulatory region is one that can directly or indirectly activate the transcription of one or more DNA sequences or genes in response to an inducer. In the absence of an inducer, the DNA sequence or gene is not transcribed. Typically, the protein factor that specifically binds to the inducible regulatory region to activate transcription may be present in an inactive form and then converted to an active form directly or indirectly by the inducer. However, the protein factor may be absent. The inducer may be a chemical, such as a protein, a metabolite, a growth regulator, a herbicide or a phenolic compound, or a physiological stress imposed directly by heat, low temperature, salt or a toxic element, or indirectly through the action of a pathogen or a disease agent, such as a virus. A plant cell containing an inducible regulatory region may be exposed to an inducer by applying the inducer externally to the cell or plant, such as by spraying, watering, heating or similar methods. Inducible regulatory elements can be derived from either plant genes or non-plant genes (see, for example, C. and Lenk, IRP, 1998, Trends Plant Sci. 3, 352-358). Examples of potential inducible promoters include, but are not limited to, tetracycline-inducible promoters (Gatz, C., 1997, Ann. Rev. Plant Physiol. Plant Mol. Biol. 48, 89-108), steroid-inducible promoters (Aoyama, T. and Chua, NH, 1997, Plant J. 2, 397-404) and ethanol-inducible promoters (Salter, MG, et al, 1998, Plant Journal 16, 127-132; Caddick, MX, et al, 1998, Nature Biotech. 16, 177-180), cytokinin-inducible IB6 and CKI1 genes (Brandstatter, I. and Kieber, JJ, 1998, Plant Cell 10, 1009-1019; Kakimoto, T., 1996, Science 274, 982-985) and the auxin-inducible element, DR5 (Ulmasov, T., et al., 1997, Plant Cell 9, 1963-1971).
[0098] Constitutive regulatory regions direct the expression of genes throughout different parts of the plant and continuously throughout plant development. Examples of known constitutive regulatory elements include the CaMV 35S transcript (p35S; Odell et al., 1985, Nature, 313:810-812; incorporated herein by reference), rice actin 1 (Zhang et al., 1991, Plant Cell, 3:1155-1165), actin 2 (An et al., 1996, Plant J., 10:107-121), or tms2 (U.S. Pat. No. 5,428,147), and triosephosphate isomerase 1 (Xu et al., 1994, Plant Physiol. 106:459-467) genes, maize ubiquitin 1 gene (Cornejo et al., 1993, Plant J. 106:459-467) genes, and the corn ubiquitin 1 gene (Cornejo et al., 1993, Plant J. 106:459-467) genes. Mol. Biol. 29:637-646), the Arabidopsis ubiquitin 1 and 6 genes (Holtorf et al, 1995, Plant Mol. Biol. 29:637-646), the tobacco translation initiation factor 4A gene (Mandel et al, 1995 Plant Mol. Biol. 29:995-1004); the cassava vein mosaic virus promoter, pCAS, (Verdaguer et al., 1996); the promoter of the small subunit of ribulose biphosphate carboxylase, pRbcS: (Outchkourov et al., 2003), and the promoter associated with pUbi (for monocots and dicots).
[0099] As used herein, the term "constitutive" does not necessarily indicate that a nucleotide sequence under the control of a constitutive regulatory region is expressed at the same level in every cell type, but rather indicates that a gene is expressed in a wide range of cell types, although variation in abundance is often observed.
[0100] The expression constructs described above can be present in vectors. The vectors can include border sequences that allow the transfer and integration of the expression cassette into the genome of the organism or host. The constructs can be plant binary vectors, such as binary transformation vectors based on pPZP (Hajdukiewicz, et al. 1994). Other exemplary constructs include pBin19 (see Frisch, DA, LW Harris-Haller, et al. 1995, Plant Molecular Biology 27:405-409).
[0101] As used herein, the terms "native", "natural protein" or "natural domain" refer to a protein or domain that has a primary amino acid sequence identical to the wild type. A native protein or domain can be encoded by a nucleotide sequence that has 100% sequence similarity to the wild type sequence. A native amino acid sequence can also be encoded by a human codon (hCod)-optimized nucleotide sequence or a nucleotide sequence that has an increased GC content when compared to the wild type nucleotide sequence, provided that the amino acid sequence encoded by the hCod-nucleotide sequence exhibits 100% sequence identity with the native amino acid sequence.
[0102] A nucleotide sequence that is a "human codon optimized" or "hCod" nucleotide sequence refers to the selection of appropriate DNA nucleotides for the synthesis of an oligonucleotide sequence or a fragment thereof that approaches a codon usage frequency typically found within oligonucleotide sequences of human nucleotide sequences. "Increased GC content" refers to the selection of appropriate DNA nucleotides for the synthesis of an oligonucleotide sequence or a fragment thereof to approach a codon usage frequency that has an increase in GC content, for example, from about 1% to about 30%, or any amount therebetween, over the length of the coding portion of the oligonucleotide sequence, when compared to the corresponding naturally occurring oligonucleotide sequence. For example, from about 1%, about 2%, about 4%, about 6%, about 8%, about 10%, about 12%, about 14%, about 16%, about 18%, about 20%, about 22%, about 24%, about 26%, about 28%, about 30%, or any amount therebetween, over the length of the coding portion of the oligonucleotide sequence. As described below, human codon-optimized nucleotide sequences, or nucleotide sequences having increased GC content (when compared to the wild-type nucleotide sequence), exhibit increased expression in plants, plant parts, or plant cells when compared to the expression of non-human optimized (or low GC content) nucleotide sequences.
[0103] Described herein are Norovirus VP1 mutant proteins (also referred to as modified VP1 proteins or modified Norovirus VP1 proteins) and methods for producing Norovirus VP1 mutant proteins in plants. Some of the modified Norovirus VP1 proteins contain specific substitutions, modifications or mutations in the S domain of non-GI.1 VP1 to the corresponding amino acids found in the GI.1 S domain. It has been observed that in certain Norovirus genotypes, mutations of specific amino acids to the corresponding amino acids found in GI.1 VP1 result in equivalent or improved VP1 and / or VLP properties compared to wild-type (non-GI.1) VP1 and / or VLP. Examples of improved properties of VP1 and / or VLP include: an increase in VP1 protein yield when expressed in a plant cell compared to the yield of a wild-type VP1 of the same genotype that does not contain the substitution, modification or mutation; an increased density of VLPs comprised of the modified VP1 protein compared to the density of VLPs comprising a wild-type VP1 of the same genotype that does not contain the substitution, modification or mutation (e.g., as determined using density gradient separation, and optionally SDS-PAGE and / or Western analysis); improved integrity, stability, or both integrity and stability, of VLPs comprised of modified VP1 proteins compared to the integrity, stability, or both of VLPs comprising a wild-type VP1 of the same genotype that does not contain the substitution, modification, or mutation; an increase in VLP yield when expressed in a plant cell compared to wild-type levels of VLP production of the same genotype not containing the substitution, modification or mutation; improved accumulation of VLPs comprised of the modified VP1 protein compared to the accumulation of VLPs comprising a wild-type VP1 of the same genotype that does not contain the substitution, modification or mutation; an increased proportion of VLPs that assemble into 38 nm VLPs as opposed to 23 nm VLPs, as compared to a wild-type VP1 of the same genotype that does not contain any substitutions, modifications or mutations; and -Combinations of these are possible.
[0104] For example, modified Norovirus VP1 proteins and methods of producing modified Norovirus VP1 proteins can include nucleotide sequences encoding VP1 proteins containing S domain substitutions, mutations or modifications at any one or more of amino acids 43, 57, 84, and 94 within the aligned sequences of Norovirus VP1 genotype GI.1 (SEQ ID NO:1; see FIG. 2C), or deletions of the peptide fragment from amino acids 39 to 46 within the aligned sequences of Norovirus VP1 genotype GI.1 (SEQ ID NO:1), or combinations thereof. Sequences encoding Norovirus VP1 mutant proteins can be optimized for human codon usage, increased GC content, or combinations thereof.
[0105] With reference to the sequences shown in FIG. 2C, the norovirus GI.1 sequence (SEQ ID NO:1) is used as a reference sequence to which other norovirus VP1 sequences may be aligned. In the "GII" family of VP1 proteins, the VP1 amino acid sequence contains a deletion of four amino acids compared to the GI.1 sequence, a deletion of three amino acids at positions 14-16, and a deletion of one amino acid at position 26. As a result, the alignment between the GII VP1 sequence and the GI VP1 sequence is offset by three amino acids after amino acid 13 and four amino acids after position 26. For example, amino acid 84 of GI.1 aligns with amino acid 80 of GII.4 (see FIG. 2C). Thus, reference to substitutions, modifications, or mutations at positions 84 (GI.1) and 80 (GII.4) refers to the same aligned amino acid. Strain Amino Acid Alignment GI: 39~46 43 57 84 94 GII:35~42 39 53 80 90
[0106] Also provided herein is a method for increasing the production of VLPs comprising modified Norovirus VP1 proteins in a plant. For example, the method may include introducing a nucleic acid encoding a Norovirus VP1 mutant protein into a plant, a plant part, or a plant cell as described herein. One or more Norovirus mutant proteins may be expressed in a plant, a plant part, or a plant cell to produce a VLP comprising one or more modified Norovirus proteins. Alternatively, the method may include providing a plant, a plant part, or a plant cell comprising a nucleic acid encoding a modified Norovirus VP1 protein as described herein, and expressing the nucleic acid encoding the modified Norovirus VP1 protein to produce a VLP comprising one or more modified Norovirus proteins.
[0107] The method of producing a VLP comprising a VP1 variant protein can also include co-expressing in the plant, plant part, or plant cell a nucleic acid sequence encoding a VP2 protein.
[0108] As used herein, the term "single construct" or "single constructs" refers to a nucleic acid vector comprising a single nucleic acid sequence. As used herein, the term "dual construct" or "dual constructs" refers to a nucleic acid vector comprising two nucleic acid sequences.
[0109] Co-expression refers to the introduction and expression of two or more nucleotide sequences, each of which encodes a protein of interest or a fragment of a protein of interest in a plant, part of a plant, or a plant cell. Two or more nucleotide sequences can be introduced into a plant, part of a plant, or a plant cell in one vector (e.g., comprising a dual construct) such that each of the two or more nucleotide sequences is under the control of a separate regulatory region. Alternatively, two or more nucleotide sequences can be introduced into a plant, part of a plant, or a plant cell in separate vectors (e.g., comprising a single construct), each vector comprising the appropriate regulatory region for expression of the corresponding nucleic acid. For example, two nucleotide sequences, each on a separate vector and introduced into separate Agrobacterium tumefaciens hosts, can be co-expressed by mixing suspensions of each A. tumefaciens host in a desired volume (e.g., equal volumes, or the ratio of each A. tumefaciens host can be varied) prior to vacuum infiltration. In this manner, co-infiltration of multiple A. tumefaciens suspensions allows for co-expression of multiple transgenes.
[0110] The nucleic acid comprising encoding a Norovirus VP1 mutant protein described herein may further comprise a sequence that enhances the expression of the Norovirus VP1 mutant protein in a plant, a part of a plant, or a plant cell. The sequence that enhances expression may include a CPMV enhancer element or a plant-derived expression enhancer that is functionally associated with the nucleic acid encoding the Norovirus VP1 mutant protein. The sequence encoding the VP1 mutant protein may also be optimized for human codon usage, increased GC content, or a combination thereof. Additionally, a nucleic acid encoding VP2 may be co-expressed with a sequence encoding the VP1 mutant protein. Co-expression of a nucleic acid encoding VP2 may result in increased yield, increased density, increased integrity, or a combination thereof, of VLPs comprising one or more types of VP1 mutant proteins.
[0111] As used herein, the term "CPMV enhancer element" refers to a nucleotide sequence encoding a 5'UTR that regulates a cowpea mosaic virus (CPMV) RNA2 polypeptide or modified CPMV sequence known in the art. For example, a CPMV enhancer element or CPMV expression enhancer includes the nucleotide sequences described in WO 2015 / 14367, WO 2015 / 103704, WO 2007 / 135480, WO 2009 / 087391, Sainsbury F., and Lomonossoff GP, (2008, Plant Physiol. 148: pp. 1212-1218), each of which is incorporated herein by reference. CPMV enhancer sequences can enhance the expression of downstream heterologous open reading frames (ORFs) to which they are connected. CPMV expression enhancers can include CPMV HT, CPMVX (X=160, 155, 150, 114), e.g., CPMV 160, CPMVX+ (X=160, 155, 150, 114), e.g., CPMV 160+, CPMV-HT+, CPMV HT+[WT115], or CPMV HT+
[0511] (WO 2015 / 143567, WO 2015 / 103704, which are incorporated herein by reference). CPMV expression enhancers can be used in plant expression systems that include a regulatory region operably linked to a CPMV expression enhancer sequence and a nucleotide sequence of interest. The term "5'UTR" or "5' untranslated region" or "5' leader sequence" refers to a region of an mRNA that is not translated. A 5'UTR typically begins at the transcription initiation site and ends immediately before the translation initiation site or start codon of the coding region. The 5'UTR may regulate the stability and / or translation of the mRNA transcript.
[0112] As used herein, the term "expression enhancer derived from a plant" refers to a nucleotide sequence derived from a plant, the nucleotide sequence encoding the 5'UTR. Examples of expression enhancers derived from plants are described in US Provisional Patent Application No. 62 / 643,053 (filed March 14, 2018; incorporated herein by reference) or Diamos AGet. al. (2016, Front Plt Sci. 7:1-15; incorporated herein by reference). Expression enhancers derived from plants can be selected from nbMT78, nbATL75, nbDJ46, nbCHP79, nbEN42, atHSP69, atGRP62, atPK65, atRP46, nb30S72, nbGT61, nbPV55, nbPPI43, nbPM64 (SEQ ID NO: 14), and nbH2A86 described in US Patent No. 62 / 643,053. Plant-derived expression enhancers can be used in plant expression systems comprising a plant-derived expression enhancer sequence and a regulatory region operably linked to a nucleotide sequence of interest.
[0113] The term "5'UTR" or "5' untranslated region" or "5' leader sequence" refers to a region of an mRNA that is not translated. The 5'UTR typically begins at the transcription start site and ends immediately before the translation start site or start codon of the coding region. The 5'UTR may regulate the stability and / or translation of the mRNA transcript.
[0114] "Operably linked" means that particular sequences interact, either directly or indirectly, to perform their intended function, such as mediating or regulating the expression of a nucleic acid sequence. The interaction of operably linked sequences can be mediated, for example, by proteins that interact with the operably linked sequences.
[0115] When one or more types of modified Norovirus VP1 proteins are expressed in a plant, plant part, or plant cell, the one or more modified VP1 proteins autoassemble into a VLP. The plant, or plant part, may be harvested under suitable extraction and purification conditions to maintain the integrity of the VLP, and the VLPs containing one or more types of VP1 mutant (modified) proteins may be purified. One or more VP1 mutant proteins may also be co-expressed with a nucleotide sequence encoding VP2, such that the VLPs may contain both modified VP1 and VP2 proteins. The present disclosure also provides for the production of one or more types of VP1 mutant proteins described herein in a plant, plant part, or plant cell, as well as the extraction and purification of one or more types of VP1 mutant proteins from a plant, plant part, or plant cell to produce a plant material, plant extract, or protein extract that contains a modified (mutant) VP1 protein.
[0116] Also provided is a plant material, plant extract, or protein extract comprising a Norovirus VP1 mutant protein as described herein. The plant material, plant extract, or protein extract may be used to induce immunity in a subject against Norovirus infection. Alternatively, the VP1 mutant protein, or VLPs comprising the VP1 mutant protein (and optionally VP2) may be purified or partially purified, and the purified or partially purified preparations may be used to induce immunity in a subject against Norovirus infection.
[0117] The present disclosure also provides compositions comprising an effective dose of one or more types of modified Norovirus VP1 proteins, or VLPs comprising one or more modified Norovirus VP1 proteins and, optionally, VP2, and a pharma- ceutically acceptable carrier, adjuvant, vehicle or excipient to induce an immune response.
[0118] Also provided herein is a method for inducing immunity to Norovirus infection in a subject, the method comprising orally, intranasally, intramuscularly, intraperitoneally, intravenously, subcutaneously, rectally or intravaginally administering to the subject one or more types of mutant (modified) Norovirus VP1 proteins, or VLPs containing one or more types of Norovirus VP1 mutant proteins.
[0119] As used herein, the term "Norovirus" refers to non-enveloped virus strains of the Norovirus genus of the Caliciviridae family, characterized by having a single-stranded positive-sense RNA. The Norovirus genome is 7,654 nucleotides in length. ORF1 encodes a nonstructural polyprotein that is cleaved by the viral 3C-like protease into six proteins, including the RNA-dependent RNA polymerase. ORF2 and ORF3 encode the major capsid protein (VP1) and minor capsid protein (VP2), respectively (see FIG. 1A).
[0120] Norovirus strains disclosed herein include any known Norovirus strain, but also include modifications to known Norovirus strains that are known to occur periodically over time. For example, Norovirus strains include, but are not limited to, Hu / GI.1 / United States / Norwalk / 1968 (GI.1; SEQ ID NO:1; FIG. 12A), Hu / GI.2 / Leuven / 2003 / BEL (GI.2; SEQ ID NO:4; FIG. 13A), Hu / GI.3 / S29 / 2008 / Lilla (GI.3; SEQ ID NO:1; FIG. 13B), Hu / GI.4 / S29 / 2008 / Lilla (GI.4; SEQ ID NO:1; FIG. 13C), Hu / GI.5 / S29 / 2008 / Lilla (GI.5; SEQ ID NO:2; FIG. 13D), Hu / GI.6 / S29 / 2008 / Lilla (GI.6; SEQ ID NO:3; FIG. 13E), Hu / GI.7 / S29 / 2008 / Lilla (GI.7; SEQ ID NO:4; FIG. 13F), Hu / GI.8 / S29 / 2008 / Lilla (GI.7; SEQ ID NO:1; FIG. 13G), Hu / GI.9 / S29 / 2008 / Lilla (GI.8; SEQ ID NO:1; FIG. 13H), Hu / GI.10 / S29 / 2008 / Lilla (GI.8; SEQ ID NO:1; FIG. 13I), Hu / GI.11 / S29 / 2008 / Lilla (GI.8; SEQ ID NO:1; FIG. 13I), Hu / GI.12 / S29 / 2008 / Lilla (GI.8; SEQ ID NO:1; FIG. 13I), Hu / GI.13 / S29 / 2008 / Lilla (GI.8; S Edet / Sweden (GI.3; SEQ ID NO: 6; Fig. 14A), Hu / GI.5 / Siklos / Hun5407 / 2013 / HUN (GI.5; SEQ ID NO: 12; Fig. 15A), Hu / GI.7 / USA / 2014 / GA5043 (GI.7; SEQ ID NO: 101; Fig. 16A), Hu / GII.1 / Ascension208 / 2010 / USA (GII.1; SEQ ID NO: 13; Fig. 16B), Hu / GII.2 / CGMH47 / 201 1 / TW (GII.2; SEQ ID NO: 14; Fig. 17A), Hu / GII.3 / Jingzhou / 2013402 / CHN (GII.3; SEQ ID NO: 15; Fig. 18A), Hu / GII.4 / Sydney / NSW0514 / 2012 / AU (GII.4; SEQ ID NO: 16; Fig. 19A), US96 / GII.4 / Dresden174 / 1997 / DE_AY741811 (SEQ ID NO: 27; Fig. 19C), FH02 / GII.4 / Farm ngtonHills / 2002 / US_AY502023 (SEQ ID NO:28; Figure 19D), Hnt04:GII.4 / Hunter-NSW504D / 2004 / AU_DQ078814 (SEQ ID NO:29; Figure 19E), 2006b:GII.4 / Shellharbour-NSW696T / 2006 / AU_EF684915 (SEQ ID NO:30; Figure 19F), NO09:GII.4 / Orange-NSW001P / 2008 / AU_GQ845367 (sequence number 31; Figure 19G), Hu / GII.5 / AlbertaEI390 / 2013 / CA (GII.5; sequence number 17; Figure 20), Hu / GII.6 / Ohio / 490 / 2012 / USA (GII.6; sequence number 20; Figure 21A), GII.7 / Musa / 2010 / All73774 (GII.7; sequence number 18; Figure 22), Hu / GII.12 / HS206 / 2010 / USA (GII.23A), GII.13 / VA173 / 2010 / H9AWU4 (GII.13; SEQ ID NO:22; FIG. 24A), GII.14_Saga_2008_JPN_ADE28701 native VP1 (GII.14; SEQ ID NO:32; FIG. 25), Hu / GII.17 / Kawasaki323 / 2014 / JP (GII.17; SEQ ID NO:24; FIG. 26A), and Hu / GII.21 / Salisbury150 / 2011 / USA (GII.21; SEQ ID NO:26; FIG. 27). Norovirus strains are known to mutate easily from year to year. Thus, Norovirus strains also include strains that have about 30% to about 100% amino acid sequence identity, or any amount therebetween, to the VP1 protein, VP2 protein, or both the VP1 protein and VP2 protein with any of the above Norovirus strains, strains listed above and in Figures 2A and 2B, provided that the VP1 protein can be expressed (i.e., produced) in a plant and that the VP1 protein induces immunity to Norovirus in a subject when the VP1 protein is administered to a subject. For example, Norovirus strains also include strains that have about 30%, 32%, 34% amino acid sequence identity, or any amount therebetween, to the VP1 protein, VP2 protein, or both the VP1 protein and VP2 protein with any of the above Norovirus strains, strains listed above and in Figures 2A and 2B, provided that the VP1 protein can be expressed (i.e., produced) in a plant and that the VP1 protein induces immunity to Norovirus in a subject when the VP1 protein is administered to a subject. , 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 100%, or any amount of amino acid sequence identity (sequence similarity, percent identity, percent similarity) therebetween. An amino acid sequence identity comparison between the S domains of the VP1 protein of several Norovirus strains, which should not be considered limiting, is shown in FIG. 2C.
[0121] When referring to particular sequences, the terms "percent similarity," "sequence similarity," "percent identity," or "sequence identity" are used, for example, as described in the University of Wisconsin GCG software program, or by manual alignment and visual inspection (see, for example, Current Protocols in Molecular Biology, Ausubel et al., eds. 1995 supplement). Methods for aligning sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be carried out, for example, using the algorithm of Smith & Waterman, (1981, Adv. Appl. Math. 2:482), by the alignment algorithm of Needleman & Wunsch, (1970, J. Mol. Biol. 48:443), by the search for similarity method of Pearson & Lipman, (1988, Proc. Natl Acad. Sci. USA 85:2444), or by computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.).
[0122] Examples of algorithms suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms described in Altschul et al., (1977, Nuc. Acids Res. 25:3389-3402) and Altschul et al., (1990, J. Mol. Biol. 215:403-410), respectively. BLAST and BLAST 2.0 are used to determine percent sequence identity of the nucleic acids and proteins of the invention with the parameters described herein. For example, the BLASTN program (for nucleotide sequences) may use as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. The BLASTP program may use as defaults a word length of 3, and an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, 1989, Proc. Natl Acad. Sci. USA 89:10915) alignment (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands, for amino acid sequences. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (see URL: ncbi.nlm.nih.gov / ).
[0123] As used herein, the term "VP1" refers to a Norovirus major capsid protein or polypeptide that contains an amino acid sequence similar to the protein or polypeptide encoded by ORF2 of one or more strains of Norovirus described herein. The major capsid protein folds into two major domains, the shell (S) domain and the protruding (P) domain (see FIG. 1B). The VP1 protein forms a dimer (FIG. 1C) when assembled into a virus-like particle, i.e., a VLP. The first part of the N-terminus of VP1 constitutes the S domain, and the remainder of the VP1 polypeptide constitutes the P domain. For example, in GI.1, the first 225 amino acids of the N-terminal VP1 protein constitute the S domain. When folded, VP1 adopts a conformation composed of a globular S domain (bottom of the ribbon structure) and a P domain (top of the ribbon structure) as shown in FIG. 1B.
[0124] As shown in Figure 1C, VP1 proteins dimerize through P domain interactions. These interactions stabilize the spontaneous assembly of norovirus capsid molecules.
[0125] Described herein is a method for producing Norovirus VP1 protein or modified Norovirus VP1 protein in a plant, plant part, or plant cell, comprising introducing a recombinant polynucleotide encoding Norovirus VP1 protein or modified VP1 protein, and incubating the plant, plant part, or plant cell under conditions that allow expression of Norovirus VP1 protein or modified Norovirus protein. However, it should be understood that Norovirus VP1 protein can be obtained from Norovirus VLPs containing VP1 protein, as described in Ausar et al. (Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR, 2006, J.Biol.Chem.281:19478-19488). For example, Norovirus VLPs containing Norovirus protein or modified Norovirus protein can dissociate into VP1 protein components at pH 8 or higher or at temperatures above 55°C, thereby producing VP1 protein.
[0126] As used herein, the terms "virus like particle," "VLP," "virus like particles," or "VLPs" refer to Norovirus-like particles that contain one or more types of Norovirus VP1 proteins, one or more types of VP1 mutant proteins, or combinations thereof, and that self-assemble into a non-replicating, non-enveloped, non-infectious viral capsid structure that lacks any portion of the Norovirus genome. For example, a VLP can contain one type of modified VP1 protein described herein, or a VLP can contain two or more different modified VP1 proteins described herein. Additionally, a VLP can contain a VP2 protein. VLPs comprising VP1 protein, VP1+VP2 protein, modified VP1 protein, or modified VP1 protein+VP2 protein are about 15 nm to about 50 nm in size or any amount therebetween, for example, 15 nm, 16 nm, 17 nm, 18 nm, 19 nm, 20 nm, 21 nm, 22 nm, 23 nm, 24 nm, 25 nm, 26 nm, 27 nm, 28 nm, 29 nm, 30 nm, 31 nm, 32 nm, 33 nm, 34 nm, 35 nm, 36 nm, 37 nm, 38 nm, 39 nm, 40 nm, 41 nm, 42 nm, 43 nm, 44 nm, 45 nm, 46 nm, 47 nm, 48 nm, 49 nm, 50 nm, or any amount therebetween. For example, for T=1 icosahedral symmetry, the VLP can be about 23 nm, or for T=3 icosahedral symmetry, the VLP can be about 38 nm to about 40 nm.
[0127] As shown in the electron micrographs in Figures 3B, 4B, 5C, 5E, 6C, 6E, 7C, 8B, 9B, 9C, 9D, 9G, 10B, 11C and 11D, the plants produced VP1 proteins and modified VP1 proteins derived from several norovirus strains that self-assembled into VLPs.
[0128] Production of norovirus VP1 protein in plants The VP1 protein was selected from the group consisting of norovirus GI.1 (SEQ ID NO: 1; FIG. 12A), GI.2 (SEQ ID NO: 4; FIG. 13A), GI.3 (SEQ ID NO: 6; FIG. 14A), GI.5 (SEQ ID NO: 12; FIG. 15A), and Hu / GI.7 / USA / 2014 / GA5043 (GI.7; SEQ ID NO: 101; FIG. 16A), provided that the VP1 protein is expressed in the plant and induces immunity to norovirus in a subject when administered to the subject. A), GII.1 (SEQ ID NO: 13; FIG. 16B), GII.2 (SEQ ID NO: 14; FIG. 17A), GII.3 (SEQ ID NO: 15; FIG. 18A), GII.4 / Sydney (SEQ ID NO: 16; FIG. 19A), GII.4 / Dresden (SEQ ID NO: 27; FIG. 19C), GII.4 / FarmingtonHills (SEQ ID NO: 28; FIG. 19D), GII.4 / Hunter (SEQ ID NO: 29; FIG. 19E), GII.4 / Shellharb our (SEQ ID NO: 30; Figure 19F), GII.4 / Orange (SEQ ID NO: 31; Figure 19G), GII.5 (SEQ ID NO: 17; Figure 20), GII.6 (SEQ ID NO: 20; Figure 21A), GII.7 (SEQ ID NO: 18; Figure 22), GII.12 (SEQ ID NO: 19; Figure 23A), GII.13 (SEQ ID NO: 22; Figure 24A), GII.14 / Saga (SEQ ID NO: 32; Figure 25), GII.17 (SEQ ID NO: 24; Figure 26A), GII.21 ( The present invention also includes any VP1 protein comprising an amino acid sequence having about 30 to about 100%, about 40 to about 100%, about 50 to about 100%, about 60 to about 100%, about 70 to about 100%, about 80 to about 100%, about 85 to about 100%, about 90 to about 100%, or about 95 to about 100%, about 98 to about 100%, or any amount of sequence identity (which may also be referred to as sequence similarity) with the VP1 amino acid sequence derived from SEQ ID NO:26; Figure 27.
[0129] The VP1 proteins described herein are modified and include substitutions, modifications or mutations of the S domain at any one or more of amino acids 43, 57, 84 and 94 in the aligned sequences of Norovirus VP1 genotype GI.1 (SEQ ID NO:1; see FIG. 2C), or deletions of the peptide fragment from amino acids 39 to 46 in the aligned sequences of Norovirus VP1 genotype GI.1 (SEQ ID NO:1), or combinations thereof. The nucleotide sequence encoding the modified Norovirus VP1 protein may be optimized for human codon usage, increased GC content, or combinations thereof. The modified VP1 protein may be expressed in a plant, a part of a plant, or a plant cell.
[0130] As shown in Figure 2C, the primary amino acid sequence of the norovirus VP1 S domain is well conserved compared to the hypervariable P domain. For example, the VP1 S domain sequences of the norovirus strains shown in Figure 2C have sequences that are 55.2-98.9% identical to the S domain of GI.1 VP1. For example, the nucleic acid sequences described herein can exhibit about 55% to about 99% sequence identity, or any amount therebetween, to the S domain of GI.1 VP1. For example, the nucleic acid sequences described herein can exhibit about 55%, about 56%, about 58%, about 60%, about 62%, about 64%, about 66%, about 68%, about 70%, about 72%, about 74%, about 76%, about 78%, about 80%, about 82%, about 84%, about 86%, about 88%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or any amount of sequence identity therebetween to the S domain of GI.1 VP1.
[0131] As previously shown in U.S. Provisional Patent Application No. 62 / 475,660 (filed March 23, 2017; incorporated herein by reference) and PCT / CA2018 / 050352 (filed March 23, 2018; incorporated herein by reference), wild-type (also referred to as native) Norovirus VP1 protein can be produced in plants and VLPs comprise the produced VP1 protein. VP1 and VP2 nucleic acid sequences were introduced into separate vectors ("VP1+VP2"; dual constructs) or into the same vector ("VP1 / VP2" or "VP1 / VP2 / 3'UTR"; single nucleic acid constructs) to allow for co-expression of VP1 and / or VP2 sequences by vacuum infiltration of leaves (from N. benthamiana) with Agrobacterium tumefaciens containing expression vectors encoding GI.1 VP1 as a single nucleic acid construct, GI.1 VP2 as a single nucleic acid construct, or both GI.1 VP1 and VP2, and leaves were examined for VP1 and / or VP2 production. Six or nine days after infiltration (6 and 9 DPI, respectively), total crude protein extracts were prepared from leaf homogenates, separated by SDS-PAGE, and stained with Coomassie Brilliant Blue dye. Leaves infiltrated with an expression vector containing a nucleotide sequence corresponding to the wild-type GI.1 ORF2 encoding the VP1 protein produced low or undetectable levels of GI.1 VP1 as determined using Coomassie stained gels. In contrast, leaves infiltrated with an expression vector containing a GI.1 VP1 nucleotide sequence that is codon-optimized for human expression (hCod) or that is GC-rich as compared to the GC content of the wild-type VP1 nucleic acid sequence produced increased amounts of GI.1 VP1 protein in Coomassie stained gels, indicating that VP1 can be expressed by itself to produce hCod GI.1 VP1 in plants.
[0132] Additionally, as described in U.S. Provisional Patent Application Nos. 62 / 475,660 and PCT / CA2018 / 050352 (filed March 23, 2017 and March 23, 2018, respectively, both incorporated herein by reference), leaves infiltrated with vectors containing either wild-type GI1 VP1 and VP2, or human codon-optimized GI1 VP1 and VP2, produced low levels of GI1 VP1 protein in Coomassie stained gels, suggesting that the presence of VP2 did not enhance expression of VP1 when co-expressed in cis on the same vector (with one promoter controlling expression) using the same configuration found in the viral genome. However, increased VP1 protein was observed when VP1 or human codon-optimized VP1 was co-expressed in trans (in separate constructs) with VP2 or hCod VP2, respectively (hCod VP1+VP2). Each of the VP1 and VP2 nucleic acid segments contained a regulatory region and a terminator, and the constructs were introduced into plants as nucleic acid complexes, which resulted in a corresponding increase in VP1 protein yield.
[0133] This observation is in contrast to that observed in insect and mammalian cells, where it has been reported that increased VP1 expression was observed only when VP1 and VP2 (or VP1+VP2+3'UTR) were co-expressed in cis and under the control of one promoter and terminator using the same configuration as found in the viral genome (Bertolotti-Ciarlet A., Crawford SE, Hutson AM, Estes MK 2003, J. Virol. 77:11603-11615). According to Bertolotti-Ciarlet (2003), no increased VP1 expression was observed in insect or mammalian cells when VP1 and VP2 were co-expressed in trans.
[0134] As described in more detail below, when expressing a modified VP1 protein in a plant, as described herein, it is preferred that the ORF3 sequence encoding VP2 is obtained from the same Norovirus genotype and strain as that used to obtain the modified VP1 sequence. In the examples provided herein, unless otherwise specified, the modified VP1 and VP2 proteins are obtained from the same Norovirus genotype and strain, and the nucleotide sequences encoding the modified VP1 and VP2 proteins are co-expressed in plants using separate expression systems, e.g., on separate plasmids, or VP1 and VP2 can be expressed on the same vector, but each of the VP1 and VP2 encoding sequences should be under the control of separate promoter and terminator sequences, such that they have separate expression systems.
[0135] In plants, the yield or extractable amount of norovirus VP1 protein and the production of VLPs containing norovirus VP1 protein vary depending on the genotype of norovirus VP1 expressed. For example, as shown in Figure 3A, expression of wild-type GI.1 VP1, GI.5 VP1 and GII.12 VP1 was robust and the protein yield was good (determined using SDS PAGE). In addition, high density wild-type GI.1 VLPs, most with well-formed capsids of 38 nm in diameter, were also produced (Figure 3B), and high density VLPs were produced from plants expressing wild-type GI.5 VLPs, GII.12 VLPs (Figure 3C) and GI.2 VLPs, (Figure 4A). In contrast, wild-type GII.4 VP1 was barely expressed in plants (Fig. 3A right panel), and low yields or undetectable amounts of VP1 protein (using SDS-PAGE) were observed following expression of other wild-type VP1 proteins in plants, e.g., GII.2 VP1, GII.3 VP1, and GII.6 VP1 (Table 5, Example 3).
[0136] Furthermore, expression of the native VP1 protein in plants can result in VLPs that are characterized by a higher proportion of 23 nm VLPs than 38 nm VLPs. For example, expression of wild-type GI.3 VP1 results in the production of a significant number of 23 nm VLPs (see FIG. 5C, left panel). Also, an increasing proportion of 23 nm VLPs results in VLPs that are characterized by low density by density gradient centrifugation (see FIG. 5B, left panel).
[0137] The present disclosure provides a nucleic acid sequence encoding a modified Norovirus VP1 protein, the modified Norovirus VP1 comprising one or more substitutions, modifications or mutations in amino acids selected from the group consisting of amino acids 43, 57, 84 and 94 in a sequence aligned with Norovirus VP1 genotype GI.1 (SEQ ID NO:1), or a deletion of a peptide fragment in a sequence aligned with amino acids 39 to 46 of Norovirus genotype VP1 GI.1 (SEQ ID NO:1), or a combination thereof. Plants expressing a nucleic acid sequence encoding a modified norovirus VP1 protein and including one or more substitutions, modifications or mutations in amino acids selected from the group consisting of amino acids 43, 57, 84 and 94 in a sequence aligned with norovirus VP1 genotype GI.1, or a deletion of the peptide fragment from amino acids 39 to 46 in a sequence aligned with norovirus genotype VP1 GI.1, or a combination thereof, exhibit comparable or improved VP1 and / or VLP properties compared to wild-type VP1 and / or VLP that do not contain the one or more substitutions, modifications or mutations.
[0138] Examples of improved properties of modified VP1 and / or VLPs include the following: an increase in the yield of the modified VP1 protein when expressed in a plant cell compared to a wild-type VP1 that does not contain one or more substitutions, modifications, or mutations (e.g., as determined using Coomassie-stained SDS-PAGE and Western analysis). For example, the increase in yield of the modified VP1 protein can range from 1.5 to 50-fold over the corresponding wild-type VP1 yield, or any amount therebetween; an increased density of VLPs comprising the modified VP1 protein as compared to density gradient separation of wild-type VP1 not comprising one or more substitutions, modifications or mutations, as determined, for example, using iodixanol density gradient separation of a protein extract, e.g., VLPs comprising the modified VP1 protein are observed in the same or a denser fraction following density gradient centrifugation; Improved integrity of VLPs comprised of modified VP1 proteins compared to wild-type VP1 that does not contain one or more substitutions, modifications or mutations. For example, the number of disrupted or partially assembled VLPs can be determined using TEM; an increase in VLP yield when expressed in plant cells compared to wild-type levels of VLP production of the same genotype not containing the substitution, modification or mutation. VLP yield may be determined on washed samples obtained from VLP-containing fractions after density gradient centrifugation using a TEM. For example, the increase in yield of VLPs containing a modified VP1 protein may range from 1.5-20 fold over the corresponding yield of VLPs containing a wild-type VP1 protein, or any amount therebetween; improved accumulation of VLPs comprised of the modified VP1 protein compared to the accumulation of VLPs containing a wild-type VP1 of the same genotype that does not contain the substitution, modification or mutation; · an increased proportion of VLPs that assemble into 38 nm VLPs as opposed to 23 nm VLPs, compared to VLPs containing a wild-type VP1 that does not contain one or more substitutions, modifications or mutations (as determined using TEM); · The combination of these improved properties.
[0139] Without wishing to be bound by theory, VLPs observed in the high density fraction after density gradient centrifugation, compared to wild-type norovirus VLPs, indicate that the assembly of VLPs containing native VP1 may be less stable when expressed in plants and extracted from plants than VLPs containing modified VP1 proteins. Thus, native VLPs may be more susceptible to the generation of abnormal capsid particles and fragmentation products. As a result, VLPs containing modified VP1 proteins, characterized by increased density, may also exhibit higher structural integrity than VLPs produced using the corresponding wild-type VP1.
[0140] The nucleic acid sequences described herein can exhibit about 50% to about 99% sequence similarity to any of the nucleic acid sequences encoding VP1 identified above and listed in Figures 2A-C, excluding GI. For example, the nucleic acid sequences described herein can be used to identify any of the nucleic acid sequences encoding VP1, e.g., Hu / GI.2 / Leuven / 2003 / BEL (GI.2; SEQ ID NO: 4; Figure 12A), Hu / GI.3 / S29 / 2008 / Lilla (GI.3; SEQ ID NO: 4; Figure 12B), Hu / GI.4 / S29 / 2008 / Lilla (GI.4; SEQ ID NO: 4; Figure 12C), Hu / GI.5 / S29 / 2008 / Lilla (GI.5; SEQ ID NO: 5; Figure 12D), Hu / GI.6 / S29 / 2008 / Lilla (GI.6; SEQ ID NO: 5; Figure 12E), Hu / GI.7 / S29 / 2008 / Lilla (GI.7; SEQ ID NO: 5; Figure 12F), Hu / GI.8 / S29 / 2008 / Lilla (GI.7; SEQ ID NO: 5; Figure 12F), Hu / GI.9 / S29 / 2008 / Lilla (GI.9; SEQ ID NO: 5; Figure 12F), Hu / GI.10 / S29 / 2008 / Lilla (GI.9; SEQ ID NO: 5; Figure 12F), Hu / GI.11 / S29 / 2008 / Lilla (GI.9; SEQ ID NO: 5; Figure 12F), Hu / GI.12 / S29 / 2008 / Lilla (GI.9; SEQ ID NO: 5; Figure 12F), Hu / GI.13 / S29 / 2008 / Lilla (GI.9; SEQ ID NO: 5; Edet / Sweden (GI.3; SEQ ID NO: 6; Figure 14A), Hu / GI.5 / Siklos / Hun5407 / 2013 / HUN (GI.5; SEQ ID NO: 12; Figure 15A), Hu / GI.7 / USA / 2014 / GA5043 (GI.7; SEQ ID NO: 101; Figure 16A), Hu / GII.1 / Ascension208 / 2010 / USA (GII.1; SEQ ID NO: 13; Figure 16B), Hu / GII.2 / CGMH47 / 2011 / T W (SEQ ID NO: 14; Figure 17A), Hu / GII.3 / Jingzhou / 2013402 / CHN (GII.3; SEQ ID NO: 15; Figure 18A), Hu / GII.4 / Sydney / NSW0514 / 2012 / AU (GII.4; SEQ ID NO: 16; Figure 19A), US96 / GII.4 / Dresden174 / 1997 / DE_AY741811 (SEQ ID NO: 27; Figure 19C), FH02 / GII.4 / FarmingtonHills / 2 19D), Hnt04:GII.4 / Hunter-NSW504D / 2004 / AU_DQ078814 (SEQ ID NO:29; FIG. 19E), 2006b:GII.4 / Shellharbour-NSW696T / 2006 / AU_EF684915 (SEQ ID NO:30; FIG. 19F), NO09:GII.4 / Orange-NSW001P / 2008 / AU_GQ845367 (SEQ ID NO:31; FIG. 19G), No. 31; Fig. 19G), Hu / GII.5 / AlbertaEI390 / 2013 / CA (GII.5; SEQ ID NO: 17; Fig. 20), Hu / GII.6 / Ohio / 490 / 2012 / USA (GII.6; SEQ ID NO: 20; Fig. 21A), G11.7 / Musa / 2010 / All73774 (GII7; SEQ ID NO: 18; Fig. 22), Hu / GII.12 / HS206 / 2010 / USA (GII.12; SEQ ID NO: 19; Fig. 23A), and GII.Norovirus V from 13 / VA173 / 2010 / H9AWU4 (SEQ ID NO:22; FIG. 24A), GII.14_Saga_2008_JPN_ADE28701 native VP1 (SEQ ID NO:32; FIG. 25), Hu / GII.17 / Kawasaki323 / 2014 / JP (GII.17; SEQ ID NO:24; FIG. 26A), Hu / GII.21 / Salisbury150 / 2011 / USA (GII.21; SEQ ID NO:26; FIG. 27) It may exhibit about 50%, about 52%, about 54%, about 56%, about 58%, about 60%, about 62%, about 64%, about 66%, about 68%, about 70%, about 72%, about 74%, about 76%, about 78%, about 80%, about 82%, about 84%, about 86%, about 88%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or any amount of sequence identity therebetween to any of the nucleic acid sequences encoding P1.
[0141] Similarly, the present invention relates to any of the VP1 sequences, e.g., Hu / GI.2 / Leuven / 2003 / BEL (GI.2; SEQ ID NO: 4; FIG. 12A), Hu / GI.3 / S29 / 2008 / Lilla (GI.3; SEQ ID NO: 4; FIG. 12B), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. Edet / Sweden (GI.3; sequence number 6; Figure 14A), Hu / GI.5 / Siklos / Hun5407 / 2013 / HUN (GI.5; sequence number 12; Figure 15A), Hu / GI.7 / USA / 2014 / GA5043 (GI.7; sequence number 101; Figure 16A), Hu / GII.1 / Ascension208 / 2010 / USA (GII.1; sequence number 13; Figure 16B), Hu / GII.2 / CGMH47 / 2011 / TW (sequence number 14; Figure 17A), Hu / GII. 18A), Hu / GII.4 / Sydney / NSW0514 / 2012 / AU (GII.4; SEQ ID NO:16; Fig. 19A), US96 / GII.4 / Dresden174 / 1997 / DE_AY741811 (SEQ ID NO:27; Fig. 19C), FH02 / GII.4 / FarmingtonHills / 2002 / US_AY502023 (SEQ ID NO:28; Fig. 19D), Hnt04:GII.4 / Hun ter-NSW504D / 2004 / AU_DQ078814 (SEQ ID NO:29; Figure 19E), 2006b:GII.4 / Shellharbour-NSW696T / 2006 / AU_EF684915 (SEQ ID NO:30; Figure 19F), NO09:GII.4 / Orange-NSW001P / 2008 / AU_GQ845367 (SEQ ID NO:31; Figure 19G), Hu / GII.5 / AlbertaEI390 / 2013 / CA (GII.5; SEQ ID NO:17; Figure 20), Hu / GII.6 / Ohio / 490 / 2012 / USA (GII.6; sequence number 20; Figure 21A), G11.7 / Musa / 2010 / All73774 (GII7; sequence number 18; Figure 22), Hu / GII.12 / HS206 / 2010 / USA (GII.12; sequence number 19; Figure 23A), GII.13 / VA173 / 2010 / H9AWU4 (sequence number 22; Figure 24A), GII.14_Saga_2008_JPN_ADE28701 native VP1 (sequence number 32; Figure 25), Hu / GII.26A), Hu / GII.21 / Salisbury150 / 2011 / USA (GII.21; SEQ ID NO:26; FIG. 27), or any amount of sequence similarity therebetween. For example, the amino acid sequences described herein may have a sequence similarity of about 30%, about 32%, about 34%, about 36%, about 38% to any of the VP1 amino acid sequences defined above, provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence may have about 40%, about 42%, about 44%, about 46%, about 48%, about 50%, about 52%, about 54%, about 56%, about 58%, about 60%, about 62%, about 64%, about 66%, about 68%, about 70%, about 72%, about 74%, about 76%, about 78%, about 80%, about 82%, about 84%, about 86%, about 88%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or any amount of sequence similarity therebetween.
[0142] The terms "VP1 mutant protein," "mutant VP1 protein," "modified VP1 protein," "modified norovirus VP1 protein," and the like refer to a norovirus VP1 protein that contains one or more substitutions, mutations, or modifications at or in the amino acids 43, 57, 84, and 94 in a sequence aligned with norovirus VP1 genotype GI.1 (SEQ ID NO:1, see Table 1 below), or a deletion of the peptide fragment from amino acids 39 to 46 in a sequence aligned with norovirus VP1 genotype GI.1 (SEQ ID NO:1), or a combination thereof. The terms "residue," "residue amino acid," and "amino acid" are used interchangeably and typically refer to an amino acid at a particular position (location) in an amino acid sequence.
[0143] [Table 1]
[0144] As used herein, the term "conserved substitution" or "conservative substitution" refers to the presence of an amino acid residue in the sequence of the GII.4 VP1 protein that is different but is of the same class of amino acid as the described substitution. For example, a nonpolar amino acid can be used to replace a nonpolar amino acid, an aromatic amino acid can be used to replace an aromatic amino acid, a polar uncharged amino acid can be used to replace a polar uncharged amino acid, and / or a charged amino acid can be used to replace a charged amino acid). Additionally, conservative substitutions can include amino acids that have an interface hydropathy value of the same sign, and generally of similar magnitude, as the amino acid substituting the corresponding wild-type amino acid.
[0145] As used herein, the term "nonpolar amino acid" refers to glycine (G, Gly), alanine (A, Ala), valine (V, Val), leucine (L, Leu), isoleucine (I, Ile), and proline (P, Pro), the term "aromatic residue" (or aromatic amino acid) refers to phenylalanine (F, Phe), tyrosine (Y, Tyr), and tryptophan (W, Trp), and the term "polar uncharged amino acid" refers to The term "charged amino acids" refers to serine (S, Ser), threonine (T, Thr), cysteine (C, Cys), methionine (M, Met), asparagine (N, Asn) and glutamine (Q, Gln), and the term "charged amino acids" refers to the negatively charged amino acids aspartic acid (D, Asp) and glutamic acid (E, Glu), and the positively charged amino acids lysine (K, Lys), arginine (R, Arg) and histidine (H, His). Other classifications of amino acids may be as follows: Amino acids with hydrophobic side chains (aliphatic): Alanine (A, Ala), Isoleucine (I, Ile), Leucine (L, Leu), Methionine (M, Met) and Valine (V, Val); Amino acids with hydrophobic side chains (aromatic): Phenylalanine (F, Phe), Tryptophan (W, Trp), Tyrosine (Y, Tyr); Amino acids with polar neutral side chains: Asparagine (N, As) n), cysteine (C, Cys), glutamine (Q, Gln), serine (S, Ser) and threonine (T, Thr); amino acids with an electrically charged side chain (acidic): aspartic acid (D, Asp), glutamic acid (E, Glu); amino acids with an electrically charged side chain (basic): arginine (R, Arg); histidine (H, His); lysine (K, Lys), glycine (G, Gly) and proline (P, Pro).
[0146] Conservative amino acid substitutions are likely to have the same effect on the activity of the resulting modified GII.4 VP1 protein as the original substitution or modification. Additional information regarding conservative substitutions can be found, for example, in Ben Bassat et al. (J. Bacteriol, 169:751-757, 1987), O'Regan et al. (Gene, 77:237-251, 1989), Sahin-Toth et al. (Protein ScL, 3:240-247, 1994), and Hochuli et al. (Bio / Technology, 6:1321-1325, 1988).
[0147] To determine relatedness of polypeptide sequences, Blosum matrices are commonly used (Henikoff et al., Proc. Natl Acad. Sci. USA, 89:10915-10919, 1992). A threshold of 90% identity was used for highly conserved target frequency in the BLOSUM90 matrix. A threshold of 65% identity was used for the BLOSUM65 matrix. A score of 0 or greater in the Blosum matrix is considered a "conservative substitution" at the selected percent identity. The following table shows examples of conservative amino acid substitutions: Table 2.
[0148] [Table 2]
[0149] In the modifications described herein, amino acids may be substituted using very highly conservative substitutions, highly conservative substitutions or conservative substitutions as outlined in Table 2, as well as aromatic amino acids, polar amino acids, polar uncharged amino acids, polar neutral amino acids or non-polar amino acids, negatively charged amino acids, positively charged amino acids, hydrophobic amino acids as described above.
[0150] As described herein, modified VP1 proteins containing one or more substitutions of amino acids at amino acids 43, 57, 84 and 94 (in GI strains; corresponding to amino acids 39, 53, 80 and 90 in GII strains) resulted in improved properties of modified VP1 proteins or VLPs produced using the modified VP1 proteins. It is understood that the improved properties are not limited to the substitution of a particular amino acid at a particular site, as one of skill in the art would understand that amino acids with similar properties can be substituted for the amino acids at the identified positions. For example, the modification Q84S involves the substitution of the glutamine at position 84 with serine, an amino acid characterized by having a polar neutral side chain. The glutamine at this position can also be substituted with an alternative amino acid, i.e., Q84X (X=S, N, C or T), characterized by having a polar neutral side chain, e.g., either asparagine, cysteine or threonine. Similarly, in E80S, which contains a substitution of glutamate at position 80 with serine, i.e., P80S (proline to serine substitution), the amino acid at this position, in addition to replacing the native amino acid with serine, can also be replaced with an amino acid having a polar neutral side chain, such as asparagine, cysteine or threonine, i.e., P80X (X=S, N, C or T). Furthermore, as described herein, additional P80X mutants may be used to produce VP1, where X is selected from S, A, N, K or H. In the modifications S94L, S90L, A94L or A90L, which include the substitution of serine or alanine with leucine (an amino acid characterized by having a hydrophobic side chain), the native amino acid may be replaced using an amino acid characterized by having a hydrophobic side chain, e.g., isoleucine, methionine, valine, or, in the case of S94X or S90X, alanine, i.e., S94X (S90X) (X=L, I, M, V or A) or A94X (A90X) (X=L, I, M or V). Furthermore, as described herein, additional S94X mutants may be used to produce VP1, where X is selected from V, I, M, T, E, D, N, Q, K or H.In modified A39V, which includes a substitution of alanine with valine at position 39 (an amino acid characterized by having a hydrophobic side chain), the native amino acid may also be substituted with an amino acid, in addition to valine, characterized by having a hydrophobic side chain, such as isoleucine, leucine or methionine, i.e., A39X (X=V, I, L or M). Furthermore, as described herein, additional A39X mutants may be used to produce VP1, where X is selected from I, M, G, S, E, D, N, Q, K or H. Modified V47P, which includes a substitution of valine with proline, may also include a substitution of valine with glycine, i.e., V47X (X=P or G). In the modified R53I, which comprises a substitution of arginine with isoleucine at position 53 (an amino acid substitution characterized by having a hydrophobic side chain), the arginine may also be substituted with an amino acid characterized by having a hydrophobic side chain in addition to isoleucine, such as leucine, valine, alanine, or methionine, i.e., R53X (X=I, L, V, A, or M). In the modified M57I, which comprises a substitution of methionine with isoleucine at position 57 (an amino acid characterized by having a hydrophobic side chain), the methionine may also be substituted with an amino acid characterized by having a hydrophobic side chain in addition to isoleucine, such as leucine, valine, or alanine, i.e., M57X (X=I, L, V, or A). Furthermore, as described herein, additional M57X mutants may be used to produce VP1, where X is selected from L, G, S, T, N, Q, K, or H.
[0151] Examples of VP1 mutant proteins (modified VP1 proteins) include, but are not limited to, the following: GI.3_Q84S VP1 (GI.3_Q84X (X=S, N, C or T) VP1): wherein the glutamine corresponding to amino acid 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a serine (GI.3_Q84S; SEQ ID NO: 98, FIG. 28A), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GI.3_Q84S VP1 protein. For example, a GI.3 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GI.3_Q84S VP1 protein (SEQ ID NO:98, FIG. 28A), provided that the substitution, modification, or mutation at the position corresponding to amino acid 84 of Norovirus VP1 genotype GI.1 remains S, N, C, or T, e.g., serine, and the GI.3 Q84X VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GI.3 VP1 can be obtained from any GI.3 strain, including but not limited to GI.3 / S29 / 2008 / Lilla Edet / Sweden (amino acid sequence SEQ ID NO: 6; nucleotide sequence SEQ ID NO: 7; Figures 14A, 14B). GI.3_S94X VP1 (X=L, I, A, V, M, T, E, D, N, Q, K or H), in which the serine corresponding to amino acid 94 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to leucine (GI.3_S94L; SEQ ID NO: 8, FIG. 28C), valine, isoleucine, methionine, threonine, aspartic acid, glutamic acid, glutamine lysine or histidine (GI.3_S94X (X=V, I, M, T, E, D, N, Q, K or H; SEQ ID NO: 292, FIG. 28M)), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GI.3_S94X VP1 protein (X=L, V, I, M, T, E, D, N, Q, K or H). For example, a GI.3 VP1 protein can be a GI.3 S94X VP1 protein (X=L, V, I, M, T, E, D, N, Q, K, or H), provided that the substitution, modification, or mutation at the position corresponding to amino acid 94 of Norovirus VP1 genotype GI.1 remains L, V, I, M, T, E, D, N, Q, K, or H, e.g., leucine, valine, isoleucine, methionine, methionine, threonine, aspartic acid, glutamic acid, glutamine lysine, or histine, and the GI.3 S94X VP1 protein elicits immunity to Norovirus when administered to a subject. VP1 protein) (SEQ ID NO:8, FIG. 28C, SEQ ID NO:292; FIG. 28M). Sequences encoding GI.3 VP1 can be obtained from any GI.3 strain, including but not limited to GI.3 / S29 / 2008 / Lilla Edet / Sweden (amino acid SEQ ID NO:6; nucleotide SEQ ID NO:7; FIG. 14A, FIG. 14B). GI.3_A43X+S94 x VP1 (X=V, L, I or M, and x= L, I, A, V, M, T, E, D, N, Q, K or H), where the alanine and serine corresponding to amino acids 43 and 94, respectively, of Norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been replaced or mutated, for example, but not limited to, valine and leucine, respectively (GI.3_A43V+S94L; SEQ ID NO: 170, FIG. 28G), or a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, with the amino acid sequence of the GI.3_A43V+S94L VP1 protein. For example, the substitution, modification or mutation at the positions corresponding to amino acids 43 and 94 of Norovirus VP1 genotype GI.1 remains V, L, I or M, e.g., valine, and L, I, A, V, M, T, E, D, N, Q, K or H, e.g., leucine, respectively, and the GI.3_A43X+S94 x The GI.3 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of the GI.3_A43V+S94L VP1 protein (SEQ ID NO: 170, FIG. 28G), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GI.3 VP1 can be obtained from any GI.3 strain, including but not limited to GI.3 / S29 / 2008 / Lilla Edet / Sweden (SEQ ID NO:6, amino acid; SEQ ID NO:7, nucleotide; Figures 14A, 14B). GI.3_M57X+S94 x VP1 (X=I, V, A, L, G, S, T, N, Q, K or H, and x=L, I, A, V, M, T, E, D, N, Q, K), where the methionine and serine corresponding to amino acids 57 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to isoleucine and leucine, respectively (GI.3_M57I+S94L; SEQ ID NO: 172, FIG. 28I), or to a sequence exhibiting about 80% to about 100% or any amount of sequence similarity with the amino acid sequence of the GI.3_M57I+S94L VP1 protein. For example, the substitution, modification or mutation at the positions corresponding to amino acids 57 and 94 of norovirus VP1 genotype GI.1 remains to be I, V, A, L, G, S, T, N, Q, K or H, e.g. isoleucine, and L, I, A, V, M, T, E, D, N, Q, K, e.g. leucine, respectively, and the methionine and serine corresponding to amino acids 57 and 94 of norovirus VP1 genotype GI.1 remain to be I, V, A, L, G, S, T ... x The GI.3 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of the GI.3_M57I+S94L VP1 protein (SEQ ID NO: 172, FIG. 28I), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GI.3 VP1 can be obtained from any GI.3 strain, including but not limited to GI.3 / S29 / 2008 / Lilla Edet / Sweden (SEQ ID NO:6, amino acid; SEQ ID NO:7, nucleotide; Figures 14A, 14B). GI.3_Q84X+S94 x , VP1 (X=S, N, C or T, and x= L, I, A, V, M, T, E, D, N, Q, K or H), where the glutamine and serine corresponding to amino acids 84 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to serine and leucine, respectively (GI.3_Q84S+S94L; SEQ ID NO: 10, FIG. 28E), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, with the amino acid sequence of the GI.3_Q84S+S94L VP1 protein. For example, the substitution, modification or mutation at the positions corresponding to amino acids 84 and 94 of norovirus VP1 genotype GI.1 remains to be S, N, C or T, e.g. serine, and L, I, A, V, M, T, E, D, N, Q, K or H, e.g. leucine, respectively, and the GI.3_Q84X+S94 x The GI.3 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of the GI.3_Q84S+S94L VP1 protein (SEQ ID NO:10, FIG. 28E), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GI.3 VP1 can be obtained from any GI.3 strain, including but not limited to GI.3 / S29 / 2008 / Lilla Edet / Sweden (SEQ ID NO:6, amino acid; SEQ ID NO:7, nucleotide; Figures 14A, 14B). GI.3_A43X+M57 z +S94 x VP1 (X=V, L, I or M, z = I, V, A, L, G, S, T, N, Q, K or H, and x=L, I, A, V, M, T, E, D, N, Q, K or H), in which the alanine, methionine, and serine corresponding to amino acids 43, 57, and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to valine, isoleucine, and leucine, respectively (GI.3_A43V+M57I+S94L; SEQ ID NO: 174, FIG. 28K), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GI.3_A43V+M57I+S94L VP1 protein. For example, the substitutions, modifications or mutations at positions corresponding to amino acids 43, 57 and 94 of norovirus VP1 genotype GI.1 remain V, L, I or M, e.g., valine, and I, V, A, L, G, S, T, N, Q, K or H, e.g., isoleucine, and L, I, A, V, M, T, E, D, N, Q, K or H, e.g., leucine, respectively, to form GI.3_A43X+M57 z +S94 x A GI.3 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of a GI.3_A43V+M57I+S94L VP1 protein (SEQ ID NO: 174, FIG. 28K), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GI.3 VP1 can be obtained from any GI.3 strain, including but not limited to GI.3 / S29 / 2008 / Lilla Edet / Sweden (SEQ ID NO:6, amino acid; SEQ ID NO:7, nucleotide; Figures 14A, 14B). GI.5_Q84S VP1 (GI.5_Q84X (X=S, N, C or T), VP1): wherein the glutamine corresponding to amino acid 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a serine (GI.5_Q84S; SEQ ID NO: 34, FIG. 29A), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GI.5_Q84S VP1 protein. For example, a GI.5 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GI.5_Q84S VP1 protein (SEQ ID NO:34, FIG. 29A), provided that the substitution, modification, or mutation at the position corresponding to amino acid 84 of Norovirus VP1 genotype GI.1 remains S, N, C, or T, e.g., serine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GI.5 VP1 can be obtained from any GI.5 strain, including but not limited to, GI.5 / Siklos / HUN5407 / 2013 / HUN (SEQ ID NO: 12, amino acid sequence; Figure 15A). GI.5_A94L VP1 (GI.5_A94X (X=L, I, M or V), VP1): wherein the alanine corresponding to amino acid 94 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a leucine (GI.5_A94L; SEQ ID NO: 36, FIG. 29C), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GI.5_A94S VP1 protein. For example, a GI.5 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GI.5_A94L VP1 protein (SEQ ID NO:36, FIG. 29C), provided that the substitution, modification, or mutation at the position corresponding to amino acid 94 of Norovirus VP1 genotype GI.1 remains L, I, M, or V, e.g., leucine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GI.5 VP1 can be obtained from any GI.5 strain, including but not limited to, GI.5 / Siklos / HUN5407 / 2013 / HUN (SEQ ID NO: 12, amino acid sequence; Figure 15A). GI.5_Q84S+A94L VP1 (GI.5_Q84X (X=S, N, C or T)+A94X (X=L, I, M or V), VP1): in which the glutamine and alanine corresponding to amino acids 84 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to serine and leucine, respectively (GI.5_Q84S+A94L; SEQ ID NO: 38, FIG. 29E), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GI.5_Q84S+A94L VP1 protein. For example, a GI.5 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GI.5_Q84S+A94L VP1 protein (SEQ ID NO:38, FIG. 29E), provided that the substitutions, modifications, or mutations at positions corresponding to amino acids 84 and 94 of Norovirus VP1 genotype GI.1 remain S, N, C, or T, e.g., serine, and L, I, M, or V, e.g., leucine, respectively, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GI.5 VP1 can be obtained from any GI.5 strain, including but not limited to, GI.5 / Siklos / HUN5407 / 2013 / HUN (SEQ ID NO: 12, amino acid sequence; Figure 15A). GI.7_M57X VP1 (X=I, V, A, L, G, S, T, N, Q, K or H), in which the methionine corresponding to amino acid 57 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to isoleucine (GI.7_M57I; SEQ ID NO: 179, FIG. 29I), valine, alanine, leucine, glycine, serine, threonine, asparagine, glutamine, lysine or histidine (GI.7_M57X VP1 (X=I, V, A, L, G, S, T, N, Q, K or H); SEQ ID NO: 290; FIG. 29M), or a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GI.7_M57X VP1 protein (X=I, V, A, L, G, S, T, N, Q, K or H). For example, a GI.7 VP1 protein can be a GI.7_M57X VP1 protein, provided that the substitution, alteration or mutation at the position corresponding to amino acid 57 of Norovirus VP1 genotype GI.1 remains I, V, A, L, G, S, T, N, Q, K or H, e.g., isoleucine, valine, alanine, leucine, glycine, serine, threonine, asparagine, glutamine, lysine or histidine, and the GI.7_M57X VP1 protein elicits immunity to Norovirus when administered to a subject. The VP1 protein (X=I, V, A, L, G, S, T, N, Q, K, or H) may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween with the amino acid sequence of the VP1 protein (X=I, V, A, L, G, S, T, N, Q, K, or H) (SEQ ID NO: 179, FIG. 29I; SEQ ID NO: 290; FIG. 29M). Sequences encoding GI.7 VP1 can be obtained from any GI.7 strain, including but not limited to, GI.7 / GA5043 / USA / 2014 (SEQ ID NO: 101, amino acids; FIG. 16A). GI.7_R84S VP1 (GI.7_R84X (X=S, N, C or T), VP1): wherein the arginine corresponding to amino acid 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a serine (GI.7_R84S; SEQ ID NO: 177, FIG. 29G), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GI.7_R84S VP1 protein. For example, a GI.7 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GI.7_R84S VP1 protein (SEQ ID NO: 177, FIG. 29G), provided that the substitution, modification, or mutation at the position corresponding to amino acid 84 of Norovirus VP1 genotype GI.1 remains S, N, C, or T, e.g., serine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GI.7 VP1 can be obtained from any GI.7 strain, including but not limited to, GI.7 / GA5043 / USA / 2014 (SEQ ID NO: 101, amino acid sequence; Figure 16A). GI.7_M57X+R84 x VP1 (X=L, I, A, V, M, T, E, D, N, Q, K, or H, and x = S, N, C or T), where the methionine and arginine corresponding to amino acids 57 and 84, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to isoleucine and serine, respectively (GI.7_M57I+R84S; SEQ ID NO: 181, FIG. 29K), or to a sequence exhibiting about 80% to about 100% or any amount of sequence similarity therebetween with the amino acid sequence of the GI.7_M57I+R84S VP1 protein. For example, the substitution, modification or mutation at the positions corresponding to amino acids 57 and 84 of norovirus VP1 genotype GI.1 remains L, I, A, V, M, T, E, D, N, Q, K or H, e.g. isoleucine, and S, N, C or T, e.g. serine, respectively, to GI.7_M57X+R84x The GI.7 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of the GI.7_M57I+R84S VP1 protein (SEQ ID NO: 181, FIG. 29K), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. Sequences encoding GI.7 VP1 can be obtained from any GI.7 strain, including, but not limited to, GI.7 / GA5043 / USA / 2014 (SEQ ID NO: 101, amino acids; FIG. 16A). GII.2_E80S VP1 (GII.2_E80X (X=S, N, C or T), VP1): wherein the glutamic acid corresponding to amino acid 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a serine (GII.2_E80S; SEQ ID NO: 85, FIG. 30A), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.2_E80S VP1 protein. For example, a GII.2 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.2_E80S VP1 protein (SEQ ID NO: 85, FIG. 30A), provided that the substitution, modification, or mutation at the position corresponding to amino acid 84 of Norovirus VP1 genotype GI.1 remains S, N, C, or T, e.g., serine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.2 VP1 can be obtained from any GII.2 strain, including but not limited to Hu / GII.2 / CGMH47 / 2011 / TW (SEQ ID NO: 14, amino acid sequence; FIG. 17A). GII.2_A90L VP1 (GII.2_A90X (X=L, I, M or V), VP1): wherein the alanine corresponding to amino acid 94 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a leucine (GII.2_A90L; SEQ ID NO: 41, FIG. 30C), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a mut GII.2_A90L VP1 protein. For example, a GII.2 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.2_A90L VP1 protein (SEQ ID NO:41, FIG. 30C), provided that the substitution, modification, or mutation at the position corresponding to amino acid 94 of Norovirus VP1 genotype GI.1 remains L, I, M, or V, e.g., leucine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.2 VP1 can be obtained from any GII.2 strain, including but not limited to Hu / GII.2 / CGMH47 / 2011 / TW (SEQ ID NO: 14, amino acid sequence; FIG. 17A). GII.2_E80S+A90L VP1 (GII.2_E80X (X=S, N, C or T)+A90X (X=L, I, M or V), VP1): in which the glutamic acid and alanine corresponding to amino acids 84 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to serine and leucine, respectively (GII.2_E80S+A90L; SEQ ID NO: 43, FIG. 30E), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the mut GII.2_E80S+A90L VP1 protein. For example, a GII.2 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.2_E80S+A90L VP1 protein (SEQ ID NO: 43, FIG. 30E), provided that the substitutions, modifications, or mutations at positions corresponding to amino acids 84 and 94 of Norovirus VP1 genotype GI.1 remain S, N, C, or T, e.g., serine, and L, I, M, or V, e.g., leucine, respectively, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.2 VP1 can be obtained from any GII.2 strain, including but not limited to Hu / GII.2 / CGMH47 / 2011 / TW (SEQ ID NO: 14, amino acid sequence; FIG. 17A). GII.2_A39V+E80S+A90L VP1 (GII.2_A39X(X=V, LI or M)+E80X(X=S, N, C or T)+A90X(X=L, I, M or V), VP1): in which the alanine, glutamic acid and alanine corresponding to amino acids 43, 84 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to valine, serine and leucine, respectively (GII.2_A39V+E80S+A90L; SEQ ID NO: 182, FIG. 30G), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GII.2_A39V+E80S+A90L VP1 protein. For example, a GII.2 VP1 protein may be represented by the general formula (I): GII.2_A39V+E80S+A90L, provided that the substitutions, modifications, or mutations at positions corresponding to amino acids 43, 84, and 94 of Norovirus VP1 genotype GI.1 remain V, I, L, or M, e.g., valine, S, N, C, or T, e.g., serine, and L, I, M, or V, e.g., leucine, respectively, and the VP1 protein elicits immunity to Norovirus when administered to a subject. It may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween with the amino acid sequence of the VP1 protein (SEQ ID NO: 182, FIG. 30G). Sequences encoding GII.2 VP1 can be obtained from any GII.2 strain, including but not limited to Hu / GII.2 / CGMH47 / 2011 / TW (SEQ ID NO: 14, amino acids; FIG. 17A). GII.2 R53I+E80S+A90L VP1 (GII.2_R53X(X=I, L, M, V or A)+E80X(X=S, N, C or T)+A90X(X=L, I, M or V), VP1): in which the arginine, glutamic acid and alanine corresponding to amino acids 57, 84 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to isoleucine, serine and leucine, respectively (GII.2_M53I+E80S+A90L; SEQ ID NO: 184, FIG. 30I), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GII.2_M53I+E80S+A90L VP1 protein. For example, a GII.2 VP1 protein may be represented by the following general formula: GII.2_M53I+E80S+A90L, provided that the substitutions, modifications, or mutations at positions corresponding to amino acids 57, 84, and 94 of Norovirus VP1 genotype GI.1 remain I, L, M, or A, e.g., isoleucine, S, N, C, or T, e.g., serine, and L, I, M, or V, e.g., leucine, respectively, and the VP1 protein elicits immunity to Norovirus when administered to a subject. It may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween with the amino acid sequence of the VP1 protein (SEQ ID NO: 184, FIG. 30I). Sequences encoding GII.2 VP1 can be obtained from any GII.2 strain, including but not limited to Hu / GII.2 / CGMH47 / 2011 / TW (SEQ ID NO: 14, amino acids; FIG. 17A). GII.2 A39V+R53I+E80S+A90L VP1 (GII.2_A39X(X=V, I, L or M)+R53X(X=I, L, M, A or V)+E80X(X=S, N, C or T)+A90X(X=L, I, M or V), VP1): in which the glutamic acid and alanine corresponding to amino acids 43, 57, 84 and 94, respectively, of the norovirus VP1 genotype GI.1 (SEQ ID NO: 1) can be, for example, substituted with valine, isoleucine, serine and leucine, respectively (GII.2_A39V+R53I+E80S+A90L; SEQ ID NO: 186, FIG. 30K), or with GII.2_A39V+R53I+E80S+A90L The amino acid sequence of the VP1 protein is mutated to a sequence that exhibits about 80% to about 100%, or any amount of sequence similarity therebetween, with the amino acid sequence of the VP1 protein. For example, the GII.2 VP1 protein is GII.2_A39V+R53I+E80S+A90L, provided that the substitutions, modifications, or mutations at positions corresponding to amino acids 43, 57, 84, and 94 of norovirus VP1 genotype GI.1 remain V, I, L, or M, e.g., valine, I, L, M, A, or V, e.g., isoleucine, S, N, C, or T, e.g., serine, and L, I, M, or V, e.g., leucine, respectively, and the VP1 protein induces immunity to norovirus when administered to a subject. It may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween with the amino acid sequence of the VP1 protein (SEQ ID NO: 186, FIG. 30K). Sequences encoding GII.2 VP1 can be obtained from any GII.2 strain, including but not limited to Hu / GII.2 / CGMH47 / 2011 / TW (SEQ ID NO: 14, amino acids; FIG. 17A). GII.3_E80S VP1 (GII.3_E80X (X=S, N, C or T), VP1): wherein the glutamic acid corresponding to amino acid 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a serine (GII.3_E80S; SEQ ID NO: 46, FIG. 31A), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a mut GII.3_E80S VP1 protein. For example, a GII.3 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.3_E80S VP1 protein (SEQ ID NO: 46, FIG. 31A), provided that the substitution, modification, or mutation at the position corresponding to amino acid 84 of Norovirus VP1 genotype GI.1 remains S, N, C, or T, e.g., serine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.3 VP1 can be obtained from any GII.3 strain, including but not limited to, GII.3 / Jingzhou / 2013402 / CHN (SEQ ID NO: 15, amino acid sequence; FIG. 18A). GII.3_A90L VP1 (GII.3_A90X (X=L, I, M or V), VP1): wherein the alanine corresponding to amino acid 94 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a leucine (GII.3_A90L; SEQ ID NO: 48, FIG. 31C), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.3_A90L VP1 protein. For example, a GII.3 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.3_A90L VP1 protein (SEQ ID NO:48, FIG. 31C), provided that the substitution, modification, or mutation at the position corresponding to amino acid 94 of Norovirus VP1 genotype GI.1 remains L, I, M, or V, e.g., leucine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.3 VP1 can be obtained from any GII.3 strain, including but not limited to, GII.3 / Jingzhou / 2013402 / CHN (SEQ ID NO: 15, amino acid sequence; FIG. 18A). GII.3_E80S+A90L VP1 (GII.3_E80X (X=S, N, C or T)+A90X (X=L, I, M or V), VP1): in which the glutamic acid and alanine corresponding to amino acids 84 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to serine and leucine, respectively (GII.3_E80S+A90L; SEQ ID NO: 50, FIG. 31E), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GII.3_E80S+A90L VP1 protein. For example, a GII.3 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.3_E80S+A90L VP1 protein (SEQ ID NO:50, FIG. 31E), provided that the substitutions, modifications, or mutations at positions corresponding to amino acids 84 and 94 of Norovirus VP1 genotype GI.1 remain S, N, C, or T, e.g., serine, and L, I, M, or V, e.g., leucine, respectively, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.3 VP1 can be obtained from any GII.3 strain, including but not limited to, GII.3 / Jingzhou / 2013402 / CHN (SEQ ID NO: 15, amino acid sequence; FIG. 18A). GII.4_A39X VP1 (X=V, I, L, M, G, S, E, D, N, Q, K, or H), in which the alanine corresponding to amino acid 43 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated to, for example, valine (GII.4_A39V; SEQ ID NO: 53, FIG. 32A), isoleucine, leucine, methionine, glycine, serine, aspartic acid, glutamic acid, asparagine, glutamine, lysine, histidine, or a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the VP1 protein, GII.4_A39X VP1 (X=V, I, L, M, G, S, E, D, N, Q, K, or H). For example, the GII.4 VP1 protein can be selected from the group consisting of GII.4_A39V, GII.4_A39X, and GII.4_A39X VP1 proteins, provided that the substitution, alteration, or mutation at the position corresponding to amino acid 43 of Norovirus VP1 genotype GI.1 remains V, I, L, M, G, S, E, D, N, Q, K, or H, e.g., valine, isoleucine, leucine, methionine, glycine, serine, aspartic acid, glutamic acid, asparagine, glutamine, lysine, or histidine, and the GII.4_A39X VP1 protein elicits immunity to Norovirus when administered to a subject. It may have about 0%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween with the amino acid sequence of the VP1 protein (SEQ ID NO:53, FIG. 32A). Sequences encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO:16, amino acid; SEQ ID NO:52, nucleotide; FIG. 19A and FIG. 19B). GII.4_V47P VP1 (GII.4_V47X (X=P or G), VP1): wherein the valine corresponding to amino acid 51 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a proline (GII.4_V47P; SEQ ID NO: 55, FIG. 32C), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GII.4_V47P VP1 protein. For example, a GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.4_V47P VP1 protein (SEQ ID NO:55, FIG. 32C), provided that the substitution, modification, or mutation at the position corresponding to amino acid 51 of Norovirus VP1 genotype GI.1 remains a P or G, e.g., a proline, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). GII.4_R53I VP1 (GII.4_R53I (X=I, L, V, A or M), VP1): wherein the arginine corresponding to amino acid 57 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to an isoleucine (GII.4_R53I; SEQ ID NO: 57, FIG. 32E), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.4_R53I VP1 protein. For example, a GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.4_R53I VP1 protein (SEQ ID NO:57, FIG. 32E), provided that the substitution, modification, or mutation at the position corresponding to amino acid 57 of Norovirus VP1 genotype GI.1 remains I, L, V, A, or M, e.g., isoleucine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). GII.4_P80X VP1 (X=S, N, C, T, A, K or H), in which the proline corresponding to amino acid 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to serine (GII.4_P80S; SEQ ID NO: 59, FIG. 32G), asparagine, cysteine, threonine, alanine, lysine, histidine, or a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.4_P80S VP1 protein. For example, the GII.4 VP1 protein can be any of the following: GII.4_P80S VP1 proteins, provided that the substitution, modification or mutation at the position corresponding to amino acid 84 of Norovirus VP1 genotype GI.1 remains S, N, C, T, A, K or H, e.g., serine, asparagine, cysteine, threonine, alanine, lysine or histidine, and the GII.4_P80X VP1 protein elicits immunity against Norovirus when administered to a subject. The sequence encoding GII.4 VP1 may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100% or any amount of sequence similarity therebetween to the amino acid sequence of the VP1 protein (SEQ ID NO:59, FIG. 32G). A sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to, GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO:16, amino acid; SEQ ID NO:52, nucleotide; FIG. 19A and FIG. 19B). GII.4_S90L VP1 (GII.4_S90X (X=L, I, M, A or V), VP1): wherein the serine corresponding to amino acid 94 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a leucine (GII.4_S90L; SEQ ID NO: 61, FIG. 32I), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.4_S90L VP1 protein. For example, a GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.4_S90L VP1 protein (SEQ ID NO: 61, FIG. 32I), provided that the substitution, modification, or mutation at the position corresponding to amino acid 94 of Norovirus VP1 genotype GI.1 remains L, I, M, A, or V, e.g., leucine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). GII.4_Δ35-42 VP1, wherein the amino acids corresponding to positions 39 to 46 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) are either deleted (GII.4_Δ35-42; SEQ ID NO: 63, FIG. 32K) or are a sequence that shows about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GII.4_Δ35-42 VP1 protein. For example, a GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.4_Δ35-42 VP1 protein (SEQ ID NO:63, FIG. 32K), provided that the amino acids corresponding to positions 39-46 of norovirus VP1 genotype GI.1 (SEQ ID NO:1) remain deleted and the VP1 protein induces immunity to norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). GII.4_SSTAVATA VP1, wherein the amino acids corresponding to positions 39 to 46 of the norovirus VP1 genotype GI.1 (SEQ ID NO: 1) are mutated to the peptide sequence SSTAVATA (SEQ ID NO: 168; GII.4_SSTAVATA; SEQ ID NO: 65, FIG. 32M), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a mut GII.4_SSTAVATA VP1 protein. For example, a GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.4_SSTAVATA VP1 protein (SEQ ID NO:65, FIG. 32M), provided that the positions corresponding to amino acids 39-46 of Norovirus VP1 genotype GI.1 remain the peptide sequence SSTAVATA and the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). ·GII.4_A39X+R53 x VP1 (X=V, I, L, M, G, S, E, D, N, Q, K or H, and x= I, L, M, A or V), where the alanine and arginine corresponding to amino acids 43 and 57, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated to, for example, valine, isoleucine, leucine, methionine, glycine, serine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine and isoleucine, respectively (e.g., GII.4_A39V+R53I; SEQ ID NO: 188, Figure 32AA), or a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.4_A39V+R53I VP1 protein. For example, the substitution, modification or mutation at the positions corresponding to amino acids 43 and 57 of norovirus VP1 genotype GI.1 remains V, I, L, M, G, S, E, D, N, Q, K or H, e.g., valine, isoleucine, leucine, methionine, glycine, serine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine, and I, L, M, V or A, e.g., isoleucine, and GII.4_A39X+R53 x The GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of the GII.4_A39V+R53I VP1 protein (SEQ ID NO: 188, FIG. 32AA), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). GII.4_A39X+P80 x VP1 (X=V, I, L, M, G, S, E, D, N, Q, K or H, and x= S, N, C, T, A, K or H), VP1): where alanine and proline, respectively corresponding to amino acids 43 and 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1), can be, for example, but not limited to, valine, isoleucine, leucine, methionine, glycine, serine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine, and serine, asparagine, cysteine, threonine, alanine, lysine or histidine (e.g., GII.4_A39V+P80S; SEQ ID NO: 67, Figure 32O), or GII.4_A39X+P80S; x The amino acid sequence of the VP1 protein is replaced or mutated to a sequence that exhibits about 80% to about 100% sequence similarity or any amount therebetween with the amino acid sequence of the VP1 protein. For example, the replacement, modification or mutation at the positions corresponding to amino acids 43 and 84 of the norovirus VP1 genotype GI.1 remains V, I, L, M, G, S, E, D, N, Q, K or H, such as valine, isoleucine, leucine, methionine, glycine, serine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine, and S, N, C, T, A, K or H, such as serine, asparagine, cysteine, threonine, alanine, lysine or histidine, respectively, and the replacement, modification or mutation at the positions corresponding to amino acids 43 and 84 of the norovirus VP1 genotype GI.1 remains V, I, L, M, G, S, E, D, N, Q, K or H, such as serine, asparagine, cysteine, threonine, alanine, lysine or histidine, respectively, and the replacement, modification or mutation at the positions corresponding to amino acids 43 and 84 of the norovirus VP1 genotype GI.1 remains S, N, C, T, A ... x The GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of the GII.4_A39V+P80S VP1 protein (SEQ ID NO:67, FIG. 32O), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). GII.4_V47P+P80S VP1(GII.4_V47X(X=P or G)+P80 x ( x = S, N, C, T, A, K or H) VP1): in which the valine and proline corresponding to amino acids 51 and 84, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been replaced or mutated, for example, to proline, and serine, asparagine, cysteine, threonine, alanine, lysine or histidine, respectively (e.g., GII.4_V47P+P80S; SEQ ID NO: 69, Figure 32Q), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.4_V47P+P80S VP1 protein. For example, the substitution, modification or mutation at positions corresponding to amino acids 51 and 84 of norovirus VP1 genotype GI.1 remains P or G, e.g., proline, and S, N, C, T, A, K or H, e.g., serine, asparagine, cysteine, threonine, alanine, lysine or histidine, respectively, GII.4_V47X+P80 x The GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of the GII.4_V47P+P80S VP1 protein (SEQ ID NO:69, FIG. 32Q), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). ·GII.4_R53I+P80S VP1(GII.4_R53X(X=I, L, V, A or M)+P80 x ( x= S, N, C, T, A, K or H), VP1): in which the arginine and proline corresponding to amino acids 57 and 84, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated to, for example, isoleucine, and serine, asparagine, cysteine, threonine, alanine, lysine or histidine, respectively (e.g., GII.4_R53I+P80S; SEQ ID NO: 71, Figure 32S), or a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.4_R53I+P80S VP1 protein. For example, the substitution, modification or mutation at positions corresponding to amino acids 57 and 84 of norovirus VP1 genotype GI.1 remains I, L, V, A or M, e.g., isoleucine, and S, N, C, T, A, K or H, e.g., serine, asparagine, cysteine, threonine, alanine, lysine, histidine, respectively, and GII.4_R53X+P80 x The GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of the GII.4_R53I+P80S VP1 protein (SEQ ID NO: 71, FIG. 32S), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). ·GII.4_P80S+S90L VP1(GII.4_P80X(X=S, N, C, T, A, K or H)+S90 x ( x=L, I, M, A or V), VP1): in which the proline and serine corresponding to amino acids 84 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated to, for example, serine, asparagine, cysteine, threonine, alanine, lysine or histidine, and leucine, respectively (e.g., GII.4_P80S+S90L; SEQ ID NO: 73, Figure 32U), or a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.4_P80S+S90L VP1 protein. For example, the substitutions, modifications or mutations at positions corresponding to amino acids 84 and 94 of norovirus VP1 genotype GI.1 remain S, N, C, T, A, K or H, e.g., serine, asparagine, cysteine, threonine, alanine, lysine or histidine, and L, I, M, A or V, e.g., leucine, respectively, of GII.4_P80X+S90 x The GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of the GII.4_P80S+S90L VP1 protein (SEQ ID NO: 73, FIG. 32U), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). ·GII.4_A39X+R53 x +P80 z VP1 (X=V, I, L, M, G, S, E, D, N, Q, K or H, x = I, L, M, A or V, and z= S, N, C, T, A, K or H), in which the alanine and arginine corresponding to amino acids 43, 57 and 84, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been replaced or mutated, e.g., to valine, isoleucine, leucine, methionine, glycine, serine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine at position 39, isoleucine at position 53, and serine, asparagine, cysteine, threonine, alanine, lysine or histidine at position 80 (e.g., GII.4_A39V+R53I+P80S; SEQ ID NO: 190, FIG. 32CC), or a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GII.4_A39V+R53I+P80S VP1 protein. For example, the substitutions, modifications or mutations at positions corresponding to amino acids 43, 57 and 84 of norovirus VP1 genotype GI.1 remain V, I, L, M, G, S, E, D, N, Q, K or H, e.g., valine, isoleucine, leucine, methionine, glycine, serine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine, I, L, M, V or A, e.g., isoleucine, and S, N, C, T, A, K or H, e.g., serine, asparagine, cysteine, threonine, alanine, lysine or histidine, respectively, of GII.4_A39X+R53 x +P80 zThe GII.4 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween to the amino acid sequence of the GII.4_A39V+R53I+P80S VP1 protein (SEQ ID NO: 190, FIG. 32CC), provided that the VP1 protein induces immunity to Norovirus when administered to a subject. The sequence encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; Figures 19A and 19B). GII.4_P80S+Δ35-42 VP1 (GII.4_P80X (X=S, N, C, T, A, K or H)+Δ35-42, VP1): in which the proline corresponding to position 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) is mutated, for example, to serine, asparagine, cysteine, threonine, alanine, lysine or histidine, and the amino acids corresponding to positions 39 to 46 of norovirus VP1 genotype GI.1 are either deleted (GII.4_P80S+Δ35-42; SEQ ID NO: 75, FIG. 32W) or are a sequence that shows about 80% to about 100% sequence similarity, or any amount therebetween, with the amino acid sequence of the GII.4_P80S+Δ35-42 VP1 protein. For example, the GII.4 VP1 protein may be GII.4_P80S+Δ35-42, provided that the substitution, alteration or mutation at the position corresponding to amino acid 84 of Norovirus genotype GI.1 remains S, N, C, T, A, K or H, e.g., serine, asparagine, cysteine, threonine, alanine, lysine or histidine, and the amino acids corresponding to positions 39-46 of Norovirus VP1 genotype GI.1 remain deleted, such that the GII.4_P80X+Δ35-42 VP1 protein induces immunity to Norovirus when administered to a subject. It may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween with the amino acid sequence of the VP1 protein (SEQ ID NO: 75, FIG. 32W). Sequences encoding GII.4 VP1 can be obtained from any GII.4 strain, including, but not limited to, GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; FIG. 19A and FIG. 19B). GII.4_P80S+SSTAVATA VP1 (GII.4_P80X (X=S, N, C, T, A, K or H)+SSTAVATA, VP1): wherein the proline corresponding to position 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) is mutated, for example, to serine, asparagine, cysteine, threonine, alanine, lysine or histidine and the amino acids corresponding to positions 39 to 46 of norovirus VP1 genotype GI.1 are mutated to the peptide sequence SSTAVATA (SEQ ID NO: 168; GII.4_P80S+SSTAVATA; SEQ ID NO: 77, FIG. 32Y), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount of sequence similarity therebetween, to the amino acid sequence of the mut GII.4_P80S+SSTAVATA VP1 protein. For example, the GII.4 VP1 protein may be GII.4_P80S+SSTAVATA, provided that the position corresponding to amino acid 84 of norovirus VP1 genotype GI.1 remains S, N, C, T, A, K or H, e.g., serine, asparagine, cysteine, threonine, alanine, lysine or histidine, and the positions corresponding to amino acids 39-46 of norovirus VP1 genotype GI.1 remain the peptide sequence SSTAVATA, such that the GII.4_P80X+SSTAVATA VP1 protein induces immunity to norovirus when administered to a subject. It may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween with the amino acid sequence of the VP1 protein (SEQ ID NO: 77, FIG. 32Y). Sequences encoding GII.4 VP1 can be obtained from any GII.4 strain, including but not limited to GII.4 / Sydney / NSW0514 / 2012 / AU (SEQ ID NO: 16, amino acid; SEQ ID NO: 52, nucleotide; FIG. 19A and FIG. 19B). GII.6_E80S VP1 (GII.6_E80X (X=S, N, C or T), VP1): wherein the glutamic acid corresponding to amino acid 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a serine (GII.6_E80S; SEQ ID NO: 79, FIG. 33A), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.6_E80S VP1 protein. For example, a GII.6 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.6_E80S VP1 protein (SEQ ID NO: 79, FIG. 33A), provided that the substitution, modification, or mutation at the position corresponding to amino acid 84 of Norovirus VP1 genotype GI.1 remains S, N, C, or T, e.g., serine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.6 VP1 can be obtained from any GII.6 strain, including, but not limited to, GII.6 / Ohio / 490 / 2012 / USA (SEQ ID NO: 20, amino acid; SEQ ID NO: 21, nucleotide; Figures 21A and 21B). GII.6_S90L VP1 (GII.6_S90X (X=L, I, M, A or V), VP1): wherein the serine corresponding to amino acid 94 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a leucine (GII.6_S90L; SEQ ID NO: 81, FIG. 33C), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.6_S90L VP1 protein. For example, a GII.6 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.6_S90L VP1 protein (SEQ ID NO: 81, FIG. 33C), provided that the substitution, modification, or mutation at the position corresponding to amino acid 94 of Norovirus VP1 genotype GI.1 remains L, I, M, or V, e.g., leucine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.6 VP1 can be obtained from any GII.6 strain, including, but not limited to, GII.6 / Ohio / 490 / 2012 / USA (SEQ ID NO: 20, amino acid; SEQ ID NO: 21, nucleotide; Figures 21A and 21B). GII.6_E80S+S90L VP1 (GII.6_E80X (X=S, N, C or T)+S90X (X=L, I, M, A or V), VP1): in which the glutamic acid and serine corresponding to amino acids 84 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to serine and leucine, respectively (GII.6_E80S+S90L; SEQ ID NO: 83, FIG. 33E), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GII.6_E80S+S90L VP1 protein. For example, a GII.6 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.6_E80S+S90L VP1 protein (SEQ ID NO: 83, FIG. 33E), provided that the substitutions, modifications, or mutations at positions corresponding to amino acids 84 and 94 of Norovirus VP1 genotype GI.1 remain S, N, C, or T, e.g., serine, and L, I, M, A, or V, e.g., leucine, respectively, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.6 VP1 can be obtained from any GII.6 strain, including, but not limited to, GII.6 / Ohio / 490 / 2012 / USA (SEQ ID NO: 20, amino acid; SEQ ID NO: 21, nucleotide; Figures 21A and 21B). GII.12_E80S VP1 (GII.12_E80X (X=S, N, C or T), VP1): wherein the glutamic acid corresponding to amino acid 84 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a serine (GII.12_E80S; SEQ ID NO: 88, FIG. 34A), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.12_E80S VP1 protein. For example, a GII.12 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.12_E80S VP1 protein (SEQ ID NO: 88, FIG. 34A), provided that the substitution, modification, or mutation at the position corresponding to amino acid 84 of Norovirus VP1 genotype GI.1 remains S, N, C, or T, e.g., serine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.12 VP1 can be obtained from any GII.12 strain, including but not limited to, GII.12 / HS206 / 2010 / USA (SEQ ID NO: 19, amino acid sequence; Figure 23A). GII.12_A90L VP1 (GII.12_A90X (X=L, I, M or V), VP1): wherein the alanine corresponding to amino acid 94 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a leucine (GII.12_A90L; SEQ ID NO: 90, FIG. 34C), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.12_A90L VP1 protein. For example, a GII.12 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.12_A90L VP1 protein (SEQ ID NO: 90, FIG. 34C), provided that the substitution, modification, or mutation at the position corresponding to amino acid 94 of Norovirus VP1 genotype GI.1 remains L, I, M, or V, e.g., leucine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.12 VP1 can be obtained from any GII.12 strain, including but not limited to, GII.12 / HS206 / 2010 / USA (SEQ ID NO: 19, amino acid sequence; Figure 23A). GII.12_E80S+A90L VP1 (GII.12_E80X (X=S, N, C or T)+A90X (X=L, I, M or V), VP1): in which the glutamic acid and alanine corresponding to amino acids 84 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to serine and leucine, respectively (GII.12_E80S+A90L; SEQ ID NO: 92, FIG. 34E), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GII.12_E80S+A90L VP1 protein. For example, a GII.12 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.12_E80S+A90L VP1 protein (SEQ ID NO: 92, FIG. 34E), provided that the substitutions, modifications, or mutations at positions corresponding to amino acids 84 and 94 of Norovirus VP1 genotype GI.1 remain S, N, C, or T, e.g., serine, and L, I, M, or V, e.g., leucine, respectively, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.12 VP1 can be obtained from any GII.12 strain, including but not limited to, GII.12 / HS206 / 2010 / USA (SEQ ID NO: 19, amino acid sequence; Figure 23A). GII.17_A39V VP1 (GII.17_A39X (X=V, I, L or M), VP1): wherein the alanine corresponding to amino acid 43 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a valine (GII.17_A39V; SEQ ID NO: 192, FIG. 34G), or a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.17_A39V VP1 protein. For example, a GII.17 VP1 protein can have about 0%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.17_A39V VP1 protein (SEQ ID NO: 192, FIG. 34G), provided that the substitution, modification, or mutation at the position corresponding to amino acid 43 of Norovirus VP1 genotype GI.1 remains V, I, L, or M, e.g., valine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.17 VP1 can be obtained from any GII.17 strain, including but not limited to Hu / GII.17 / Kawasaki323 / 2014 / JP (SEQ ID NO: 24, amino acid; SEQ ID NO: 25, nucleotide; Figures 26A and 26B). GII.17 R53I VP1 (GII.17_R53I (X=I, L, V, A or M), VP1): wherein the arginine corresponding to amino acid 57 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to an isoleucine (GII.17_R53I; SEQ ID NO: 194, FIG. 34I), or a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.17_R53I VP1 protein. For example, a GII.17 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.17_R53I VP1 protein (SEQ ID NO: 194, FIG. 34I), provided that the substitution, modification, or mutation at the position corresponding to amino acid 57 of Norovirus VP1 genotype GI.1 remains I, L, V, A, or M, e.g., isoleucine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.17 VP1 can be obtained from any GII.17 strain, including but not limited to Hu / GII.17 / Kawasaki323 / 2014 / JP (SEQ ID NO: 24, amino acid; SEQ ID NO: 25, nucleotide; Figures 26A and 26B). GII.17_A90L VP1 (GII.4_A90X (X=L, I, M or V), VP1): wherein the serine corresponding to amino acid 94 of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) has been mutated, for example, to a leucine (GII.17_A90L; SEQ ID NO: 196, FIG. 34K), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.17_A90L VP1 protein. For example, a GII.17 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.17_A90L VP1 protein (SEQ ID NO: 196, FIG. 34K), provided that the substitution, modification, or mutation at the position corresponding to amino acid 94 of Norovirus VP1 genotype GI.1 remains L, I, M, or V, e.g., leucine, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.17 VP1 can be obtained from any GII.17 strain, including but not limited to Hu / GII.17 / Kawasaki323 / 2014 / JP (SEQ ID NO: 24, amino acid; SEQ ID NO: 25, nucleotide; Figures 26A and 26B). GII.17_A39V+R53I VP1 (GII.17_A39X (X=V, I, L or M)+R53X (X=I, L, M, A or V), VP1): in which the alanine and arginine corresponding to amino acids 43 and 57, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to valine and isoleucine, respectively (GII.17_A39V+R53I; SEQ ID NO: 198, FIG. 34M), or to a sequence exhibiting about 80% to about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of the GII.17_A39V+R53I VP1 protein. For example, a GII.17 VP1 protein can have about 0%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.17_A39V+R53I VP1 protein (SEQ ID NO: 198, FIG. 34M), provided that the substitutions, modifications, or mutations at positions corresponding to amino acids 43 and 57 of Norovirus VP1 genotype GI.1 remain V, I, L, or M, e.g., valine, and I, L, M, V, or A, e.g., isoleucine, respectively, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.17 VP1 can be obtained from any GII.17 strain, including but not limited to Hu / GII.17 / Kawasaki323 / 2014 / JP (SEQ ID NO: 24, amino acid; SEQ ID NO: 25, nucleotide; Figures 26A and 26B). GII.17_E80S+A90L VP1 (GII.4_E80X (X=S, N, C or T)+A90X (X=L, I, M or V), VP1): in which the glutamic acid and alanine corresponding to amino acids 84 and 94, respectively, of norovirus VP1 genotype GI.1 (SEQ ID NO: 1) have been mutated, for example, to serine and leucine, respectively (GII.17_E80S+A90L; SEQ ID NO: 200, FIG. 34O), or to a sequence exhibiting about 80% to about 100% sequence similarity, or any amount therebetween, to the amino acid sequence of the GII.17_E80S+A90L VP1 protein. For example, a GII.17 VP1 protein can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or any amount of sequence similarity therebetween, to the amino acid sequence of a GII.17_E80S+A90L VP1 protein (SEQ ID NO: 200, FIG. 34O), provided that the substitutions, modifications, or mutations at positions corresponding to amino acids 84 and 94 of Norovirus VP1 genotype GI.1 remain S, N, C, or T, e.g., serine, and L, I, M, or V, e.g., leucine, respectively, and the VP1 protein elicits immunity to Norovirus when administered to a subject. The sequence encoding GII.17 VP1 can be obtained from any GII.17 strain, including but not limited to Hu / GII.17 / Kawasaki323 / 2014 / JP (SEQ ID NO: 24, amino acid; SEQ ID NO: 25, nucleotide; Figures 26A and 26B).
[0152] VLP yield An example of the improved properties of VP1 can be seen by comparing the yield of VLPs containing GI.3 VP1 protein, shown with reference to FIG. 5B (see Example 3). Expression of modified Norovirus VP1 proteins GI.3_S94X (X=L, V, I, M, T, E, D, N, Q, K or H) (see FIG. 5F), GI.3_M57I+S94L (see FIG. 5D) and GI.3_Q84S+S94L (see FIG. 5B) in plants resulted in comparable or higher VLP yields compared to the yield of wild-type GI.3 VP1. Furthermore, expression of modified Norovirus VP1 proteins GI.7_M57X (X=I, L, G, S, T, N, Q, K or H) (see FIG. 6F) in plants resulted in comparable or higher VLP yields compared to the yield of wild-type GI.7 VP1.
[0153] Similar improved properties of increased VLP yields are shown with reference to Figures 9A-9E and 9H. Compared to VLPs containing wild-type GII.4 VP1, norovirus modified VP1 proteins GII.4_R53I (Figure 9D), GII.4_P80X (X = S, A, N, K or H) (Figures 9B and 9H), GII.4_P80S+R53I (Figure 9D), GII.4_P80S+A39X (X = V, I, M, T, E, D, N, Q, K or H) (Figures 9C and 9I), GII. VLPs containing GII.4_P80S+S90L (Figure 9B), GII.4_P80S+Δ35-42 (Figure 9C), GII.4_P80S+SSTAVATA (Figure 9F) and GII.4_A39V+R53I_P80S (Figure 9G) showed enhanced VLP yields in plants, while GII.4_A39V and GII.4_V47P showed a slight increase in protein yield.
[0154] Increased VLP yields compared to wild type were also observed in plant extracts expressing GII.6_S90L VP1 (Figures 10A and 10B).
[0155] VLPs containing modified VP1 proteins with amino acid substitutions at position 84 (GI strains) or 80 (GII strains; corresponding to or aligned with position 84 of GI.1 VP1) showed the same (GI.3_Q84S; GI.5_Q84S, see also Figure 6B; GII.3_E80S, see also Figure 8A) or increased (GI.7_R84S; GI.7_M57I+R84S; see also Figure 6D; GII.4_P80S, see also Figures 9B-9F; GII.12_E80S) VLP yields when compared to the yields of VLPs containing the corresponding wild-type (native) VP1 proteins.
[0156] VLPs containing modified VP1 proteins with amino acid substitutions at position 94 (GI strains) or 90 (GII strains; corresponding to or aligned with position 94 of GI.1 VP1) showed the same or increased VLP yields when compared to the yields of VLPs containing the corresponding wild-type or native VP1 proteins for all modified VP1 proteins tested (GI.3_S94X (X=L, V, I, M, T, E, D, N, Q, K or H) (Figures 5B and 5F); GI.5_A94L (see Figure 6B); GII.2_A90L (see Figure 7B); GII.4_S90L (see Figure 9B); GII.6_S90L (see Figure 10A); GII.12_A90L (see Figure 11B); and GII.17_A90L (see Figure 11D).
[0157] Similarly, VLPs containing modified VP1 proteins with amino acid substitutions at positions 84 and 94 (GI strains) or 80 and 90 (GII strains; corresponding to or aligned with positions 84 and 94 of GI.1 VP1) showed increased VLP yields when compared to the yields of VLPs containing the corresponding wild-type or native VP1 proteins for all modified VP1 proteins tested (GI.3_Q84S+S94L, see also Figure 5B; GI.5_Q84S+A94L, see also Figure 6B; GII.2_E80S+A90L, see also Figures 7B and 7C; GII.4_P80S+S90L, see also Figure 9B; GII.12_E80S+A90L, see also Figure 11B).
[0158] Additional modifications were also observed to increase VLP yields. These modifications include GI.3_M57I+S94L (Figure 5D), GI.7_M57I (Figure 6D), GI.7_M57I+R84S (Figure 6D), GII.2_A39V+E80S+A90L (Figure 7C), GII.2_R53I+E80S+A90L (Figure 7C), GII.4_R53I (Figure 9D), GII.4_A39V+P80X (X=S, A, N, K or H) (Figures 9C and 9I); GII.4_R53I+P80S (Figure 9D); GII.4_V47P+P80S (Figure 9E); GII.4_Δ35-42+P80S (Figure 9C) and GII.4_A39V+R53I+P80S (Figure 9G).
[0159] VLP size, density, stability and quality As shown in Figure 5B, mutant norovirus VP1 proteins GI.3_S94L and GI.3_Q84S+S94L exhibited improved properties of VLPs with higher density (determined by Coomassie-stained SDS PAGE of iodixanol density gradient fractions of protein extracts) than wild-type norovirus GI.3 VP1, such that VLPs were observed in fraction 1 (F1) and peaked in fractions F2-F6. These results indicate that assembly of native GI.3 VLPs may be less stable than GI.3_S94L VLPs, and native GI.3 VLPs may be more susceptible to the generation of aberrant capsid particles and fragmentation products. As a result, VLPs containing GI.3_S94L VP1, GI.3_M57I+S94L and GI.3_Q84S+S94L VP1 exhibit higher structural integrity than wild-type GI.3 VP1. Additionally, a higher relative proportion of 38 nm diameter VLPs to 23 nm diameter VLPs was observed in VLPs containing GI.3_S94L VP1, GI.3_M57I+S94L and GI.3_Q84S+S94L VP1 compared to the wild type, as determined using transmission electron microscopy (TEM) (Figures 5C and 5E).
[0160] VLPs composed of GI.5_Q84S VP1, GI.5_A94L VP1 or GI.5_Q84S+A94L VP1 proteins showed increased yields, with GI.5_Q84S+A94L VP1 also showing higher density, stability and structural integrity (similar to that described above for VLPs produced using modified GI.3 VP1) than wild-type norovirus GI.5 VP1 (Figure 6B). As shown in Figure 6C, the resulting VLPs had fewer damaged VLP particles and a higher relative proportion of 38 nm diameter particles compared to 23 nm diameter VLPs compared to wild-type.
[0161] VLPs composed of GI.7_R84S, GI.7_M57I, and GI.7_M57I+R84S VP1 proteins were also observed to exhibit similar or higher densities compared to wild-type norovirus GI.7 VP1 (Figure 6D). As shown in Figure 6E, the modified VLPs had fewer damaged VLP particles and a higher relative proportion of 38 nm diameter particles compared to the wild-type VLPs.
[0162] VLPs composed of GII.2_E80S+A90L, GII.2_A39V+E80S+A90L VP1 proteins exhibited higher density, stability and structural integrity (similar to that described above) than wild-type norovirus GII.2 VP1 (Figure 7C). As shown in Figure 7C, the modified VLPs had fewer damaged VLP particles and a higher relative proportion of 38 nm diameter particles compared to the wild-type VLPs.
[0163] Expression of GII.3_E80S in planta resulted in VLPs with particles of 38 nm in diameter (Fig. 8B), although the yield of VP1 protein (determined by SDS-PAGE) remained low.
[0164] As shown in Figures 9B, 9C, 9D and 9G, the modified VP1 proteins, GII.4_A39V, GII.4_V47P, GII.4_R53I, GII.4_P80S, GII.4_S90L, GII.4_A39V+P80S, GII.4_R53I+P80S, GII.4_P80S+S90L, GII.4_P80S+Δ35-42 and GII.4_A39V+R53I+P80S all exhibited VLPs with higher density, stability and structural integrity than VLPs containing the wild-type GII.4 VP1 protein. Furthermore, VLPs containing GII.4_A39V+P80S, GII.4_R53I+P80S, GII.4_P80S+S90L, GII.4_P80S+Δ35-42 and GII.4_A39V+R53I+P80S all showed improved viral capsid integrity and fewer damaged particles as seen by TEM (Figures 9B, 9C, 9D and 9E). VLPs containing GII.4_A39V+P80S and GII.4_P80S+Δ35-42 also showed a higher proportion of 38 nm diameter particles compared to 23 nm diameter particles compared to wild-type GII.4 VLPs (Figures 9B and 9C). VLPs were also produced from GII.4_V47P; GII.4_V47P+P80S, GII.4_SSTAVATA; GII.4_P80S+SSTAVATA (Figures 9E and 9F).
[0165] As shown in Figures 10A and 10B, expression of the modified Norovirus VP1 protein GII.6_S90L resulted in VLPs with a diameter of 38 nm, as determined using transmission electron microscopy (TEM).
[0166] VLPs containing GII.12_E80S, GII.12_A90L and GII.12_E80S+A90L also exhibited improved properties, with a higher density of 38 nm diameter VLPs than VLPs containing wild-type GII.12 VP1 (Figure 11C), as determined using transmission electron microscopy (TEM).
[0167] VLPs containing GII.17_A39V, GII.17_A90L and GII.17_R53I also exhibited improved properties, with a higher density of 38 nm diameter VLPs than VLPs containing wild-type GII.17 VP1, as determined using transmission electron microscopy (TEM) (Figure 11D).
[0168] Inducing immunity against norovirus infection "Immune response" generally refers to a response of a subject's adaptive immune system. The adaptive immune system generally includes humoral and cellular responses. The humoral response is an aspect of immunity mediated by secreted antibodies produced in cells of the B lymphocyte system (B cells). Secreted antibodies bind to antigens on the surface of invading microorganisms (such as viruses or bacteria), thereby alerting them for destruction. Humoral immunity is generally used to refer to antibody production and associated processes, as well as antibody effector functions, including Th2 cell activation and cytokine production, memory cell generation, opsonization promotion of phagocytosis, pathogen elimination, and the like. The terms "modulate" or "modulation" and the like refer to an increase or decrease in a particular response or parameter as determined by any of several commonly known or used assays, some of which are exemplified herein.
[0169] A cellular response is an immune response that does not involve antibodies, but rather involves the activation of macrophages, natural killer cells (NK), antigen-specific cytotoxic T lymphocytes, and the release of various cytokines in response to antigens. Cellular immunity is generally used to refer to several Th cell activations, Tc cell activations, and T cell responses. Cellular immunity may be particularly important in the response to viral infections.
[0170] For example, induction of antigen-specific CD8 positive T lymphocytes can be measured using an ELISPOT assay. Stimulation of CD4 positive T lymphocytes can be measured using a proliferation assay. Anti-Norovirus antibody titers can be quantified using an ELISA assay. The isotype of antigen-specific or cross-reactive antibodies can also be measured using anti-isotype antibodies (e.g., anti-IgG, anti-IgA, anti-IgE, or anti-IgM). Methods and techniques for performing such assays are well known in the art.
[0171] The presence or level of cytokines may also be quantified. For example, T helper cell responses (Th1 / Th2) are characterized by measuring IFN-γ and IL-4 secreting cells by ELISA (e.g., BD Biosciences OptEIA kit). Peripheral blood mononuclear cells (PBMCs) or splenocytes obtained from the subject may be cultured and the supernatant analyzed. T lymphocytes may also be quantified by fluorescence activated cell sorting (FACS) using marker-specific fluorescent labels and methods known in the art.
[0172] Microneutralization assays may also be performed to characterize the subject's immune response, see, for example, the method of Rowe et al., 1973. Virus neutralization titers may be quantified by several methods, including: crystal violet fixation / staining of cells followed by counting of lytic plaques (plaque assay); microscopic observation of cell lysis in in vitro cultures; and 2) ELISA and spectrophotometric detection of Norovirus.
[0173] As used herein, the term "epitope" or "epitopes" refers to that structural portion of an antigen to which an antibody specifically binds.
[0174] Immune responses to plant-produced wild-type norovirus native GI.1 (SEQ ID NO: 1) VLPs were performed using BALB / c mice (Example 4). For example, GI.3_Q84S (construct 4140; SEQ ID NO: 167), GI.3_S94L (construct 4141; SEQ ID NO: 9), GI.3_A43V+S94L (construct 4179; SEQ ID NO: 169), GI.3_M57I+S94L (construct 4180; SEQ ID NO: 171), GI.3_P84S+S94L (construct 4142; SEQ ID NO: 11), GI.3_A43V+M57I+S94L (construct 4181; SEQ ID NO: 173), GI.5_Q84S (construct 4130; SEQ ID NO: 35), GI.5_A94L (construct 4131; SEQ ID NO: 37), GI.5_Q84S+A94L (construct 4132; SEQ ID NO: 39), GI.7_R84S (construct 4210; SEQ ID NO: 176), GI.7_M57I (construct 4217; SEQ ID NO: 178), GI.7_M57I+R84S (construct 4218; SEQ ID NO: 180), GII.2_E80S (construct 4143; SEQ ID NO: 86), GII.2_A90L (construct 4144; SEQ ID NO: 42), GII.2_Q80S +A90L (construct 4145; SEQ ID NO: 44), GII.2_A39V+Q80S+A90L (construct 4182; SEQ ID NO: 183), GII.2_R53I+Q80S+A90L (construct 4183; SEQ ID NO: 185), GII.2_A39V+R53I+Q80S+A90L (construct 4184; SEQ ID NO: 187), GII.3_E80S (construct 4146; SEQ ID NO: 47), GII.3_A90L (construct 4147; SEQ ID NO: 49), GII.3_E80S+A90L ( Construct 4148; SEQ ID NO: 51), GII.4_A39V (Construct 4155; SEQ ID NO: 54), GII.4_V47P (Construct 4156; SEQ ID NO: 56), GII.4_R53I (Construct 4157; SEQ ID NO: 58), GII.4_P80S (Construct 4133; SEQ ID NO: 60), GII.4_S90L (Construct 4134; SEQ ID NO: 62), GII.4_Δ35-42 (Construct 4158; SEQ ID NO: 64), GII.4_SSTAVATA (Construct 4159; SEQ ID NO: 66).GII.4_A39V+R53I (construct 4185; SEQ ID NO: 189), GII.4_A39V+P80S (construct 4165; SEQ ID NO: 68), GII.4_V47P+P80S (construct 4166; SEQ ID NO: 70), GII.4_R53I+P80S (construct 4167; SEQ ID NO: 72), GII.4_P80S+S90L (construct 4135; SEQ ID NO: 74), GII. GII.4_Δ35-42+P80S (construct 4168; SEQ ID NO: 76), GII.4_P80S+SSTAVATA (construct 4169; SEQ ID NO: 78), GII.4_A39V+R53I+P80S (construct 4186; SEQ ID NO: 191), GII.6_E80S (construct 4149; SEQ ID NO: 80), GII.6_S90L (construct 4150; SEQ ID NO: 82), GII.6_E8 GII.12_E80S+S90L (construct 4151; SEQ ID NO: 84), GII.12_E80S (construct 4136; SEQ ID NO: 89), GII.12_A90L (construct 4137; SEQ ID NO: 91), GII.12_E80S+A90L (construct 4138; SEQ ID NO: 93), GII.17_A39V (construct 4234; SEQ ID NO: 193), GII.17_R53I (construct 4235; SEQ ID NO: Mice may be administered plant-produced modified VP1 proteins or VLPs containing modified VP1 proteins produced using GII.17_A90L (construct 4232; SEQ ID NO: 197), GII.17_A39V+R53I (construct 4236; SEQ ID NO: 199), GII.17_E80S+A90L (construct 4233; SEQ ID NO: 201) or combinations thereof. Serum samples from blood collected from animals were analyzed by ELISA for GI.1 VLP-specific total IgG and IgA antibodies using GI.1 VLP-coated plates. Referring to FIG. 3D, for each treatment group, mice immunized with plant norovirus native VP1 VLPs from the GI.1 genotype show GI.1 VLP-specific IgG antibody titers in the serum. The IgG titer levels induced by each treatment were statistically higher (p<0.05) than the titers quantified for the placebo group. IgG titer levels increased in a dose-dependent manner (significant differences were detected between 1 μg and 10 μg treatments formulated with or without Alhydrogel; p < 0.05).A significant increase in IgG titer levels was detected in each treatment group from day 21 to day 42 (p<0.05). These results collectively demonstrate the ability of plant-produced norovirus native VP1 VLPs to induce a strong immune response in mice.
[0175] Accordingly, provided herein is a method of producing an antibody or antibody fragment, comprising administering to a subject or host animal a modified Norovirus VP1 protein, or a Norovirus VLP comprising one or more modified VP1 proteins, thereby producing an antibody or antibody fragment. A modified Norovirus VP1 protein (either a GI VP1 protein or a GII VP1 protein) comprising one or more substitutions, modifications or mutations at amino acid residues selected from amino acid residues 43, 57, 84 and 94 in a sequence aligned with Norovirus VP1 genotype GI.1 (SEQ ID NO:1); a deletion of a peptide fragment from amino acids 39-46 in a sequence aligned with Norovirus VP1 genotype GI.1 (SEQ ID NO:1); one or more substitutions, modifications or mutations at amino acids corresponding to amino acid residues 39-46 of Norovirus VP1 genotype GI.1 are mutated to the sequence SSTAVATA or a combination thereof, and wherein the nucleotide sequence is not derived from a genotype GI.1 Norovirus VP1. The VLP may further comprise a Norovirus VP2 protein.
[0176] Also provided is a composition for eliciting an immune response comprising an effective dose of a VLP comprising a modified Norovirus VP1 protein and a pharma- ceutically acceptable carrier, adjuvant, vehicle or excipient.
[0177] Plant Expression The constructs of the invention can be introduced into plant cells using Ti plasmids, Ri plasmids, plant viral vectors, direct DNA transformation, microinjection, electroporation, etc. For reviews of such techniques, see, e.g., Weissbach and Weissbach, Methods for Plant Molecular Biology, Academy Press, New York VIII, pp. 421-463 (1988); Geison and Corey, Plant Molecular Biology, 2d Ed. (1988); and Miki and Iyer, Fundamentals of Gene Transfer in PlantsSee, In Plant Metabolism, 2d Ed. DT. Dennis, DH Turpin, DD Lefebrvre, DB Layzell (eds), Addison Wesly, Langmans Ltd. London, pp. 561-579 (1997). Other methods include direct DNA uptake (using liposome electroporation), e.g., using protoplasts, microinjection, microprojectiles or whiskers, and vacuum infiltration.For example, Bilang, et al. (1991, Gene 100:247-250), Scheid et al. (1991, Mol. Gen. Genet. 228:104-112), Guerche et al. (1987, Plant Science 52:111-116), Neuhause et al. (1987, Theor. Appl. Genet.75:30-36), Klein et al.(2987,Nature 327:70-73);Freeman et al.(1984,Plant Cell Physiol.29:1353), Howell et al.(1980,Science 208:1265), Horsch et al.(1985,Science 227:1229-1231), DeBlock et al. (1989, Plant Physiology 91:694-701), Methods for Plant Molecular Biology (Weissbach and Weissbach, eds., Academic Press Inc., 1988), Methods in Plant Molecular Biology (Schuler and Zielinski, eds., Academic Press Inc., 1989), WO 92 / 09696, WO 94 / 00583, EP 331083, EP 175966, Liu and Lomonossoff (2002, J Virol Meth., 105:343-348), European Patent No. 290395, International Publication No. WO 8706614, U.S. Pat. Nos. 4,945,050, 5,036,006 and 5,100,792, U.S. patent application Ser. No. 08 / 438,666, filed May 10, 1995, and U.S. patent application Ser. No. 07 / 951,715, filed September 25, 1992, all of which are incorporated herein by reference.
[0178] Transient expression methods may be used to express the constructs of the present invention (see D'Aoust et al., 2009, Methods in molecular biology, Vol 483, pages 41-50; Liu and Lomonossoff, 2002, Journal of Virological Methods, 105:343-348; incorporated herein by reference). Alternatively, vacuum-based transient expression methods such as those described by Kapila et al. (1997, Plant Sci. 122, 101-108; incorporated herein by reference), or WO 00 / 063400, WO 00 / 037663 (incorporated herein by reference) may be used. These methods may include, for example, but are not limited to, agroinoculation or agroinfiltration, syringe infiltration, although other transient methods may also be used as described above. By agroinoculation, agroinfiltration or syringe infiltration, a mixture of Agrobacteria containing the desired nucleic acid penetrates the intercellular spaces of tissues, such as leaves, above-ground parts of the plant (including stems, leaves and flowers), other parts of the plant (stems, roots, flowers) or the whole plant. The Agrobacteria infect after passing through the epidermis and transfer t-DNA copies into the cells. The t-DNA is transcribed as an episome and the mRNA is translated, leading to the production of the protein of interest in the infected cell, but the passage of the t-DNA inside the nucleus is transient.
[0179] Also considered part of the present invention are transgenic plants, plant cells or seeds comprising the genetic constructs of the present invention, which may be used as suitable platform plants for transient protein expression as described herein. Methods for regenerating whole plants from plant cells are also known in the art (see, for example, Guerineau and Mullineaux (1993, Plant transformation and expression vectors. In: Plant Molecular Biology Labfax (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148). Generally, transformed plant cells are cultured in an appropriate medium which may contain a selection agent such as an antibiotic, where a selectable marker is used to facilitate identification of transformed plant cells. Once callus is formed, shoot formation can be promoted by using appropriate plant hormones according to known methods, and the shoots transferred to rooting medium to regenerate plants. The plants may then be used to establish repetitive generations from seeds or using vegetative propagation techniques. Transgenic plants can also be generated without the use of tissue culture. Methods for stable transformation and regeneration of these organisms are well established in the art and known to those skilled in the art. Available techniques are described in detail in Vasil et al. (Cell Culture and Somatic Cell Genetics of Plants, Vol I, Il and III, Laboratory (Procedures and Their Applications, Academic Press, 1984), and Weissbach and Weissbach (Methods for Plant Molecular Biology, Academic Press, 1989). The method for obtaining transformed and regenerated plants is not critical to the present invention.
[0180] When a plant, plant part or plant cell is transformed or co-transformed with more than one nucleic acid construct, the nucleic acid constructs may be introduced into Agrobacterium in one transfection such that the nucleic acids are pooled and bacterial cells are transfected. Alternatively, the constructs may be introduced sequentially. In this case, a first construct is introduced into Agrobacterium as described, and the cells are grown under selective conditions (e.g., in the presence of an antibiotic) in which only a single transformed bacterium can grow. Following this first selection step, a second nucleic acid construct is introduced into Agrobacterium as described, and the cells are grown under doubly selective conditions in which only doubly transformed bacteria can grow. The doubly transformed bacterium can then be used to transform a plant, plant part or plant cell as described herein, or may be subjected to an additional transformation step to receive a third nucleic acid construct.
[0181] Alternatively, where a plant, plant part or plant cell is to be transformed or co-transformed with two or more nucleic acid constructs, the nucleic acid constructs may be introduced into the plant by co-infiltrating the plant, plant part or plant cell with a mixture of Agrobacterium cells, each Agrobacterium cell containing one or more of the constructs to be introduced into the plant. The concentrations of the various Agrobacteria populations containing the desired constructs may be varied during the infiltration process to vary the relative expression levels within the plant, plant part or plant cell of the nucleotide sequences of interest within the constructs.
[0182] Thus, provided herein is a plant, plant part, plant cell, or plant extract comprising one or more modified Norovirus VP1 proteins, or a Norovirus VLP comprising one or more modified VP1 proteins. The one or more modified Norovirus VP1 proteins, including one or more substitutions, modifications, or mutations at positions selected from amino acid residues 43, 57, 84, and 94 in a sequence aligned with Norovirus VP1 genotype GI.1 (SEQ ID NO:1); a deletion of a peptide fragment from amino acid 39 to 46 in a sequence aligned with Norovirus VP1 genotype GI.1 (SEQ ID NO:1); or a combination thereof, and the nucleotide sequence is not derived from genotype GI.1 Norovirus VP1. The VLP may further comprise a Norovirus VP2 protein.
[0183] Also provided herein are plants, plant parts, plant cells, or plant extracts comprising a polynucleotide sequence encoding one or more modified Norovirus VP1 proteins. The one or more modified Norovirus VP1 proteins, including one or more substitutions, modifications, or mutations at positions selected from amino acid residues 43, 57, 84, and 94 in a sequence aligned with Norovirus VP1 genotype GI.1 (SEQ ID NO:1); a deletion of a peptide fragment from amino acids 39 to 46 in a sequence aligned with Norovirus VP1 genotype GI.1 (SEQ ID NO:1); or a combination thereof, and the nucleotide sequence is not derived from a genotype GI.1 Norovirus VP1.
[0184] A list of norovirus strains and constructs is shown in Table 3. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8]
[0185] The invention is further illustrated in the following examples.
[0186] Example 1: Norovirus VP1 constructs Candidate sequences for VP1 and VP2 are available in Genbank (see Figures 2A and 2B). Non-limiting examples of these sequences are as follows:
[0187] Hu / GI.2 / Leuven / 2003 / BEL (GI.2; SEQ ID NO: 4; Figure 13A);
[0188] Hu / GI.3 / S29 / 2008 / Lilla Edet / Sweden (GI.3; SEQ ID NO:6; Figure 14A);
[0189] Hu / GI.5 / Siklos / Hun5407 / 2013 / HUN (GI.5; SEQ ID NO: 12; Figure 15A);
[0190] Hu / GI.7 / USA / 2014 / GA5043 (GI.7, SEQ ID NO: 101, FIG. 16A)
[0191] Hu / GII.1 / Ascension208 / 2010 / USA (GII.1; SEQ ID NO: 13; Figure 16C);
[0192] Hu / GII.2 / CGMH47 / 2011 / TW (GII.2; SEQ ID NO: 14; Figure 17A);
[0193] Hu / GII.3 / Jingzhou / 2013402 / CHN (GII.3; SEQ ID NO: 15; Figure 18A);
[0194] Hu / GII.4 / Sydney / NSW0514 / 2012 / AU (GII.4; SEQ ID NO: 16; Figure 19A);
[0195] US96 / GII.4 / Dresden174 / 1997 / DE_AY741811 (GII.4; SEQ ID NO:27; Figure 19C);
[0196] FH02 / GII.4 / FarmingtonHills / 2002 / US_AY502023 (GII.4; SEQ ID NO:28; Figure 19D);
[0197] Hnt04:GII.4 / Hunter-NSW504D / 2004 / AU_DQ078814 (GII.4; SEQ ID NO:29; Figure 19E);
[0198] 2006b:GII.4 / Shellharbour-NSW696T / 2006 / AU_EF684915 (GII.4; SEQ ID NO:30; Figure 19F);
[0199] NO09:GII.4 / Orange-NSW001P / 2008 / AU_GQ845367 (GII.4; SEQ ID NO:31; Figure 19G);
[0200] GII.14_Saga_2008_JPN_ADE28701 Native VP1 (GII.14; SEQ ID NO: 32; Figure 25);
[0201] Hu / GII.5 / AlbertaEI390 / 2013 / CA (GII.5; SEQ ID NO: 17; Figure 20);
[0202] Hu / GII.6 / Ohio / 490 / 2012 / USA (GII.6; SEQ ID NO:20; Figure 21A);
[0203] G11.7 / Musa / 2010 / All73774 (GII.7; SEQ ID NO: 18; Figure 22);
[0204] Hu / GII.12 / HS206 / 2010 / USA (GII.12; SEQ ID NO: 19; Figure 23A);
[0205] GII.13 / VA173 / 2010 / H9AWU4 (GII.13; SEQ ID NO:22; Figure 24A);
[0206] Hu / GII.17 / Kawasaki323 / 2014 / JP (GII.17; SEQ ID NO:24; Figure 26A);
[0207] Hu / GII.21 / Salisbury150 / 2011 / USA (GII.21; sequence number 26; Figure 27).
[0208] The following constructs were prepared using the primers listed in Table 4. [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6]
[0209] WT GI.1 Norovirus VP1: A2X35S / CPMV 160 / wt VP1 GI.1 / NOS (construct no. 2724) The human codon-optimized sequence encoding VP1 from norovirus strain GI.1 / Norwalk / 1968 / US was cloned into the 2X35S / CPMV 160 / NOS expression system using the following PCR-based method: Primers IF-NoV(US68)VP1(ORF2)(hCod).c (SEQ ID NO:102) and IF-NoV(US68)VP1(ORF2)(hCod).r (SEQ ID NO:103) were used to amplify a fragment containing the GI.1 VP1 coding sequence using the human codon-optimized GI.1 VP1 gene sequence (SEQ ID NO:3) as a template. For sequence optimization, the GI.1 / Norwalk / 1968 / US VP1 protein sequence (Genbank accession number NP_056821) was reverse translated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned into the 2X35S / CPMV 160 / NOS expression system using the In-Fusion cloning system (Clontech, Mountain View, CA). Construct #1190 (SEQ ID NO:162; Figures 38A and 48) was digested with SacII and StuI restriction enzymes, and the linearized plasmid was used in the In-Fusion assembly reaction. Construct #1190 is an acceptor plasmid for "In Fusion" cloning of a gene of interest in a 2X35S / CPMV 160 / NOS-based expression cassette. Construct #1190 also incorporates a gene construct for co-expression of the TBSV P19 suppressor of silencing under the alfalfa plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid, and the sequence from the left T-DNA border to the right T-DNA border is shown in SEQ ID NO:162. The resulting construct was given the number 2724 (Figure 38B; SEQ ID NO: 163). The amino acid sequence of native VP1 from Norovirus strain GI.1 / Norwalk / 1968 / US is shown in SEQ ID NO: 1. A diagram of plasmid 2724 is shown in Figure 39A.
[0210] 2X35S / CPMV 160 / GII.4_P80S(hCod) / NOS+MAR(Construct No. 4133) The human codon-optimized sequence encoding VP1 from GII.4 / Sydney / NSW0514 / 2012 / AU, containing a P80S substitution in the S domain, was cloned into the 2X35S / CPMV 160 / NOS+MAR expression system using the following PCR-based method: In the first round of PCR, primers IF-GII.4Syd12VP1.c (SEQ ID NO: 130) and GII.4(P80S).r (SEQ ID NO: 138) were used to amplify a fragment containing the S domain, with the P80S amino acid mutated, using the human codon-optimized GII.4 VP1 gene sequence (SEQ ID NO: 52) as template. GII.4(P80S).c (SEQ ID NO: 139) and IF-GII.4Syd12VP1.r (SEQ ID NO: 131) were used to amplify a second fragment containing the P80S substitution, with the remainder of the S and P domains, using the human codon-optimized GII.4 VP1 gene sequence (SEQ ID NO: 52) as template. For sequence optimization, the GII.4 / Sydney / NSW0514 / 2012 / AU VP1 protein sequence (Genbank accession number AFV08795) was reverse translated and optimized for human codon usage, GC content and mRNA structure. The PCR products from both amplifications were then mixed and used as template for a second round of amplification using IF-GII.4Syd12VP1.c (SEQ ID NO: 130) and IF-GII.4Syd12VP1.r (SEQ ID NO: 131) as primers. The final PCR product was cloned into the 2X35S / CPMV 160 / NOS+MAR expression system using the In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 3677 (SEQ ID NO: 164; Figure 38C and Figure 49) was digested with SacII and StuI restriction enzymes and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 3677 is an acceptor plasmid for "In Fusion" cloning of a gene of interest in a 2X35S / CPMV 160 / NOS+MAR based expression cassette.Construct no. 1190 also incorporates a genetic construct for co-expression of the TBSV P19 suppressor of silencing under the alfalfa plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid, the sequence from the left T-DNA border to the right T-DNA border is shown in SEQ ID NO: 164. The resulting construct was given the number 4133 (Figure 38D; SEQ ID NO: 165). The amino acid sequence of the mutant GII.4_P80S is shown in SEQ ID NO: 59. A diagram of plasmid 4133 is shown in Figure 44E.
[0211] 2X35S / CPMV 160 / GII.4_P80S+S90L(hCod) / NOS+MAR(Construct No. 4135) The human codon-optimized sequence encoding VP1 from GII.4 / Sydney / NSW0514 / 2012 / AU, containing the P80S and S90L substitutions in the S domain, was cloned into the 2X35S / CPMV 160 / NOS+MAR expression system using the following PCR-based method: In the first round of PCR, primers IF-GII.4Syd12VP1.c (SEQ ID NO: 130) and GII.4(S90L).r (SEQ ID NO: 140) were used to amplify a fragment containing the S domain, with the P80S and S90L amino acids mutated, using the human codon-optimized GII.4_P80S VP1 gene sequence (SEQ ID NO: 60) as template. GII.4(S90L).c (SEQ ID NO: 141) and IF-GII.4Syd12VP1.r (SEQ ID NO: 131) were used to amplify a second fragment containing the S and P domains, using the human codon-optimized GII.4_P80S VP1 gene sequence (SEQ ID NO: 60) as a template. For sequence optimization, the GII.4 / Sydney / NSW0514 / 2012 / AU VP1 protein sequence (Genbank accession number AFV08795) was reverse translated and optimized for human codon usage, GC content and mRNA structure. The PCR products from both amplifications were then mixed and used as template for a second round of amplification, using IF-GII.4Syd12VP1.c (SEQ ID NO: 130) and IF-GII.4Syd12VP1.r (SEQ ID NO: 131) as primers. The final PCR product was cloned into the 2X35S / CPMV 160 / NOS+MAR expression system using the In-Fusion cloning system (Clontech, Mountain View, CA). Construct #3677 (SEQ ID NO:164; Figure 38C and Figure 49) was digested with SacII and StuI restriction enzymes and the linearized plasmid was used in an In-Fusion assembly reaction. Construct #3677 is an acceptor plasmid for "In Fusion" cloning of a gene of interest into a 2X35S / CPMV 160 / NOS+MAR based expression cassette.Construct no. 1190 also incorporates a genetic construct for co-expression of the TBSV P19 suppressor of silencing under the alfalfa plastocyanin gene promoter and terminator. The backbone is the pCAMBIA binary plasmid, and the sequence from the left T-DNA border to the right T-DNA border is shown in SEQ ID NO: 164. The resulting construct was given the number 4135 (SEQ ID NO: 166). The amino acid sequence of the mutant GII.4_P80S+S90L is shown in SEQ ID NO: 73. A diagram of plasmid 4135 is shown in Figure 44L.
[0212] A summary of wild-type and mutant VP1 and VP2 proteins, primers, templates and products are shown in Tables 3 and 4. VP1 proteins with single, double, triple and quadruple modifications, substitutions or mutations were constructed using the same methods described above, see construct no. 4133 for single modifications and construct no. 4135 for double, triple and quadruple modifications. VP2 proteins are assembled using essentially the same methods described for construct no. 2724.
[0213] Example 2: Method Agrobacterium tumefaciens transfection Agrobacterium tumefaciens strain AGL1 was transfected by electroporation with native norovirus VP1, native norovirus VP2, or norovirus VP1 mutant protein expression vectors using the method described by D'Aoust et al., 2008 (Plant Biotech. J. 6:930-40). OD 600The transfected Agrobacterium was grown until the NA was 0.6-1.6. The Agrobacterium suspension was centrifuged before use and resuspended in infiltration medium (10 mM MgCl2 and 10 mM MES pH 5.6).
[0214] Preparation of plant biomass, inoculum and agroinfiltration N. benthamiana plants were grown from seeds in flat surfaces filled with a commercial peat moss substrate. Plants were grown in a greenhouse under a 16 / 8 photoperiod and a 25°C day / 20°C night temperature regime. Three weeks after sowing, individual seedlings were selected, transplanted into pots, and grown in the greenhouse for an additional three weeks under the same environmental conditions.
[0215] Agrobacteria grow at an OD of 0.6–1.6 on YEB medium supplemented with 10 mM 2-(N-morpholino)ethanesulfonic acid (MES), 20 μM acetosyringone, 50 μg / ml kanamycin, and 25 μg / ml carbenicillin, pH 5.6. 600 Agrobacteria transfected with each native norovirus VP1, native norovirus VP2 or norovirus VP1 mutant expression vector were grown until a total of 10 ...
[0216] Leaf harvest and total protein extract After incubation, the above-ground parts of the plants were harvested, frozen at -80°C and finely ground. Total soluble protein was extracted by homogenizing (Polytron) each sample of freeze-ground plant material in 2 volumes of cold 100 mM phosphate buffer pH 7.2 + 150 mM NaCl, 0.4 μg / ml metabisulfite and 1 mM phenylmethylsulfonyl fluoride. After homogenization, the slurry was centrifuged at 10,000g for 10 minutes at 4°C and these clarified crude extracts (supernatants) were saved for analysis.
[0217] Total protein content of clarified crude extracts was determined by Bradford assay (Bio-Rad, Hercules, California) using bovine serum albumin as a reference standard. Proteins were separated by SDS-PAGE under reducing conditions using Criterion™ TGX Stain-Free™ precast gels (Bio-Rad Laboratories, Hercules, CA). Proteins were visualized by staining the gels with Coomassie brilliant blue. Alternatively, proteins were visualized using the Gel Doc™ EZ Imaging System (Bio-Rad Laboratories, Hercules, CA) and electrophoretically transferred to polyvinylene difluoride (PVDF) membranes (Roche Diagnostics Corporation, Indianapolis, Indiana) for immunodetection. Prior to immunoblotting, membranes were blocked with 5% skim milk and 0.1% Tween-20 in Tris-buffered saline (TBS-T) for 16–18 h at 4°C.
[0218] Protein analysis and immunoblotting Immunoblotting was performed by first incubation with the primary mAb 242P antibody specific for VP1 from GI and GII genotypes, diluted 1 / 500 in 2% skim milk in TBS-Tween 20 0.1%. Peroxidase-conjugated goat anti-mouse (Jackson Immunoresearch, Cat. No. 115-035-146) diluted 1 / 10000 was used as the secondary antibody for chemiluminescence detection, diluted in 2% skim milk in TBS-Tween 20 0.1%. Immunoreactive complexes were detected by chemiluminescence using luminol as substrate (Roche Diagnostics Corporation). Horseradish peroxidase-enzyme conjugation of human IgG antibodies was performed using the EZ-Link Plus® Activated Peroxidase Conjugation Kit (Pierce, Rockford, Ill.).
[0219] Analysis of VLP formation / iodixanol gradient Proteins were extracted from the frozen biomass by mechanical extraction in a blender with 2 volumes of extraction buffer (100 mM phosphate buffer pH 7.2 + 150 mM NaCl). The slurry was filtered through a large pore nylon filter to remove large debris and centrifuged at 5000 g for 5 min at 4° C. The supernatant was collected and centrifuged again at 5000 g for 30 min (4° C.) to further remove debris. The supernatant is then loaded onto a discontinuous iodixanol density gradient. Analytical density gradient centrifugation was performed as follows: a 38 ml tube containing a discontinuous iodixanol density gradient (1 ml iodixanol 45%, 2 ml 35%, 2 ml 33%, 2 ml 31%, 2 ml 29% and 5 ml 25%) in acetate buffer was prepared and overlaid with 25 ml of extract containing virus-like particles. The gradient was centrifuged at 175000 g for 4 h (4° C.). After centrifugation, 1 ml fractions were collected from bottom to top and the fractions were analyzed by SDS-PAGE combined with protein staining or Western blot.
[0220] Electron microscopy After centrifugation of the partially clarified plant extracts on a discontinuous iodixanol density gradient as described above, fractions containing the sample (1 ml / fraction) were pooled, mixed with 100 mM PBS pH 7.2 + 150 mM NaCl buffer to completely fill the tube, and centrifuged at 100000 g for 120 min. The pellet was resuspended in 300-1000 μl of buffer depending on the amount of VP1.
[0221] Carbon-coated copper grids with 200 nm mesh size were made hydrophilic by placing them carbon side up on Whatman paper in a Petri dish and incubating overnight at 4 °C. 20 μl of pooled fractions from density gradient centrifugation observed by transmission electron microscopy (TEM) were deposited on parafilm and the grids were floated carbon side down and incubated at room temperature for 5 min. The grids were then washed four times on a 20 μl drop of water, draining excess water from the last wash by contacting the side of the grid to Whatman paper. The grids are then incubated for 1 min on a 20 μl drop of 2% aqueous uranyl acetate. The grids are allowed to dry on the Whatman paper for 5 min. Observations were made under a transmission electron microscope at magnifications ranging from 10,000X to 150,000X.
[0222] Example 3: Production of VP1 protein and VLPs in plants Agrobacterium tumefaciens containing expression vectors encoding wild-type norovirus VP1 or mutant norovirus VP1 constructs enabling expression of VP1 sequences were vacuum infiltrated into N. benthamiana leaves and the leaves were examined for VP1 protein and / or VLP production as described in Example 2. Nine days after infiltration (DPI), total crude protein extracts prepared from leaf homogenates were separated by SDS-PAGE and stained with Coomassie (VP1 production) or separated using a discontinuous iodixanol density gradient (VLP production) as described in Example 2 above. Fractions from the density gradient were examined using Coomassie stained SDS-PAGE. Norovirus VP1 protein appears in a band at approximately 55-60 kDa. The presence of VP1 protein within fractions of the density gradient indicates fractions where VLPs equilibrate during density gradient centrifugation. The yield of VLPs obtained from the peak fractions after density gradient centrifugation was also determined.
[0223] The yield or amount of wild-type norovirus VP1 protein extracted from plants varies depending on the genotype of norovirus VP1 expressed. Wild-type GI.1 VP1, GI.5 VP1, and GII.12 VP1 show readily detectable protein yields as measured using SDS PAGE (Figure 3A). In contrast, wild-type GII.4 VP1 is barely expressed in plants (Figure 3A right panel), and low or undetectable amounts of VP1 protein (using SDS-PAGE) were observed after expression of, for example, wild-type GII.2 VP1, GII.3 VP1, and GII.6 VP1 (Table 5). [Table 5]
[0224] GI.3 VLPs and VLPs containing modified GI.3 VP1 proteins Norovirus GI.3 VP1 constructs with a glutamine to serine substitution at position 84 (Q84S) provided yields comparable to wild-type GI.3 VP1, whereas norovirus GI.3 VP1 constructs with a serine to leucine substitution at position 94 (S94L), or combinations of substitutions including the S94L substitution, demonstrated increased yields of VLPs containing VP1 protein compared to VLPs containing wild-type GI.3 VP1, ranging from 1.9-3.8-fold increase (S94L), a 4.2-fold increase (A43V+S94L), a 1.8-fold increase (Q84S+S94L), and a 10.2-fold increase (A34V+M57I+Q84S+S94L). Furthermore, constructs with a serine to leucine, valine, isoleucine, methionine, threonine, glutamic acid, aspartic acid, asparagine, glutamine, lysine or histidine substitution at position 94 (GI.3_S94X (X = L, V, I, M, T, E, D, N, Q, K or H)) showed an increase in yield of about 1.2 to about 2.75 fold compared to VLPs containing the wild-type GI.3 VP1 protein (Figure 5F).
[0225] As shown in Figures 5B and 5D, expression of norovirus GI.3 constructs with a serine to leucine substitution at position 94 (S94L) or combinations including a glutamine to serine substitution at position 84 (Q84S) and a serine to leucine substitution at position 94 (Q84S+S94L) or a methionine to isoleucine substitution at position 57 (M57I+S94L) shifted VLPs to higher density fractions (F2-F6; 31-35% iodixanol) compared to VLPs containing wild-type GI.3 VP1, which segregated primarily into lower density fractions (F8-F11; 25-29% iodixanol).
[0226] VLPs composed of modified GI.3 VP1 proteins with the S94L substitution, the Q84S+S94L combination, or the M57I+S94L combination produced fewer damaged virus particles and a higher ratio of 38 nm particles to 23 nm particles compared to wild-type GI.3 VLPs (Figures 5C and 5E).
[0227] GI.5 VLPs and VLPs containing modified GI.5 VP1 proteins Norovirus GI.5 VP1 constructs with a serine to proline substitution at position 84 (Q84S), an alanine to leucine substitution at position 94 (A94L), or a combination of these substitutions (Q84S+A94L) showed comparable yields of VP1 protein in plant extracts when compared to the yield of wild-type GI.5 VP1 protein expressed in plants (Figure 6A). After gradient purification, centrifugation, and resuspension, the norovirus GI.5 construct with an alanine to leucine substitution at position 94 (A94L) showed increased yield, a 1.5-fold increase, when compared to wild-type GI.5 VP1.
[0228] As shown in Figure 6B, a GI.5 VP1 construct with a glutamine to serine substitution at position 84 combined with an alanine to leucine substitution at position 94 (Q84S+A94L) resulted in a VP1 protein that exhibited a shift to higher density iodixanol fractions (29-31%) compared to wild-type GI.5 VP1 (predominantly found in the 25-29% iodixanol fraction). The VLP preparations also had fewer damaged virus particles when compared to wild-type GI.5 VLPs (Figure 6C).
[0229] GI.7 VLPs and VLPs containing modified GI.7 VP1 proteins Norovirus GI.7 VP1 constructs with an arginine to serine substitution at position 84 (R84S), a methionine to isoleucine substitution at position 57 (M57I), or a combination of these substitutions (M57I+R84S) showed increased yields of VP1 protein after gradient purification, centrifugation, and resuspension when compared to wild-type GI.7 VP1. Furthermore, GI.7 constructs with a methionine to isoleucine, leucine, glycine, serine, threonine, asparagine, glutamine, lysine, or histidine substitution at position 57 (GI.7_M57X (X=I, L, G, S, T, N, Q, K, or H)) showed increased yields of about 1.1 to about 1.95-fold compared to VLPs containing wild-type GI.7 VP1 protein (Figure 6F).
[0230] As shown in Figure 6D, GI.7 VP1 constructs with M57I, R84S, or M57I+R84S substitutions resulted in VP1 protein that exhibited a shift to higher density iodixanol fractions (31-35%) compared to wild-type GI.7 VP1. GI.7 VLP preparations with M57I, R84S, or M57I+R84S substitutions also contained the same or fewer damaged virus particles when compared to wild-type GI.7 VLPs (Figure 6E).
[0231] GII.2 VLPs and VLPs containing modified GII.2 VP1 proteins Expression of the modified norovirus VP1 proteins GII.2_A90L and GII.2_E80S+A90L in plants increased the yield of VP1 protein compared to the yield of wild-type GII.2 VP1 (see Figure 7A).
[0232] Norovirus GII.2 VP1 constructs with a glutamate to serine substitution at position 84 and an alanine to leucine substitution at position 90 (E84S+A90L), an alanine to valine substitution at position 39, a glutamate to serine substitution at position 84 and an alanine to leucine substitution at position 90 (A39S+E84S+A90L), an arginine to isoleucine substitution at position 53, a glutamate to serine substitution at position 84 and an alanine to leucine substitution at position 90 (R53I+E84S+A90L), an alanine to valine substitution at position 39, an arginine to isoleucine substitution at position 53, a glutamate to serine substitution at position 84 and an alanine to leucine substitution at position 90 (A39V+R53I+E84S+A90L), all of which were identical to wild-type GII.2. Compared to VP1, there was an increased yield of VP1 protein after gradient purification, centrifugation and resuspension.
[0233] Expression of GII.2 VP1 constructs with a glutamic acid to serine substitution at position 80 (E80S), an alanine to leucine substitution at position 90 (A90L), or a glutamic acid to serine substitution at position 80 and an alanine to leucine substitution at positions 80 and 90 (E80S+A90L) produced VLPs comparable to wild-type GII.2 (Figure 7B). GII.2 VLP preparations with E80S+A90L or A39V+E80S+A90L substitutions also contained the same or fewer damaged virus particles when compared to wild-type GII.2 VLPs (Figure 7C).
[0234] GII.3 VLPs and VLPs containing modified GII.3 VP1 proteins A norovirus GII.3 VP1 construct with a substitution of glutamic acid by serine at position 80 (E80S) showed comparable yields of VP1 protein in plant extracts when compared to the yield of wild-type GII.3 VP1 protein expressed in planta. Yields of VLPs containing either the wild-type or modified VP1 proteins were generally lower.
[0235] Expression of a GII.3 VP1 construct carrying a glutamic acid to serine substitution at position 80 (E80S) produced comparable production of VLPs that were present in the iodixanol fraction (35%) at a density comparable to that of wild-type GII.3 (Fig. 8B ).
[0236] GII.4 VLPs and VLPs containing modified GII.4 VP1 proteins 9A, 9H and 9I, an arginine to isoleucine substitution at position 53 (R53I); a proline to serine, alanine, asparagine, lysine or histidine substitution at position 80 (P80X (X=S, A, N, K or H)); a serine to leucine substitution at position 90 (S90L); an alanine to valine, isoleucine, methionine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine substitution at position 39 in combination with a proline to serine substitution at position 80 (S90L); Norovirus GII.4 VP1 constructs with a deletion at positions 35 to 42 (Δ35-42) combined with a substitution (A39X (X = V, I, M, T, E, D, N, Q, K, or H)) (A39V+P80S); an arginine to isoleucine substitution at position 53 combined with a proline to serine substitution at position 80 (R53I+P80S); a serine to leucine substitution at position 90 combined with a proline to serine substitution at position 80 (P80S+S90L); and a proline to serine substitution at position 80 (Δ35-42+P80S) increased VP1 protein yields after plant extraction compared to VP1 yields using wild-type GII.4.
[0237] For each modified GII.4 VP1 protein tested, VLP yields containing the various modified GII.4 VP1 proteins were higher than VLP yields containing wild-type GII.4 VP1 protein. A 10-fold increase in VLP yield was observed for VLPs containing GII.4_A39V VP1, an approximately 1.4-fold to approximately 2.7-fold increase in VLP yield was observed for VLPs containing GII.4_P80X (X=S, A, N, K, H), a greater than 8-fold increase in VLP yield was observed for VLPs containing either GII.4_S90L VP1 or GII.4_Δ35-42+P80S VP1, a 14-fold increase in VLP yield was observed for VLPs containing GII.4_P80S+P90L VP1, and a 15-fold increase in VLP yield was observed for VLPs containing GII.4_A39X+P80S VP1 (X=V, I, M, G.S., E, D, N, Q, K or H), GII.4_R53I+P80S (21-fold increase) or GII.4_A39V+P80S+A90L VP1 (38.5-fold increase), a 1.3- to 3.4-fold increase in VLP yield was observed, a 5-fold increase in VLP yield was observed for VLPs containing GII.4_A39V+R53I VP1, a 4-fold increase in VLP yield was observed for VLPs containing GII.4_V47P+P80S VP1, and a 1.5-fold increase in VLP yield was observed for VLPs containing GII.4_R53I VP1.
[0238] Results for VLPs containing modified GII.4 proteins are shown in Figures 9B-9D and 9G. Proline to serine substitution at position 80 (P80S; Figures 9B, 9C, 9D); serine to leucine substitution at position 90 (S90L; Figure 9B); alanine to valine substitution at position 39 combined with proline to serine substitution at position 80 (A39V+P80S; Figure 9C); arginine to isoleucine substitution at position 53 combined with proline to serine substitution at position 80 (R53I+P80S; Figure 9D); serine to leucine substitution at position 90 combined with proline to serine substitution at position 80 (R53I+P80S; Figure 9D); Constructs containing GII.4 VP1 with a proline to serine substitution at position 80 combined with a leucine substitution (P80S+S90L; Figure 9B); a proline to serine substitution at position 80 combined with a deletion at positions 35-42 (P80S+Δ35-42; Figure 9C), and an alanine to valine substitution at position 39 combined with a proline to serine substitution at position 80 and a serine to leucine substitution at position 90 (GII.4_A39V+P80S+A90L; Figure 9G) produced VLPs that were present in the high density iodixanol fraction (29-33%).
[0239] VLPs containing GII.4 VP1 proteins with a P80S substitution in combination with an S90L substitution (P80S+S90L; Figure 9B); an A39V substitution in combination with a P80S substitution (A39V+P80S; Figure 9C); a P80S substitution in combination with a deletion at positions 35-42 (Δ35-42+P80S; Figure 9C); an R53I substitution in combination with a P80S substitution (R53I+P80S; Figure 9D); and an alanine to valine substitution at position 39 in combination with a proline to serine substitution at position 80 and a serine to leucine substitution at position 90 (GII.4_A39V+P80S+A90L; Figure 9G) showed less viral particle damage and / or a higher ratio of 38 nm particles:23 nm particles compared to wild-type GII.4 VLPs.
[0240] GII.6 VLPs and VLPs containing modified GII.6 VP1 proteins A greater than 2.2-fold increase in VLP yield (determined after gradient purification, centrifugation and resuspension) was also observed with plant extracts expressing GII.6_S90L VP1 compared to the wild type. GII.12 VLPs and VLPs containing modified GII.12 VP1 proteins
[0241] Modified GII.12, e.g., GII.12 containing a glutamic acid to serine substitution at position 80 (E80S), an arginine to leucine substitution at position 90 (A90L), or a combination of these substitutions (E80S+A90L), resulted in an approximately 1.2- to 1.4-fold increase in yield compared to wild-type (determined after gradient purification, centrifugation, and resuspension; Figure 11A).
[0242] GII.12 constructs with a glutamic acid to serine substitution at position 80 (E80S); an alanine to leucine substitution at position 90 (A90L); and combinations thereof (E80S+A90L) resulted in expression of GII.12 VP1 protein present in the high density iodixanol fractions (33-35%) compared to wild-type GII.12 VP1 (31-33%).
[0243] GII.17 VLPs and VLPs containing modified GII.17 VP1 proteins Modified GII.17, e.g., GII.17 containing an alanine to valine substitution at position 39 (A39V), an arginine to isoleucine substitution at position 53 (R53I), or an alanine to leucine substitution at position 90 (A90L), resulted in an increase in yield of about 1.1-fold to about 3.4-fold compared to wild-type (determined after gradient purification, centrifugation, and resuspension).
[0244] GII.17 constructs with an alanine to valine substitution at position 39 (A39V), an arginine to isoleucine substitution at position 53 (R53I), or an alanine to leucine substitution at position 90 (A90L) resulted in expression of GII.17 VP1 protein present in the high-density iodixanol fraction (33-35%) compared with wild-type GII.12 VP1 (31-33%).
[0245] Taken together, the above results indicate that protein components from high-density iodixanol gradient fractions indicate that Norovirus VP1 protein and modified Norovirus VP1 proteins were found to self-assemble into VLPs in planta. Isolated VLPs composed of mutant VP1 proteins exhibited structural conformations similar to wild-type Norovirus virion particles.
[0246] Example 4: Immune response using VP1 Immune responses to challenge with Norovirus native GI.1 (SEQ ID NO:1) VLPs were studied using 6-8 week old female BALB / c mice (Charles River Laboratories). Thirty-seven mice were randomized into four groups of eight mice for the Norovirus VLP vaccine and one group of five mice for placebo. All groups were injected using intramuscular immunization. All groups were immunized with a two-dose regimen, with a boost immunization administered 3 weeks after the primary immunization.
[0247] Two groups (8 mice) of non-anesthetized mice were immunized with the plant-derived VLP native VP1 from the Norovirus GI.1 genotype vaccine (1 or 10 μg) for intramuscular administration to the hind leg. A placebo group (5 mice) was immunized using the same route and regimen as the candidate vaccine, using vaccine buffer (PBS, pH 6.0).
[0248] To measure the potential benefit of an adjuvant, two groups of animals (8 animals) were immunized with 1 or 10 μg of plant-derived VLP norovirus vaccine plus one volume of Alhydrogel 2% (alum, Cedarlane Laboratories Ltd., Burlington, Ontario, Canada) administered intramuscularly into the hind limb of unanesthetized mice. All groups were immunized according to a prime-boost regimen, with the boost immunization occurring 3 weeks after the primary immunization.
[0249] Mice were evaluated through clinical observations throughout their lives, following daily monitoring for mortality and clinical signs, weekly detailed examinations, injection site observations, and body weight measurements. All animals were kept under observation and sacrificed on day 42 for macroscopic examination. Blood was collected from all animals prior to dosing on days 0, 21, and 42 (21 days after each immunization). Samples were processed to separate serum for specific antibody response analysis.
[0250] Serum samples from blood taken from all animals on days 21 and 42 were analyzed separately by ELISA for GI.1 VLP-specific total IgG and IgA antibodies using GI.1 VLP-coated plates. Pre-immune serum samples (day 0 - pre-dose) taken from all animals were pooled by treatment group and each pool was analyzed to ensure they were negative (or below the analytical test cutoff).
[0251] Descriptive statistics were performed using GraphPad Prism software (version 6.05; GraphPad Software, La Jolla, CA, USA). Antibody titers measured for each group were reported as geometric mean titers (GMT) with 95% confidence intervals (CI). Half of the values at the limit of detection were due to antibody titers below the detection limit of the method specific for the antibody tested. Thus, in this study, an animal was considered to be a positive responder if the GMT value of the determined condition was equal to or greater than the detection limit of the method (LOQ=100). Statistical comparisons between IgG titers of treatment groups were performed using one-way ANOVA followed by Tukey's test on log10 transformed data. Comparisons between the placebo group and each treatment group were also performed using one-way ANOVA followed by post hoc Dunnett's test on log10 transformed data.
[0252] GL.1 VLP-specific total IgG titers measured on serum samples obtained from all animals after IM immunization with one (day 21) and two (day 42) doses of 1 μg or 10 μg of each formulation. Total IgG titers were measured by ELISA using GI.1 VLP-coated plates (LOQ=100). Results are shown in Figure 3D. Total IgG titers per treatment group (n=8 animals / group) are expressed by geometric mean titers (GMT) with 95% confidence intervals. Statistical comparisons between IgG titers of treatment groups were performed using one-way ANOVA followed by Tukey's test on log10 transformed data. Comparisons between placebo and each treatment group were also performed using one-way ANOVA followed by post hoc Dunnett's test on log10 transformed data. Significant differences are annotated as letters in Figure 3D (same letters indicate that no significant differences were detected between treatment groups; p>0.05).
[0253] Similarly, as described herein, for example, GI.3_Q84S (construct 4140; SEQ ID NO: 167), GI.3_S94L (construct 4141; SEQ ID NO: 9), GI.3_A43V+S94L (construct 4179; SEQ ID NO: 169), GI.3_M57I+S94L (construct 4180; SEQ ID NO: 171), GI.3_P84S+S94L (construct 4142; SEQ ID NO: 11), GI.3_A43V+M57I+S94L (construct 4181; SEQ ID NO: 173), GI.5 ...5_Q84S (construct 4140; S 4S (construct 4130; SEQ ID NO: 35), GI.5_A94L (construct 4131; SEQ ID NO: 37), GI.5_Q84S+A94L (construct 4132; SEQ ID NO: 39), GI.7_R84S (construct 4210; SEQ ID NO: 176), GI.7_M57I (construct 4217; SEQ ID NO: 178), GI.7_M57I+R84S (construct 4218; SEQ ID NO: 180), GII.2_E80S (construct 4143; SEQ ID NO: 86), GII.2_A90L (construct 4144; SEQ ID NO: 42), GII.2_E80S+A90L (construct 4145; SEQ ID NO: 44), GII.2_A39V+E80S+A90L (construct 4182; SEQ ID NO: 183), GII.2_R53I+E80S+A90L (construct 4183; SEQ ID NO: 185), GII.2_A39V+R53I+E80S+A90L (construct 4184; SEQ ID NO: 187), GII.3_E80S (construct 4146; SEQ ID NO: 47), GII.3_A90L (construct 4147; SEQ ID NO: 49), GII.3_E80S+ A90L (construct 4148; sequence number 51), GII.4_A39V (construct 4155; sequence number 54), GII.4_V47P (construct 4156; sequence number 56), GII.4_R53I (construct 4157; sequence number 58), GII.4_P80S (construct 4133; sequence number 60), GII.4_S90L (construct 4134; sequence number 62), GII.4_Δ35-42 (construct 4158; sequence number 64), GII.4_SSTAVATA (construct 4159; sequence number 66).GII.4_A39V+R53I (construct 4185; SEQ ID NO: 189), GII.4_A39V+P80S (construct 4165; SEQ ID NO: 68), GII.4_V47P+P80S (construct 4166; SEQ ID NO: 70), GII.4_R53I+P80S (construct 4167; SEQ ID NO: 72), GII.4_P80S+S90L (construct 4135; SEQ ID NO: 74), GII.4_ Δ35-42+P80S (construct 4168; SEQ ID NO: 76), GII.4_P80S+SSTAVATA (construct 4169; SEQ ID NO: 78), GII.4_A39V+R53I+P80S (construct 4186; SEQ ID NO: 191), GII.6_E80S (construct 4149; SEQ ID NO: 80), GII.6_S90L (construct 4150; SEQ ID NO: 82), GII.6_E80S+S 90L (construct 4151; SEQ ID NO: 84), GII.12_E80S (construct 4136; SEQ ID NO: 89), GII.12_A90L (construct 4137; SEQ ID NO: 91), GII.12_E80S+A90L (construct 4138; SEQ ID NO: 93), GII.17_A39V (construct 4234; SEQ ID NO: 193), GII.17_R53I (construct 4235; SEQ ID NO: 195), Plant-produced modified VP1 proteins produced using GII.17_A90L (construct 4232; sequence number 197), GII.17_A39V+R53I (construct 4236; sequence number 199), GII.17_E80S+A90L (construct 4233; sequence number 201) or combinations thereof may be administered to mice following the same protocol as described in this example.
[0254] Mouse immune response to norovirus native VP1 VLPs
[0255] As shown in FIG. 3D, mice immunized with plant-derived Norovirus native VP1 VLPs from the GI.1 genotype exhibited GI.1 VLP-specific IgG antibody titers in serum, which were detected for each treatment group on days 21 and 42. The IgG titer levels induced by each treatment on days 21 and 42 were statistically higher than the titers quantified for the placebo group (p<0.05). IgG titer levels increased daily in a dose-dependent manner, as shown by the significant difference (p<0.05) detected between the 1 μg and 10 μg treatments with or without alhydrogel, and at doses of 1 μg and 10 μg, the addition of alhydrogel to the NoV VLP vaccine significantly enhanced the induced immune response (p<0.05). A significant increase in IgG titer levels was detected for each treatment group from days 21 to 42 (p<0.05). These results collectively demonstrate the ability of plant-produced norovirus native VP1 VLPs to induce potent immune responses in mice.
[0256] Similar results have been obtained, for example, with GI.3_Q84S (construct 4140; SEQ ID NO: 167), GI.3_S94L (construct 4141; SEQ ID NO: 9), GI.3_A43V+S94L (construct 4179; SEQ ID NO: 169), GI.3_M57I+S94L (construct 4180; SEQ ID NO: 171), GI.3_P84S+S94L (construct 4142; SEQ ID NO: 11), GI.3_A43V+M57I+S94L (construct 4181; SEQ ID NO: 173), following the same protocol as described in this example. ), GI.5_Q84S (construct 4130; SEQ ID NO: 35), GI.5_A94L (construct 4131; SEQ ID NO: 37), GI.5_Q84S+A94L (construct 4132; SEQ ID NO: 39), GI.7_R84S (construct 4210; SEQ ID NO: 176), GI.7_M57I (construct 4217; SEQ ID NO: 178), GI.7_M57I+R84S (construct 4218; SEQ ID NO: 180), GII.2_E80S (construct 4143; SEQ ID NO: 86), GII.2_A90L (construct 4144; SEQ ID NO: no. 42), GII.2_E80S+A90L (construct 4145; SEQ ID NO: 44), GII.2_A39V+E80S+A90L (construct 4182; SEQ ID NO: 183), GII.2_R53I+E80S+A90L (construct 4183; SEQ ID NO: 185), GII.2_A39V+R53I+E80S+A90L (construct 4184; SEQ ID NO: 187), GII.3_E80S (construct 4146; SEQ ID NO: 47), GII.3_A90L (construct 4147; SEQ ID NO: 49), GII.3_E80S (construct 4148; SEQ ID NO: 50), GII.3_E80S (construct 4149; SEQ ID NO: 51), GII.3_E80S (construct 4150; SEQ ID NO: 52), GII.3_E80S (construct 4151; SEQ ID NO: 53), GII.3_E80S (construct 4152; SEQ ID NO: 54), GII.3_E80S (construct 4153; SEQ ID NO: 55), GII.3_E80S (construct 4154; SEQ ID NO: 56), GII.3_E80S (construct 4155; SEQ ID NO: 57), GII.3_E80S (construct 4156; SEQ ID NO: 59), GII.3_E80S (construct 4157; SEQ ID NO: 59), GII.3_E80S (construct 4158; SEQ ID NO: 51), GII.3_E80S (construct 4159; SEQ ID 0S+A90L (construct 4148; sequence number 51), GII.4_A39V (construct 4155; sequence number 54), GII.4_V47P (construct 4156; sequence number 56), GII.4_R53I (construct 4157; sequence number 58), GII.4_P80S (construct 4133; sequence number 60), GII.4_S90L (construct 4134; sequence number 62), GII.4_Δ35-42 (construct 4158; sequence number 64), GII.4_SSTAVATA (construct 4159; sequence number 66).GII.4_A39V+R53I (construct 4185; SEQ ID NO: 189), GII.4_A39V+P80S (construct 4165; SEQ ID NO: 68), GII.4_V47P+P80S (construct 4166; SEQ ID NO: 70), GII.4_R53I+P80S (construct 4167; SEQ ID NO: 72), GII.4_P80S+S90L (construct 4135; SEQ ID NO: 74), GII.4_Δ35-42+P80S (construct 4168; SEQ ID NO: 76), GII.4_P80S+SSTAVATA (construct 4169; SEQ ID NO: 78), GII.4_A39V+R53I+P80S (construct 4186; SEQ ID NO: 191), GII.6_E80S (construct 4149; SEQ ID NO: 80), GII.6_S90L (construct 4150; SEQ ID NO: 82), GII.6_E80S+S90L (construct 4151; SEQ ID NO: 84), GII.12_E80S (construct 4136; SEQ ID NO: 89), GII.12_A90L (construct 4137; SEQ ID NO: 91), GII.12_E80S+A90L (construct 4138; SEQ ID NO: 93), GII.17_A39V (construct 4234; SEQ ID NO: 193), GII.17_R53I (construct 4235; sequence number 195), GII.17_A90L (construct 4232; sequence number 197), GII.17_A39V+R53I (construct 4236; sequence number 199), GII.17_E80S+A90L (construct 4233; sequence number 201) or combinations thereof.
[0257] All citations are incorporated herein by reference.
[0258] The present invention has been described with respect to one or more embodiments. However, it will be apparent to those skilled in the art that many variations and modifications can be made to the subject matter described. The scope of the claims should not be limited by the preferred embodiments described in the examples, but should be given the broadest interpretation consistent with the description as a whole.
Claims
1. A modified Norovirus VP1 protein, comprising the amino acid sequence of a wild-type Norovirus VP1 protein and one or more amino acid substitutions of the wild-type Norovirus VP1, wherein the one or more amino acid substitutions consist of one or more amino acid substitutions at positions selected from amino acids 43, 57, 84, and 94 in a sequence aligned with a reference sequence of SEQ ID NO:1; however: - substitutions for amino acid 43 at positions in the aligned sequences are to valine, isoleucine, leucine, methionine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine; - substitutions for amino acid 57 at positions in the aligned sequences are to isoleucine, leucine, valine, alanine, glycine, serine, threonine, asparagine, glutamine, lysine or histidine; the substitution for amino acid 84 at position 84 in the aligned sequences is to serine, asparagine, alanine, lysine or histidine; and / or - substitutions for amino acid 94 at positions in the aligned sequences are to leucine, isoleucine, methionine, valine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine; and The wild-type Norovirus VP1 protein is not of genotype GI.
1.
2. 2. The modified Norovirus VP1 protein of claim 1, wherein the wild-type Norovirus VP1 is selected from the group consisting of genotypes GI.3, GI.5, GI.7, GII.2, GII.3, GII.4, GII.6, GII.12 and GII.
17.
3. A recombinant polynucleotide encoding the modified Norovirus VP1 protein of claim 1 or 2.
4. 4. The recombinant polynucleotide of claim 3, wherein the codon usage of the nucleotide sequence is optimized for human codon usage, increased GC content, or a combination thereof, and / or the polynucleotide comprises a vector.
5. A virus-like particle (VLP) comprising the modified Norovirus VP1 protein of claim 1 or 2.
6. The VLP of claim 5 , further comprising a Norovirus VP2 protein.
7. 1. A method for producing a Norovirus VP1 protein, or a VP1 comprising said Norovirus VP1 protein, in a plant, plant part, or plant cell, comprising: Introduction of the recombinant polynucleotide of claim 3 or 4 into a plant, a part of a plant, or a plant cell; Incubating the plant, plant part, or plant cell under conditions that allow expression of the Norovirus VP1 protein.
8. In the introducing step, a second polynucleotide encoding a Norovirus VP2 protein is introduced into the plant, plant part, or plant cell; Incubating conditions permit co-expression and co-production of both the Norovirus VP1 protein and the Norovirus VP2 protein in the plant, plant part, or plant cell. The method of claim 7.
9. 9. The method of claim 7 or 8, further comprising the step of harvesting the plant, plant part, or plant cell.
10. or further comprising the steps of extracting, purifying, or extracting and purifying the Norovirus VP1 protein, or both the Norovirus VP1 protein and the Norovirus VP2 protein, from the plant, plant part, or plant cell; extracting, purifying, or extracting and purifying virus-like particles (VLPs) from the plant, plant part, or plant cell, wherein the VLPs are virus-like particles (VLPs) that contain a Norovirus VP1 protein or both a Norovirus VP1 protein and a Norovirus VP2 protein.
10. The method of claim 9.
11. A plant, a plant part, or a plant cell comprising the modified norovirus VP1 protein according to claim 1 or 2. A recombinant polynucleotide according to claim 3 or 4, or A VLP according to claim 5 or 6.
12. A composition for inducing an immune response comprising an effective dose of a modified Norovirus VP1 protein described in claim 1 or 2 or a VLP described in claim 5 or 6, and a pharma- ceutically acceptable carrier, adjuvant, vehicle or excipient.
13. 7. A vaccine comprising an effective dose of a modified Norovirus VP1 protein of claim 1 or 2 or a VLP of claim 5 or 6 for inducing an immune response.
14. A modified Norovirus VP1 protein as described in claim 1 or 2 or a VLP as described in claim 5 or 6 for use in inducing immunity against Norovirus infection in a subject.
15. The modified VP1 protein or VLP for use according to claim 14, wherein the VP1 protein or VLP is administered orally, intranasally, intramuscularly, intraperitoneally, intravenously, subcutaneously, rectally or intravaginally to a subject.
16. A method for producing a modified Norovirus VP1 protein, comprising: (i) providing a Norovirus VP1 protein, provided that the Norovirus VP1 protein is not of the GI.1 genotype; and (ii) substituting one or more amino acids in the amino acid sequence of the Norovirus VP1 protein with one or more of the following: a substitution of the amino acid at amino acid position 43 in a sequence aligned with the reference sequence of SEQ ID NO:1 with valine, isoleucine, leucine, methionine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine; a substitution of the amino acid at amino acid position 57 in a sequence aligned with the reference sequence of SEQ ID NO:1 with isoleucine, leucine, valine, alanine, glycine, serine, threonine, asparagine, glutamine, lysine, or histidine; A substitution of an amino acid at amino acid position 84 in a sequence aligned with the reference sequence of SEQ ID NO:1 with serine, asparagine, alanine, lysine, or histidine; and Substitution of the amino acid at amino acid position 94 in a sequence aligned with the reference sequence of SEQ ID NO:1 with leucine, isoleucine, methionine, valine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine.
17. Norovirus VP1 protein, comprising one or more amino acid substitutions at amino acid positions 43, 57, 84, and 94 in a sequence aligned with the reference sequence of SEQ ID NO:1, with the proviso that: The substitution at amino acid position 43 in a sequence aligned with the reference sequence of SEQ ID NO:1 is a substitution of the amino acid with isoleucine, methionine, aspartic acid, glutamic acid, asparagine, glutamine, lysine or histidine; The substitution at amino acid position 57 in the sequence aligned with the reference sequence of SEQ ID NO:1 is a substitution of the amino acid with leucine, alanine, glycine, serine, glutamine or histidine; The substitution at amino acid position 84 in the sequence aligned with the reference sequence of SEQ ID NO:1 is a substitution of the amino acid with asparagine, alanine or lysine; The substitution at amino acid position 94 in the sequence aligned with the reference sequence of SEQ ID NO:1 is a substitution of the amino acid with isoleucine, methionine, valine, threonine, asparagine, lysine or histidine; and The wild-type norovirus VP1 protein is not of the GI.1 genotype.
Citation Information
Patent Citations
Virus-like particles containing a complex capsid amino acid sequence for enhanced cross-reactivity
JP2011530295A
Method for preparing plant-derived VLPs
JP2013505025A
Monoclonal antibodies that neutralize a norovirus
US20160009788A1
Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use
US20160102136A1
Formulations for small intestinal delivery of RSV and norovirus antigens
WO2016200951A1
